Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents

Non-brain-penetrating thiocarbamate derivatives formulated with specific carriers enhance the solubility and bioavailability of A2A inhibitors, addressing side effects and improving cancer treatment efficacy by restoring immune function in tumors.

JP2024167310AInactive Publication Date: 2024-12-03ITEOS THERAPEUTICS SA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024146108
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-09-27
Filing Date
2024-08-28
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing A2A inhibitors developed for CNS diseases cross the blood-brain barrier, leading to potential harmful side effects when used for cancer treatment due to higher adenosine levels in tumors, and they have low solubility and oral bioavailability, necessitating improved pharmaceutical formulations for effective oral administration.

Method used

Development of non-brain-penetrating thiocarbamate derivatives as A2A inhibitors, formulated with specific carriers like lauroylpolyoxyl-32 glyceride and D-alpha-tocopherol-polyethylene glycol-1000 succinate, combined with anticancer agents such as checkpoint inhibitors, to enhance solubility and bioavailability for oral cancer treatment.

Benefits of technology

The formulation provides suitable oral bioavailability and efficacy of A2A inhibitors, effectively restoring immune function within the tumor environment and enhancing the anticancer effects of combined therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167310000069
    Figure 2024167310000069
  • Figure 2024167310000070
    Figure 2024167310000070
  • Figure 2024167310000071
    Figure 2024167310000071
Patent Text Reader

Abstract

To provide a pharmaceutical composition useful for oral dosing in the treatment of cancer.SOLUTION: A pharmaceutical composition contains hydrochloride of a) and b) polyethylene glycol. Preferably, the hydrochloride is (+)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazine-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e]1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-one hydrochloride.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to thiocarbamate derivatives that are useful as A2A adenosine receptor (A2AR) inhibitors.

[0002] In particular, the present invention relates to a pharmaceutical composition comprising a thiocarbamate derivative as an adenosine A2A receptor inhibitor. The pharmaceutical composition of the present invention is particularly useful for oral administration in the treatment of cancer.

[0003] The present invention also relates to a combination comprising an A2A adenosine receptor (A2AR) inhibitor and an anti-cancer agent. The A2AR inhibitor is a thiocarbamate derivative of formula (I) as defined below. The anti-cancer agent is, for example, an immunotherapeutic agent such as a checkpoint inhibitor. The present invention further relates to a pharmaceutical composition and a kit of parts comprising said combination. The combination of the present invention is particularly useful for the treatment and / or prevention of cancer. [Background technology]

[0004] Many of the immunosuppressive mechanisms in tumors are shared with physiological immune regulation in normal tissues. Such immune regulation is crucial in keeping the immune system under control to block autoreactive immune responses and to prevent ongoing immune responses from causing significant tissue damage. Lack of physiological immune regulation often leads to extreme immune activation that accompanies autoimmunity. For example, CTLA-4 is a physiological mechanism that negatively regulates T cell activity by blocking costimulatory signals through CD28-B7 interactions. Lack of CTLA4 leads to nonspecific T cell activation, and CTLA-4-deficient mice die within weeks due to massive lymphocytic tissue infiltration. PD-1 also provides T cell inhibitory signals upon interaction with its ligands PD-L1 and PD-L2. PD-1 deficiency in mice is known to cause various types of autoimmune diseases depending on the genetic lineage.

[0005] In addition to cell surface transducers of immunosuppressive signals, e.g., CTLA-4 and PD-1, anti-inflammatory cytokines (IL-10, TGF-β), enzymes (indoleamine-2,3-dioxygenase), and specialized immunoregulatory cells (regulatory T cells, myeloid-derived suppressor cells, MDSCs) are involved in immunosuppression in the tumor microenvironment. Such immunosuppressive mechanisms play a key role in controlling immune responses in normal tissues. As tumors exploit such physiological immunoregulatory mechanisms to defend tissues from immune attack, such mechanisms intended to prevent inflammatory complications are now found to be the main obstacles hindering spontaneous cancer regression and immunological cancer therapy. Identification of immunosuppressive mechanisms in tumors has provided molecular targets to restore antitumor immune responses. Therefore, these negative immunoregulatory mechanisms, so-called immune checkpoints, have become the focus of drug discovery. Antibodies against PD1, PDL1, or CTLA4 are approved as anticancer therapies for a number of indications, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, and hepatocellular carcinoma, as well as treatment for patients with solid tumors that have one of two specific genetic characteristics known as mismatch repair deficiency and microsatellite instability high (regardless of cancer type).

[0006] Extracellular adenosine is known to be an inhibitor of immune function. While intracellular adenosine is involved in energy metabolism, nucleic acid metabolism, and the methionine cycle, extracellular adenosine plays an important role in intercellular signaling. The signal is transmitted by G protein-coupled adenosine receptors on the cell surface and is involved in the nervous, cardiovascular, and immune systems. It affects a variety of physiological functions, including

[0007] Tumors contain high levels of extracellular adenosine, and it has been suggested that its immunosuppressive effects and catabolic energy generation may benefit tumor cells (Allard et al., Curr. Opin. Pharmacol., 2016, 29, 7-16; Otta A., Frontiers in Immunology, 2016, 7:109). This high level of extracellular adenosine is likely due to overexpression of the enzyme CD73, which is involved in the generation of extracellular adenosine. Numerous tumors overexpress CD73, and the following tumors all express intermediate or high levels of CD73 by immunohistochemistry on more than 50% of the tumor surface: breast, carcinoid, cervical, colon, endometrial, glioma, head and neck, liver, lung, melanoma, ovarian, pancreatic, prostate, kidney, gastric, thyroid, and urothelial carcinomas (www.proteinatlas.org).

[0008] Of the four known adenosine receptors, the A2A adenosine receptor (A2AR) is the subtype that is predominantly expressed on most immune cells. Stimulation of A2AR generally results in immunosuppressive signals that inhibit the activities of T cells (proliferation, cytokine production, cytotoxicity), NK cells (cytotoxicity), NKT cells (cytokine production, upregulation of CD40L), macrophages / dendritic cells (antigen presentation, cytokine production), and neutrophils (oxidative burst). The presence of high levels of extracellular adenosine in tumors has been found to play a key role in evading antitumor immune responses. Notably, it was shown that A2AR-deficient mice can spontaneously regress inoculated tumors, whereas wild-type mice are completely devoid of similar tumor regression. A2AR antagonists were also beneficial to tumor-bearing wild-type animals. Importantly, depletion of T and NK cells prevented the delay of tumor growth by A2AR antagonists, suggesting an enhanced antitumor cellular immune response. The effector functions of T cells and NK cells are sensitive to A2AR stimulation. In addition, when activated in the presence of A2AR agonists, the effector functions of T cells are persistently impaired even after removal of the A2AR agonist. This result suggests that the adenosine-rich environment within tumors may induce anergic T cells against tumor cells.

[0009] Therefore, given that A2A receptors are expressed on most immune cells, particularly effector immune cells such as T cells and NK cells, and that A2A receptors are associated with tissues that produce adenosine, A2A inhibitors may be useful in all cancer indications.

[0010] As a result, there is a need for A2A inhibitors that can restore immune function within the tumor environment.

[0011] Adenosine is known to be an endogenous regulator of several other physiological functions, for example, in the central nervous system (CNS) balance, where adenosine is known to induce sedative, anxiolytic, and antiepileptic effects.

[0012] Therefore, A2A inhibitors have been developed previously to treat depression and neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease (Pinna A., CNS Drugs, 2014, 28, 455). One of the most recent A2A inhibitors developed for the treatment of CNS diseases is preladenant (Hodgson RA et al., J. Pharmacol. Exp. Ther., 2009, 330(1), 294-303; Hauser RA et al., JAMA Neurol., 2015, 72(12), 1491-500).

[0013] However, such previously developed A2A inhibitors targeted A2A receptors in the CNS. It was designed to cross the blood-brain barrier in order to

[0014] Considering the higher levels of adenosine in tumors compared to the brain, much larger amounts of compound would be required to achieve the desired effect on immune function restoration for cancer treatment. Therefore, in order to avoid adverse side effects, A2A inhibitors with limited, if any, CNS penetration should be provided, in contrast to previously developed A2A inhibitors.

[0015] The Applicant has provided in International Patent Application PCT / EP2018 / 058301 a series of non-brain-penetrant A2A inhibitors, which are thiocarbamate derivatives useful for restoring immune function within the tumor environment.

[0016] However, this compound has very low solubility in aqueous buffers and exhibits low intestinal solubility, resulting in low oral bioavailability. As a result, there is a need for pharmaceutical formulations suitable for oral administration of this compound.

[0017] As demonstrated in the experimental section below, Applicants hereby provide pharmaceutical compositions that allow suitable oral bioavailability of thiocarbamate A2A inhibitors. Furthermore, the anti-cancer effects of anti-cancer agents, such as immunotherapeutic agents, chemotherapeutic agents, or anti-angiogenic agents, or combinations thereof, may still be insufficient, which may be at least partially due to the immune evasion mechanisms of tumors as described above. No specific combination of A2AR inhibitors (particularly thiocarbamate derivatives disclosed in WO2018 / 178338) with other anticancer drugs has been reported. Herein, the applicant provides a combination comprising an adenosine A2A receptor inhibitor disclosed in WO2018 / 178338 and another anticancer drug, for example an immunosuppressant such as a checkpoint inhibitor. [Prior art documents] [Patent documents]

[0018] [Patent Document 1] International Publication No. 2018 / 178338 [Non-patent literature]

[0019] [Non-Patent Document 1] Allard et al.,Curr.Opin.Pharmacol.,2016,29,7-16 [Non-Patent Document 2] Otta A.,Frontiers in Immunology,2016,7:109 [Non-Patent Document 3] Pinna A.,CNS Drugs,2014,28,455 [Non-Patent Document 4] Hodgson RA et al.,J.Pharmacol.Exp.Ther.,2009,330(1),294-303 [Non-Patent Document 5] Hauser RA et al.,JAMA Neurol.,2015,72(12),1491-500 Summary of the Invention [Means for solving the problem]

[0020] Thus, the present invention provides (a) a compound of formula (I) as defined hereinafter, or a pharma- ceutically acceptable salt or solvate thereof; [ka] (b) a liquid carrier selected from lauroyl polyoxyl-32 glyceride, D-α-tocopherol-polyethylene glycol-1000 succinate, and mixtures thereof; and (c) optionally, one or more other pharma- ceutically acceptable carriers, diluents, excipients, and / or adjuvants.

[0021] In one embodiment, the compound of formula (I) is of the sub-formula defined below, in particular of formula (Ia), (Ia-1), (Ia-1a), (Ia-1b), (Ia-1c), or (Ia-1d). In one embodiment, the compound of formula (I) is one of those listed in Table 1 below. In a specific embodiment, the compound of formula (I) is selected from the following: (R,S)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (+)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; and pharma- ceutically acceptable salts or solvates thereof.

[0022] In one embodiment, the compound of formula (I) is in the form of a salt, wherein the salt is a hydrochloride or an esylate salt.

[0023] In one embodiment, the pharmaceutical composition of the invention further comprises PEG 400 and / or PEG 3350. In one embodiment, the pharmaceutical composition of the invention further comprises caprylic acid.

[0024] In one embodiment, the pharmaceutical composition of the present invention further comprises an antioxidant, which may be, for example, butylated hydroxytoluene (BHT).

[0025] In one embodiment, the pharmaceutical composition of the present invention further comprises a wetting agent, preferably, the wetting agent is selected from sodium lauryl sulfate, vitamin E TPGS, docusate sodium, polysorbate 80, and poloxamer 407, more preferably, the wetting agent is sodium lauryl sulfate.

[0026] In one embodiment, the pharmaceutical composition of the present invention further comprises a precipitation inhibitor, preferably the precipitation inhibitor is selected from hydroxypropyl methylcellulose, methylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone-polyvinyl acetate copolymer, polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and poloxamer 407, more preferably hydroxypropyl methylcellulose.

[0027] In one embodiment, in the pharmaceutical composition of the invention, the compound of formula (I) is present in an amount ranging from 1% to 20% w / w, preferably from 5% to 15% w / w, more preferably about 10% w / w.

[0028] In one embodiment, in the pharmaceutical composition of the invention, the lipid carrier is present in an amount ranging from 55% to 99% w / w, preferably from 60% to 95% w / w, more preferably from 70% to 90% w / w.

[0029] In one embodiment, the pharmaceutical composition of the present invention can be formulated as a capsule, tablet, or granule. In one embodiment, when the pharmaceutical composition of the present invention is formulated as a capsule, the capsule shell is composed of gelatin, and optionally additional components such as polyethylene glycol and sodium lauryl sulfate are included in the capsule shell.

[0030] The present invention further relates to a method of treating cancer comprising administering to a patient in need thereof a therapeutically acceptable effective amount of a pharmaceutical composition according to the present invention, hi one embodiment, the cancer is selected from breast cancer, carcinoid, cervical cancer, colon cancer, endometrial cancer, glioma, head and neck cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, gastric cancer, thyroid cancer, and urothelial cancer.

[0031] Thus, the present invention provides (a) Formula (I): [ka] (In the formula, R 1 and R2 is as defined below), or a pharma- ceutically acceptable salt or solvate thereof; (b) at least one anticancer agent.

[0032] In one embodiment, the compound of formula (I) is of formula (Ia), (Ia-1), or (Ia-1b) as defined below: In one embodiment, the compound of formula (I) is one of those listed in Table 1 below.

[0033] In one embodiment, the anti-cancer agent is selected from an immunotherapeutic agent, a chemotherapeutic agent, an anti-angiogenic agent, a multidrug resistance associated protein inhibitor, a radiotherapeutic agent, and any combination thereof.

[0034] In one embodiment, the immunotherapeutic agent is selected from a checkpoint inhibitor, a checkpoint agonist, an IDO inhibitor, a PI3K inhibitor, an adenosine receptor inhibitor, an adenosine-generating enzyme inhibitor, a CD40 agonist, an IL2 mutant, an immune cell, a therapeutic vaccine, or any combination thereof.

[0035] In one embodiment, the checkpoint inhibitor is an inhibitor of a checkpoint protein selected from PD-1, PD-L1, CTLA-4, and TIGIT.

[0036] In one embodiment, the inhibitor of PD-1 is an anti-PD-1 antibody, the inhibitor of PD-L1 is an anti-PD-L1 antibody, the inhibitor of CTLA-4 is an anti-CTLA-4 antibody, and the inhibitor of TIGIT is an anti-TIGIT antibody.

[0037] In one embodiment, the chemotherapeutic agent is an anticancer alkylating agent, an anticancer antimetabolite, an anticancer antibiotic, a plant-derived anticancer drug, an anticancer platinum coordination compound, a Parp inhibitor, an antihormonal In one embodiment, the anticancer antibiotic is doxorubicin. In one embodiment, the anticancer platinum coordination compound is oxaliplatin. In one embodiment, the chemotherapeutic combination is selected from (i) a combination consisting of folinic acid, fluorouracil, and oxaliplatin; (ii) a combination consisting of carboplatin and paclitaxel; and (iii) a combination consisting of gemcitabine and nab-paclitaxel.

[0038] In one embodiment, the combination of the invention comprises at least one compound of formula (I) as defined herein and at least two anti-cancer agents as defined herein.

[0039] The present invention also provides (a) at least one compound of formula (I) as defined herein; (b) at least one anti-cancer agent as defined herein.

[0040] The present invention further comprises: (a) a first portion comprising at least one compound of formula (I) as defined herein; (b) a second part comprising at least one anti-cancer drug as defined herein.

[0041] In one embodiment the combination, pharmaceutical composition or kit-of-parts according to the invention is for medical use.

[0042] In one embodiment the combination, pharmaceutical composition or kit-of-parts according to the invention is for use in the treatment and / or prevention of cancer.

[0043] In one embodiment, the cancer is selected from breast cancer, carcinoid, cervical cancer, colon cancer, endometrial cancer, glioma, head and neck cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, gastric cancer, thyroid cancer, and urothelial cancer.

[0044] In one embodiment, the components of a combination or kit-of-parts according to the invention are intended to be administered sequentially and / or simultaneously to a patient in need thereof.

[0045] In one embodiment, the components of a combination or kit-of-parts according to the invention are intended to be administered via different routes of administration to a patient in need thereof.

[0046] definition In the present invention, the following terms have the following meanings.

[0047] The term "aldehyde" refers to the group --CHO.

[0048] The term "alkenyl" refers to an unsaturated hydrocarbyl group that contains one or more carbon-carbon double bonds and may be linear or branched. Suitable alkenyl groups contain 2 to 6 carbon atoms, preferably 2 to 4 carbon atoms, and even more preferably 2 to 3 carbon atoms. Examples of alkenyl groups are ethenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and its isomers, 2-hexenyl and its isomers, 2,4-pentadienyl, and the like.

[0049] The term "alkenylcarbonyl" refers to the group -(C=O)-alkenyl, where alkenyl is as defined herein.

[0050] The term "alkenylcarbonylamino" refers to the group -NH-(C=O)-alkenyl, where alkenyl is as defined herein.

[0051] The term "alkoxy" refers to the group --O-alkyl, where alkyl is as defined herein.

[0052] The term "alkyl" refers to a group of the formula C n H 2n+1(wherein n is a number equal to or greater than 1). Generally, the alkyl groups of the present invention contain 1 to 8 carbon atoms, and more preferably, the alkyl groups of the present invention contain 1 to 6 carbon atoms. The alkyl groups may be linear or branched. Suitable alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl.

[0053] The term "alkylaminoalkyl" refers to the group -alkyl-NH-alkyl, where alkyl is as defined herein.

[0054] The term "alkylaminoalkylaminocarbonyl" refers to the group -(C=O)-NH-alkyl-NH-alkyl, where alkyl is as defined herein.

[0055] The term “(alkylaminoalkyl)(alkyl)aminocarbonyl” refers to the group —(C═O)—NR 1 R 2 In the formula, R 1 is an alkyl group, and R 2 is an -alkyl-NH-alkyl group, where alkyl is as defined herein.

[0056] The term "alkylaminoalkylcarbonyl" refers to the group -(C=O)-alkyl-NH-alkyl, where alkyl is as defined herein.

[0057] The term "alkylcarbonyl" refers to the group -(C=O)-alkyl, where alkyl is as defined herein.

[0058] The term "alkylheteroaryl" refers to any heteroaryl substituted with an alkyl group, where alkyl is as defined herein.

[0059] The term "alkyloxycarbonyl" refers to the group -(C=O)-O-alkyl, where alkyl is as defined herein.

[0060] The term "alkylsulfonyl" refers to the group -SO2-alkyl, where alkyl is as defined herein.

[0061] The term "alkylsulfonealkyl" refers to the group -alkyl-SO2-alkyl, where alkyl is as defined herein.

[0062] The term "alkylsulfonimidoyl" refers to the group -S(=O)(=NH)-alkyl, where alkyl is as defined herein.

[0063] The term "alkylsulfoxide" refers to the group -(S=O)-alkyl, where alkyl is as defined herein.

[0064] The term "alkylsulfoxidealkyl" refers to the group -alkyl-SO-alkyl, where alkyl is as defined herein.

[0065] The term "alkyne" refers to compounds that are unsaturated due to the presence of one or more carbon-carbon triple bonds. Alkynyl groups typically and preferably have the same number of carbon atoms as given above for alkyl groups. Non-limiting examples of alkynyl groups are ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyl and its isomers, 2-hexynyl and its isomers, and the like.

[0066] The term "alkynealkyl" refers to the group -alkyl-alkyne, where alkyl and alkyne are defined herein.

[0067] The term "amino" refers to the group -NH2.

[0068] The term "aminoalkyl" refers to the group -alkyl-NH2, where alkyl is as defined herein.

[0069] The term "aminoalkylaminocarbonyl" refers to the group -(C=O)-NH-alkyl-NH2, where alkyl is as defined herein.

[0070] The term "aminoalkylcarbonylamino" refers to the group -NH-(C=O)-alkyl-NH2, where alkyl is as defined herein.

[0071] The term "aminocarbonyl" refers to the group -(C=O)-NH2.

[0072] The term “(aminocarbonylalkyl)(alkyl)amino” refers to the group —NR 1 R 2 In the formula, R 1 is an alkyl group, and R 2 is an -alkyl-(C=O)-NH group, where alkyl is as defined herein.

[0073] The term "aminocarbonylalkylamino" refers to the group -NH-alkyl-(C=O)-NH2, where alkyl is as defined herein.

[0074] The term "aminosulfonyl" refers to the group -SO2-NH2.

[0075] The term "antioxidant" refers to an agent that reduces or prevents the oxidation of other substances.

[0076] The term "aryl" refers to a polyunsaturated aromatic hydrocarbyl group having a single ring (i.e., phenyl) or multiple aromatic rings fused together (e.g., naphthyl), typically containing 5 to 12, preferably 5 to 10, atoms, more preferably 5 or 6 membered aryl. Non-limiting examples of aryl include phenyl, naphthalenyl.

[0077] The term "carbonyl" refers to the group -(C=O)-.

[0078] The term "carbonylamino" refers to the group -NH-(C=O)-.

[0079] The term "cycloalkyl" refers to a cyclic alkyl group, i.e., a monovalent, saturated, or unsaturated hydrocarbyl group having one or two ring structures. Cycloalkyl includes monocyclic or bicyclic hydrocarbyl groups. Cycloalkyl groups may contain three or more carbon atoms in the ring, and according to the present invention generally contain 3 to 10, more preferably 3 to 8 carbon atoms, and even more preferably, the cycloalkyl is a 5- or 6-membered cycloalkyl. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Not determined.

[0080] The term "cycloalkyloxy" refers to the group --O-cycloalkyl, where cycloalkyl is as defined herein.

[0081] The term "dialkylamino" refers to the group -NR 1 R 2 R 1 and R 2 are each independently an alkyl group as defined herein.

[0082] The term "dialkylaminoalkyl" refers to the group -alkyl-NR 1 R 2 R 1 and R 2 are each independently an alkyl group as defined herein.

[0083] The term "dialkylaminoalkylaminocarbonyl" refers to the group -(C=O)-NH-alkyl-NR 1 R 2 R 1 and R 2 are all alkyl groups as defined herein.

[0084] The term "dialkylaminoalkylcarbonyl" refers to the group -(C=O)-alkyl-NR 1 R 2 R 1 and R 2 are all alkyl groups as defined herein.

[0085] The term "dihydroxyalkyl" refers to an alkyl group, as defined herein, substituted with two hydroxyl (-OH) groups.

[0086] The term "halo" or "halogen" refers to fluoro, chloro, bromo, or iodo.

[0087] The term "heteroaryl" refers to an aryl group, as defined herein, in which at least one carbon atom is replaced by a heteroatom. In other words, it refers to a ring system containing an aromatic monocyclic ring of 5-12 carbon atoms, or two rings fused together, usually containing 5-6 atoms, in which one or more carbon atoms in the ring are replaced by oxygen, nitrogen, and / or sulfur atoms, in which the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. Non-limiting examples of such heteroaryls include oxazolyl, thiazolyl, imidazolyl, furanyl, and pyrrolyl. Preferably, the heteroaryl is a 5- or 6-membered heteroaryl, and more preferably, the 5- or 6-membered heteroaryl is furyl.

[0088] The term "heterocyclyl" refers to a non-aromatic, fully saturated, or partially unsaturated cyclic group having at least one heteroatom in a ring containing at least one carbon atom (e.g., a 3- to 7-membered monocyclic, a 7- to 11-membered bicyclic, or one containing a total of 3 to 10 ring atoms). Preferably, the heterocyclyl is a 5- or 6-membered heterocyclyl. Each ring of a heteroatom-containing heterocyclic group may have 1, 2, 3, or 4 heteroatoms selected from nitrogen, oxygen, and / or sulfur atoms, where the heteroatom nitrogen and sulfur may be optionally oxidized and the heteroatom nitrogen may be optionally quaternized. The heterocyclic group may be attached to any heteroatom or carbon atom of the ring or ring system, as valence permits. The rings of a polycyclic heterocycle may be fused, bridged, and / or joined through one or more spiro atoms. Non-limiting examples of heterocyclic groups include aziridinyl, oxiranyl, thiiranyl, piperidinyl, azetidinyl, 2-imidazolinyl, pyrazolidinylimidazolidinyl, isoxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, succinimidyl, 3H-indolyl, indolinyl, isoindolinyl, 2H-pyrrolyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 4H-quinolizinyl, 2-oxopiperazinyl, piperazinyl, homopiperazinyl, 2-piperazinyl, Lazolinyl, 3-pyrazolinyl, tetrahydro-2H-pyranyl, 2H-pyranyl, 4H-pyranyl, 3,4-dihydro-2H-pyranyl, oxetanyl, thietanyl, 3-dioxolanyl, 1,4-dioxanyl, 2,5-dioximidazolidinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, indolinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydroquinolinyl, tetrahydroisoquinolin-1- ... isoquinolin-2-yl, tetrahydroisoquinolin-3-yl, tetrahydroisoquinolin-4-yl, thiomorpholin-4-yl, 1-oxide-1-thiomorpholin-4-yl, 1-dioxide-1-thiomorpholin-4-yl, 1,3-dioxolanyl, 1,4-oxathianyl, 1,4-dithianyl, 1,3,5-trioxanyl, 1H-pyrrolidinyl, tetrahydro-1,1-dioxothiophenyl, N-formylpiperazinyl, and morpholin-4-yl.

[0089] The term "heterocyclylalkylaminocarbonyl" refers to the group -(C=O)-NH-alkyl-heterocyclyl, where alkyl and heterocyclyl are as defined herein.

[0090] The term "(heterocyclyl)(alkyl)aminoalkyl" refers to the group -alkyl-NR 1 R 2 In the formula, R 1 is an alkyl group, and R 2 is a heterocyclyl group, where alkyl and heterocyclyl are as defined herein.

[0091] The term "heterocyclylcarbonyl" refers to the group -(C=O)-heterocyclyl, where heterocyclyl is as defined herein.

[0092] The term "heterocyclylalkyl" refers to the group -alkyl-heterocyclyl, where alkyl and heterocyclyl are as defined herein.

[0093] The term "heterocyclyloxy" refers to the group --O-heterocyclyl, where heterocyclyl is as defined herein.

[0094] The term "heterocyclylsulfonyl" refers to the group -SO2-heterocyclyl, where heterocyclyl is as defined herein.

[0095] The term "hydroxyalkyl" refers to the group -alkyl-OH, where alkyl is as defined herein. The term "hydroxyalkylaminoalkyl" refers to the group -alkyl-NH-alkyl-OH, where alkyl is as defined herein.

[0096] The term "hydroxycarbonyl" refers to the group -C(=O)-OH, where carbonyl is as defined herein. In other words, "hydroxycarbonyl" corresponds to a carboxylic acid group.

[0097] The term "oxo" refers to the substituent ═O.

[0098] The term "sulfonylamino" refers to the group -NH-SO2.

[0099] The term "about" preceding a number encompasses values ​​above and below that number by 10% (such as above and below 1%). It should be understood that the value that the term "about" refers to is itself preferably also expressly disclosed.

[0100] The term "administration" or variations thereof (e.g., "administering") refers to administration of an active agent or ingredient (e.g., an A2AR inhibitor) alone or as part of a pharma- ceutical acceptable composition. or anti-cancer agent) to a patient in order to treat or prevent a condition, symptom, or disease.

[0101] The term "autologous" refers to any material that is derived from the same individual into which it is later reintroduced.

[0102] The term "allogeneic" refers to any material derived from a different individual of the same species as the individual into which the material is introduced. Two or more individuals are said to be allogeneic to one another if the genes located at one or more loci are not identical.

[0103] In some aspects, allogeneic material from individuals of the same species may be sufficiently genetically distinct to interact antigenically.

[0104] "I C 50 The term "half maximal inhibitory concentration" refers to the concentration of inhibitor required for 50% inhibition in vitro.

[0105] The term "inhibitor" refers to a natural or synthetic compound that has the biological effect of inhibiting or significantly reducing or downregulating the expression of a gene and / or protein, or inhibiting or significantly reducing the biological activity of a protein. Thus, an "A2AR inhibitor" refers to a compound that has the biological effect of inhibiting or significantly reducing or downregulating the biological activity of the A2A receptor.

[0106] The term "human" refers to subjects of both sexes at any stage of development (i.e., neonate, infant, juvenile, adolescent, adult).

[0107] The term "patient" refers to a warm-blooded animal or mammal, more preferably a human, awaiting or receiving medical care, or being the subject or recipient of medical treatment.

[0108] The term "pharmaceutical acceptable" means that the components of a pharmaceutical composition are compatible with each other and not harmful to the subject to which it is administered.

[0109] The expression "pharmaceutically acceptable carrier, diluent, excipient, and / or adjuvant" refers to a substance that does not produce side effects, allergic reactions, or other harmful reactions when administered to an animal, preferably a human. It includes any inactive substance, such as, for example, solvents, cosolvents, antioxidants, surfactants, stabilizers, emulsifiers, buffers, pH adjusters, preservatives (or preservatives), antibacterial and antifungal agents, isotonicity agents, granulating or binding agents, lubricants, disintegrants, glidants, diluents or fillers, adsorbents, dispersing agents, suspending agents, coating agents, bulking agents, stripping agents, absorption retardants, sweeteners, flavoring agents, etc. For human administration, preparations should meet the standards of sterility, pyrogenicity, general safety, and purity required by regulatory authorities, such as, for example, the FDA or EMA.

[0110] As used herein, the term "pre-drug" means any compound that is modified to form a drug species, which modification can occur either inside or outside the body, before or after the pre-drug reaches the area of ​​the body requiring administration of the drug.

[0111] As used herein, the terms "prevent", "preventing" and "prevention" refer to a method of delaying or eliminating the onset of a condition or disease and / or its attendant symptoms, barring a patient from contracting a condition or disease, or reducing a patient's risk of contracting a condition or disease.

[0112] The term "prodrug" as used herein refers to a pharmacologically acceptable derivative of a compound of formula (I), such as an ester or amide, whose in vivo biotransformation product produces a biologically active drug. Prodrugs are generally characterized by increased bioavailability and are readily metabolized in vivo to the biologically active compound.

[0113] The term "therapeutically effective amount" or "therapeutically effective dose" refers to an amount or dose of an active ingredient intended to (1) delay or prevent the onset of cancer in a subject; (2) reduce the severity or incidence of cancer; (3) slow or stop the progression, severity, or worsening of one or more symptoms of cancer affecting the subject; (4) effect an improvement in the symptoms of cancer affecting the subject; or (5) cure the cancer affecting the subject, without causing significant negative or harmful side effects to the subject. A therapeutically effective amount may be administered prior to the onset of cancer as a prophylactic or preventative treatment. Alternatively, or in addition, a therapeutically effective amount may be administered after the onset of cancer as a therapeutic treatment.

[0114] The term "treating" or "treatment" refers to curative treatment, where the aim is to prevent or slow down the targeted pathological condition or disease. A subject or mammal is successful in "treating" a disease or disorder or condition if, after undergoing treatment according to the present invention, the subject or mammal shows an observable and / or measurable reduction or elimination of one or more of the following: reduction in the number of cancer cells; and / or some alleviation of one or more symptoms associated with a particular disease or condition; reduced morbidity and mortality, and improved quality of life issues. The above parameters for assessing the success and improvement of disease treatment can be easily measured by routine procedures familiar to physicians.

[0115] The term "subject" refers to a mammal, preferably a human. In one embodiment, the subject has been diagnosed with cancer. In one embodiment, the subject is a patient, preferably a human patient, awaiting or undergoing medical treatment, or being the subject of a medical procedure, or being monitored for the development or progression of a disease, such as cancer. In one embodiment, the subject is a human patient being treated and / or monitored for the development or progression of cancer. In one embodiment, the subject is male. In another embodiment, the subject is female. In one embodiment, the subject is an adult. In another embodiment, the subject is a child. The term "tumor-specific antigen" or "tumor-associated antigen" refers to an antigen that is specifically and / or abundantly expressed by cancer or tumor cells. T cells expressing T cell receptors that recognize and bind to the antigen may be referred to as tumor-specific or tumor-associated antigen-recognizing T cells, tumor-specific or tumor-associated antigen-specific T cells, tumor-specific or tumor-associated antigen-specific T cells, or tumor-specific or tumor-associated antigen-directed T cells.

[0116] The term "vaccine" refers to a preparation containing a substance or group of substances (i.e., vaccines) intended to induce and / or enhance a targeted immune response in a subject against an infectious agent (such as a virus, bacteria, fungus, or parasite) or against cancer cells. Vaccination is used to prevent a subject from always suffering from a particular disease or to only suffer from a mild case of the disease. Therapeutic vaccination aims to treat a particular disease in a subject. For example, a therapeutic anti-cancer vaccine may contain one tumor-associated antigen, or multiple tumor-associated antigens, and aims to induce and / or enhance a cell-mediated immune response, in particular a T-cell immune response, against cancer cells expressing said tumor-associated antigen(s). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0117] A2AR inhibitors The present invention relates to a pharmaceutical composition comprising at least one A2A adenosine receptor (A2AR) inhibitor and a combination of an anticancer drug. The A2AR inhibitor is a thiocarbamate derivative, in particular a thiocarbamate derivative such as those disclosed in PCT / EP2018 / 058301. More preferably, the A2AR inhibitor is a thiocarbamate derivative of formula (I) as described below.

[0118] In one embodiment, the thiocarbamate derivative A2AR inhibitor has formula (I): [ka] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 represents a 5- or 6-membered heteroaryl or a 5- or 6-membered aryl, the heteroaryl or aryl group being optionally substituted with one or more substituents selected from C1-C6 alkyl (preferably methyl) and halo (preferably fluoro or chloro), preferably R 1 represents a 5-membered heteroaryl, more preferably R 1 stands for frill; R 2 represents a 6-membered aryl or a 6-membered heteroaryl; The heteroaryl or aryl group is optionally substituted with one or more substituents selected from halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino, and alkylsulfonealkyl; The above substituents are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydrocarbyl, hydroxyalkyl, hydroxyalkylamino ... or substituted with one or more substituents selected from oxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; Alternatively, a heteroaryl or aryl group is optionally substituted with two substituents that, together with the atom to which they are attached, form a 5- or 6-membered aryl ring, a 5- or 6-membered heteroaryl ring, a 5- or 6-membered cycloalkyl ring, or a 5- or 6-membered heterocyclyl ring, and optionally includes oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, hete and substituted with one or more substituents selected from: aryl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

[0119] In one embodiment, preferred compounds of formula (I) have the formula (Ia): [ka] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 represents a 5- or 6-membered heteroaryl or a 5- or 6-membered aryl, the heteroaryl or aryl group being optionally substituted with one or more substituents selected from C1-C6 alkyl (preferably methyl) and halo (preferably fluoro or chloro), preferably R 1 represents a 5-membered heteroaryl, more preferably R 1 stands for frill; X 1 and X 2 each independently represents C or N; X 1 If N, then R 1’ does not exist or X 1 If C, then R 1’represents H, halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino, or alkylsulfonealkyl; The above substituents are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydride, substituted with one or more substituents selected from alkyloxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; R 2’ is H, halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxyl, represents a carbonyl, a heterocyclylcarbonyl, an alkylsulfoxide, an alkylsulfonyl, an aminosulfonyl, a heterocyclylsulfonyl, an alkylsulfonimidoyl, a carbonylamino, a sulfonylamino, or an alkylsulfonealkyl; The above substituents are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydrocarbyl, hydroxyalkyl, hydroxyalkylamino ... or substituted with one or more substituents selected from oxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; Or, R 1’ and R 2’together with the atoms to which they are attached form a 5- or 6-membered aryl ring, a 5- or 6-membered heteroaryl ring, a 5- or 6-membered cycloalkyl ring, or a 5- or 6-membered heterocyclyl ring, and are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkyla substituted with one or more substituents selected from amino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; R 3’ X 2 does not exist if N, or X 2 If C, then R 3’ represents H or halo, preferably H or F; R 4’ represents H or halo, preferably H or F; R 5’ represents H or halo, preferably H or F.

[0120] In one specific embodiment of the present invention, R 1represents a 5- or 6-membered heteroaryl or a 5- or 6-membered aryl, the heteroaryl or aryl group being optionally substituted with one or more substituents selected from C1-C6 alkyl (preferably methyl) and halo (preferably fluoro or chloro). 1 represents a 5-membered heteroaryl, more preferably R 1 represents a frill.

[0121] In a specific embodiment of the present invention, X 1 and X 2 each independently represents C or N. In another specific embodiment, X 1 and X 2 Both represent C.

[0122] In one specific embodiment of the present invention, R 1’ X 1 does not exist when N.

[0123] In another specific embodiment, X 1 If C, then R 1’represents H, halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino, or alkylsulfonealkyl, wherein the above substituents are optionally selected from oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, a and substituted with one or more substituents selected from alkyl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

[0124] In a preferred embodiment, R 1’The substituents are optionally substituted with one or more substituents selected from halo, hydroxy, alkyl, heterocyclylalkyl, hydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, heterocyclylalkylaminocarbonyl, (aminocarbonylalkyl)(alkyl)amino, hydroxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, heterocyclylcarbonyl, alkylsulfoxide, and alkylsulfonealkyl.

[0125] In one specific embodiment of the present invention, R 2’represents H, halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino, or alkylsulfonealkyl, wherein the above substituents are optionally oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)( (alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl and substituted with one or more substituents selected from alkyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

[0126] In a preferred embodiment, R 2’The substituents are optionally substituted with one or more substituents selected from oxo, halo, hydroxy, cyano, alkyl, heterocyclylalkyl, dihydroxyalkyl, dialkylaminoalkyl, heteroaryl, alkylheteroaryl, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, heterocyclylalkylaminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, alkylsulfoxide, alkylsulfonealkyl.

[0127] In another specific embodiment of the invention, R 1’ and R 2’ together with the atoms to which they are attached form a 5- or 6-membered aryl ring, a 5- or 6-membered heteroaryl ring, a 5- or 6-membered cycloalkyl ring, or a 5- or 6-membered heterocyclyl ring, and are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, and substituted with one or more substituents selected from: (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

[0128] In one specific embodiment of the present invention, R 3’ X 2 is absent when R is N. 3’ X 2 When is C, it represents H or halo. In a preferred embodiment, R 3’ X 2 When is C, it represents H or F.

[0129] In one specific embodiment of the present invention, R 4’ represents H or halo. In a preferred embodiment, R 4’ represents H or F.

[0130] In one specific embodiment of the present invention, R 5’ represents H or halo. In a preferred embodiment, R 5’ represents H or F.

[0131] In one embodiment, a preferred compound of formula (Ia) has the formula (Ia-1): [ka] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 , R 1’ , R 2’ , R 3’ , R 4’ , and R 5’ is as defined in formula (Ia).

[0132] In one embodiment, a preferred compound of formula (Ia-1) is of formula (Ia-1a): [ka] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 and R 3’ is as defined in formula (Ia); R 1’’is an oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxy, and represents an alkyl or heterocyclyl group substituted with one or more groups selected from the group consisting of alkoxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

[0133] In one specific embodiment of the present invention, R 1’’is an oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxy, and represents an alkyl or heterocyclyl group substituted with one or more groups selected from the group consisting of alkoxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

[0134] In a preferred embodiment, R 1’’ is hydroxy, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, hydroxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, hetero It represents an alkyl or heterocyclyl group substituted with one or more groups selected from cyclylcarbonyl, alkylsulfoxide, and alkylsulfonealkyl.

[0135] In one embodiment, preferred compounds of formula (Ia-1) have the formula (Ia-1b): [ka] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 and R 3’ is as defined in formula (Ia); R 1’ represents H or halo, preferably H or F; R 2’’ is an oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxy, and represents an alkyl or heterocyclyl group substituted with one or more groups selected from the group consisting of alkoxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

[0136] In one specific embodiment of the present invention, R 1’ represents H or halo. In a preferred embodiment, R 1’ represents H or F.

[0137] In one specific embodiment of the present invention, R 2’’ is an oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxy, and represents an alkyl or heterocyclyl group substituted with one or more groups selected from the group consisting of alkoxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

[0138] In a preferred embodiment, R 2’’ represents an alkyl or heterocyclyl group substituted with one or more groups selected from hydroxy, cyano, heteroaryl, alkylheteroaryl, alkyne, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, alkylsulfoxide, and alkylsulfonealkyl.

[0139] In one embodiment, preferred compounds of formula (Ia-1) have the formula (Ia-1c) or (Ia-1d): [ka] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 and R 3’ is as defined in formula (Ia); R 1’ represents H or halo, preferably H or F; R 2’ represents H or halo, preferably H or F; R 1i and R 1ii each independently represents hydrogen, hydroxy, alkyl, alkenyl, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkynealkyl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxidealkyl, or alkylsulfonealkyl; R 2i and R 2iiare each independently hydrogen, hydroxy, alkyl, alkenyl, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkynealkyl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl

[0046] It represents heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxidealkyl, or alkylsulfonealkyl.

[0140] In one specific embodiment of the present invention, R 1’ represents H or halo. In a preferred embodiment, R 1’ represents H or F.

[0141] In one specific embodiment of the present invention, R 2’ represents H or halo. In a preferred embodiment, R 2’ represents H or F.

[0142] In one specific embodiment of the present invention, R 1i and R 1iieach independently represents hydrogen, hydroxy, alkyl, alkenyl, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkynealkyl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxidealkyl, or alkylsulfonealkyl.

[0143] In a preferred embodiment, R 1i and R 1ii each independently represents hydrogen, alkyl, heterocyclylalkyl, hydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, or heterocyclylalkylaminocarbonyl.

[0144] In one specific embodiment of the present invention, R 2i and R 2iieach independently represents hydrogen, hydroxy, alkyl, alkenyl, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkynealkyl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxidealkyl, or alkylsulfonealkyl.

[0145] In a preferred embodiment, R 2i and R 2ii each independently represents hydrogen, alkyl, heterocyclylalkyl, dihydroxyalkyl, dialkylaminoalkyl, or heterocyclylalkylaminocarbonyl. 2i and R 2 ii each independently represents hydrogen, alkyl, or dialkylaminoalkyl.

[0146] In one embodiment, preferred compounds of formula (Ia) have the formula (Ia-2) or (Ia-3): [ka] [ka] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 , R 2’ , R 3’ , R 4’ , and R 5’ is as defined in formula (Ia).

[0147] Particularly preferred compounds of formula (I) of the present invention are those listed in Table 1 below, as well as pharma- ceutically acceptable salts and solvates thereof. Table 1 [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13]

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-22

Table 1-23

Table 1-24

Table 1-25

Table 1-26

Table 1-27

Table 1-28

Table 1-29

Table 1-30

[0148] In Table 1, the term "Cpd" refers to compound.

[0149] The compounds in Table 1 were named using ChemBioDraw® Ultra version 12.0 (PerkinElmer).

[0150] In one embodiment, the compound of formula (I) is selected from: (R,S)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one (compound 7); (+)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one (compound 8a) and (−)-5-Amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one (compound 8b).

[0151] In specific embodiments, the compound of formula (I) is selected from: (R,S)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one (compound 7); and (+)-5-Amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one (compound 8a).

[0152] In a preferred embodiment, the compound of formula (I) is (+)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one (compound 8a).

[0153] In one embodiment, the present invention also relates to the enantiomers, salts, solvates, polymorphs, multi-component complexes, and liquid crystals of the compounds of formula (I) and sub-formulas thereof.

[0154] In one embodiment, the present invention also relates to polymorphs and crystal phases of compounds of formula (I) and sub-formulas thereof, prodrugs and isomers thereof (including optical isomers, geometric isomers and tautomeric isomers), and isotopically labeled compounds of formula (I) and sub-formulas thereof.

[0155] The compounds of formula (I) and its subformulas may contain asymmetric centers and therefore may exist in different stereoisomeric forms. The present invention therefore encompasses all possible stereoisomers, including not only racemates but also individual enantiomers and non-racemic mixtures thereof. When a compound is desired as a single enantiomer, it can be obtained by stereospecific synthesis, by resolution of the final product or any convenient intermediate, or by chiral chromatographic methods, each of which are known in the art. Resolution of the final product, intermediate, or starting material can be carried out by any suitable method known in the art.

[0156] The compounds of the present invention may be in the form of pharmaceutically acceptable salts. The pharmaceutically acceptable salts of the compounds of formula (I) and its subformulas include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include acetate, adipate, aspartate, benzoate, besylate, bicarbonate / carbonate, bisulfate / sulfate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hybenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isothioate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate, and xinafoate. Suitable base salts are formed from bases which form non-toxic salts. Examples include aluminum salts, arginine salts, benzathine salts, calcium salts, choline salts, diethylamine salts, diolamine salts, glycine salts, lysine salts, magnesium salts, meglumine salts, olamine salts, potassium salts, sodium salts, tromethamine salts, 2-(diethylamino)ethanol salts, ethanolamine salts, morpholine salts, 4-(2-hydroxyethyl)morpholine salts, and zinc salts. Hemi-salts of acids and bases can also be formed, such as hemi-sulfate and hemicalcium salts. Preferred pharma-ceutically acceptable salts include hydrochloride / chloride salts, hydrobromide / bromide salts, bisulfate / sulfate salts, nitrates, citrates, tosylates, esylates, and acetate salts. Particularly preferred are In a preferred embodiment, the compound of formula (I) is in the form of an HCl salt or an esylate salt.

[0157] When the compounds of the present invention contain a basic group in addition to an acidic group, the compounds of the present invention can also form internal salts, and such compounds are within the scope of the present invention. When the compounds of the present invention contain a hydrogen-donating heteroatom (e.g., NH), the present invention also includes salts and / or isomers formed by the transfer of said hydrogen atom to a basic group or atom within the molecule.

[0158] Pharmaceutically acceptable salts of the compounds of formula (I) and sub-formulas thereof include (i) reacting a compound of formula (I) with a desired acid; (ii) reacting a compound of formula (I) with a desired base; (iii) removing an acid- or base-labile protecting group from a suitable precursor of a compound of formula I, or ring-opening a suitable cyclic precursor, such as a lactone or lactam, with a desired acid; or (iv) can be prepared by one or more of the following methods: converting one salt of a compound of formula (I) to another salt by reaction with an appropriate acid or by using a suitable ion exchange column.

[0159] All of these reactions are usually carried out in solution. The salts can precipitate from solution and be collected by filtration or recovered by evaporation of the solvent. The degree of ionization in the salts can vary from completely ionized to nearly non-ionized.

[0160] The compounds of the present invention can be administered in the form of a pharma- ceutically acceptable salt. The term "pharma-ceutically acceptable salt" includes acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methyl bromide, bromide, methyl nitrate, calcium edetate, methyl sulfate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estholate, palmitate, esylate, pantothenate, fumarate, lysine ... The term "acid salt" is intended to include all acceptable salts which can be used as dosage forms to modify solubility or hydrolysis characteristics or can be used in sustained release or prodrug formulations, such as phosphate / diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycolylarsanilate, sulfate, hexylresorcinate, subacetate, hydrabamate, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, theoclate, iodide, tosylate, isothioate, triethiodide, lactate, pamoate, valerate, and the like. Depending on the specific function of the compound of the present invention, pharma- ceutically acceptable salts of the compounds of the present invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and the like, and those formed from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethyl-amine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.

[0161] These salts can be prepared by standard procedures, for example by reacting the free acid with a suitable organic or inorganic base. When a basic group such as amino is present, acid salts, i.e., hydrochloride, hydrobromide, acetate, pamoate, esylate, tosylate, etc., can be used as formulations.

[0162] In addition, with regard to salts of the compounds of the present invention, generally, pharma- ceutically acceptable salts are preferred, but in the broadest sense, it should be noted that non-pharma-ceutically acceptable salts that can be used, for example, for isolating and / or purifying the compounds of the present invention are also included in the present invention. For example, salts formed with optically active acids or bases can be used to form diastereoisomeric salts that can facilitate the separation of optically active isomers of the compounds of formula (I) above.

[0163] The compounds of the present invention may be in the form of pharmaceutically acceptable solvates.The pharmaceutically acceptable solvates of the compounds of formula (I) and its sub-formulas contain stoichiometric or substoichiometric amounts of one or more pharmaceutically acceptable solvent molecules, such as ethanol or water.The term "hydrate" refers to when the solvent is water.

[0164] The present invention also generally encompasses pharma- ceutically acceptable pre- and prodrugs of the compounds of formula (I) and subformulas thereof.

[0165] Also, where an alcohol group is present, pharma- ceutically acceptable esters, such as acetates, maleates, pivaloyloxymethyl, and the like, can be used and are known in the art to have altered solubility or hydrolysis characteristics and are used as sustained-release or prodrug formulations.

[0166] Pharmaceutical Compositions Thus, the present invention relates to a pharmaceutical composition comprising as a pharma- ceutical active ingredient an A2A inhibitor, preferably a thiocarbamate derivative, more preferably a thiocarbamate derivative of formula (I) above, and at least one pharma- ceutically acceptable carrier, diluent, excipient, and / or adjuvant.

[0167] In one embodiment, the pharmaceutical composition of the present invention comprises an A2A inhibitor, such as a thiocarbamate derivative of formula (I) above, and at least one lipid carrier. In one embodiment, the lipid carrier is selected from lauroyl polyoxyl-32 glyceride, D-α-tocopherol-polyethylene glycol-1000 succinate, and mixtures thereof. In one embodiment, the lipid carrier is lauroyl polyoxyl-32 glyceride. In another embodiment, the lipid carrier is -α-tocopherol-polyethylene glycol-1000 succinate. In another embodiment, the lipid carrier is a mixture of lauroyl polyoxyl-32 glyceride and D-α-tocopherol-polyethylene glycol-1000 succinate.

[0168] Thus, in one embodiment, the present invention provides a method for producing a composition comprising: (a) formula (I); [ka] (In the formula, R 1 and R 2 is as defined above), or a pharma- ceutically acceptable salt or solvate thereof; (b) a lipid carrier selected from lauroyl polyoxyl-32 glyceride, D-α-tocopherol-polyethylene glycol-1000 succinate, and mixtures thereof; (c) optionally, providing a pharmaceutical composition comprising one or more other pharma- ceutically acceptable carriers, diluents, excipients, and / or adjuvants.

[0169] In one embodiment, the present invention provides (a) A compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof,1 and R 2 is as defined above); (b) lauroyl polyoxyl-32 glyceride; (c) optionally, providing a pharmaceutical composition comprising one or more other pharma- ceutically acceptable carriers, diluents, excipients, and / or adjuvants.

[0170] In another embodiment, the present invention provides (a) A compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, 1 and R 2 is as defined above); (b) D-α-tocopherol-polyethylene glycol-1000 succinate; and (c) optionally, providing a pharmaceutical composition comprising one or more other pharma- ceutically acceptable carriers, diluents, excipients, and / or adjuvants.

[0171] active ingredient Thus, the pharmaceutical composition of the present invention comprises, as a pharma- ceutical active ingredient, a compound of formula (I) or a pharma- ceutical acceptable salt or solvate thereof, 1 and R 2 is as defined above).

[0172] All of the embodiments relating to A2AR inhibitors detailed above apply to the pharmaceutical compositions of the present invention.

[0173] Lipid Carriers The pharmaceutical compositions of the present invention include a lipid carrier, preferably lauroyl polyoxyl-32 glyceride, D-α-tocopherol-polyethylene glycol-1000 succinate, or a mixture thereof.

[0174] In one embodiment, the pharmaceutical composition of the invention comprises lauroyl polyoxyl-32 glyceride. This excipient corresponds to Gelucire® 44 / 14 manufactured by Gattefosse (Saint-Priest-France). This excipient is also known under the following references: - Lauroyl polyoxyl-32 glycerides NF / USP (NF: National Formulary; USP: United States Pharmacopeia); - Lauroyl Macrogol-32 Glycerides EP (European Pharmacopoeia); - Hydrogenated Coconut PEG-32 Esters (INCI); - CAS number 57107-95-6.

[0175] Gelucire® 44 / 14 corresponds to a well-defined multicomponent substance composed of mono-, di- and triglycerides of lauric acid (C12) and PEG-32 mono- and diesters. Gelucire® 44 / 14 has a melting point in the range of 42.5°C to 47.5°C (44°C average) and a hydrophilic / lipophilic balance (HLB) value of 14.

[0176] Gelucire® 44 / 14 is used to enhance the wettability, dissolution, solubility, and bioavailability of active ingredients.

[0177] In another embodiment, the pharmaceutical composition of the invention comprises D-α-tocopherol-polyethylene glycol-1000 succinate, which corresponds to Vitamin E TPGS and is also known under the following references: - D-α-tocopherol polyethylene glycol-1000 succinate; - Tocophersolan; - Tocofersolan; - VEGS; - α-[4-[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-1,4-dioxobutyl]-ω-hydroxy-poly(oxy-1,2-ethanediyl); - Vitamin E PEG Succinate; - CAS number 9002-96-4.

[0178] Vitamin E TPGS corresponds to a well-defined substance consisting of D-α-tocopherol (vitamin E) complexed with polyethylene glycol 1000 via a succinic acid linker, with a melting point in the range of 37°C to 41°C and a hydrophilic / lipophilic balance (HLB) value of 13.

[0179] Vitamin E TPGS is used to enhance the wettability, solubility, solubility, and bioavailability of active ingredients.

[0180] The pharmaceutical compositions may include Vitamin E TPGS in addition to, or in place of, lauroyl polyoxyl-32 glyceride.

[0181] Further ingredients The pharmaceutical compositions of the present invention may optionally contain one or more other pharma- ceutically acceptable carriers, diluents, excipients, and / or adjuvants.Such suitable carriers, diluents, excipients, and / or adjuvants for use in preparing dosage forms will be apparent to those skilled in the art, see the latest edition of Remington's Pharmaceutical Sciences.

[0182] In particular, the pharmaceutical composition of the present invention may optionally contain such inactive substances commonly used in pharmaceutical formulations, such as cosolvents, antioxidants, surfactants, wetting agents, emulsifiers, buffers, pH adjusters, preservatives (or preservatives), isotonicity agents, stabilizers, granulating agents or binders, precipitation inhibitors, lubricants, disintegrants, glidants, diluents or fillers, adsorbents, dispersing agents, suspending agents, bulking agents, release agents, sweeteners, flavoring agents, and the like.

[0183] According to one embodiment, the pharmaceutical composition of the present invention comprises one or more pharma- ceutically acceptable inactive ingredients selected from the following: caprylic acid, polyethylene glycol, propylene glycol, ethanol, glycerol, dimethyl sulfoxide, dimethylacetamide, dimethylisosorbide, cellulose derivatives (including hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, and hydroxypropylmethylcellulose acetate succinate), Cremophor RH40 (Polyoxyl 40 hydrogenated castor oil), Cremophor EL (Polyoxyl 35 hydrogenated castor oil), Polysorbate 20 (Polyoxyethylene sorbitan monolaurate), Polysorbate 80 (Polyoxyethylene sorbitan monooleate), Poloxamer 188 (Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)), Poloxamer 407 (Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)), Cole), Vitamin E TPGS (Vitamin E Polyethylene Glycol Succinate), solutol HS15 (Polyoxyethylated 12-Hydroxystearic Acid), labrasol (Caprylocaproyl Polyoxyl-8 Glyceride), labrafil M1944 (oleoyl polyoxyl-6 glyceride), polyvinylpyrrolidone (also called povidone, preferably polyvinylpyrrolidone K17, K19, K29-K32, K90), polyvinylpyrrolidone-polyvinyl acetate copolymer, polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®), polylactide-polyethylene glycol block copolymer, carboxymethylcellulose (Na / Ca), polyethylene glycol methyl ether-block-poly(DL-lactide) copolymer, sodium lauryl sulfate, sodium docusate, propylene glycol monolaurate, propylene glycol dilaurate, propylene glycol monocaprylate, polyethylene glycol 660 12-monostearate, poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1, sodium lauryl sulfate.

[0184] In a preferred embodiment, the pharmaceutical composition of the present invention comprises one or more pharma- ceutically acceptable co-solvents. Preferably, the co-solvents are selected from caprylic acid, polyethylene glycol (PEG), propylene glycol, ethanol, dimethyl sulfoxide, dimethylacetamide, dimethylisosorbide, and mixtures thereof. In a specific embodiment, the pharmaceutical composition of the present invention comprises caprylic acid and / or PEG. Advantageously, when the composition comprises PEG as a co-solvent, the PEG is of low molecular weight, preferably, the PEG is PEG400. In an alternative embodiment, when the composition comprises PEG, the PEG is of medium molecular weight, preferably, the PEG is PEG3350.

[0185] In one embodiment, the pharmaceutical composition of the present invention further comprises one or more antioxidants, preferably, the antioxidant is selected from butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), citric acid, sodium metabisulfite, ascorbic acid, methionine, and vitamin E, more preferably, the antioxidant is BHT.

[0186] In some embodiments, surfactants such as polyethylene glycol, polyoxyethylene sorbitan fatty acid esters, sorbitan esters, sodium docusate, sodium lauryl sulfate, polysorbates (20, 80, etc.), poloxamers (188, 407, etc.), Pluronic® polyols, polyoxyethylene sorbitan monoethers (TWEEN®-20, TWEEN®-80, etc.), vitamin E TPGS (vitamin E polyethylene glycol succinate), Cremophor RH40 (polyoxyl 40 hydrogenated castor oil), Cremophor EL (polyoxyl 35 hydrogenated castor oil), polyethylene glycol 660 12-monostearate, solutol HS15 (polyoxyethylated 12-hydroxystearic acid), labrasol (caprylocaproyl polyoxyl-8 glyceride), labrafil M1944 (oleoyl polyoxyl-6 glyceride), polylactide-polyethylene glycol block copolymer, polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®), etc. are added.

[0187] In some embodiments, wetting agents are added, such as sodium lauryl sulfate, vitamin E TPGS, sodium docusate, polysorbate 80, poloxamer 407, etc. A preferred wetting agent is poloxamer 407.

[0188] In some embodiments, emulsifiers, such as carbomer, carrageenan, lanolin, lecithin, mineral oil, oleic acid, oleyl alcohol, pectin, poloxamer, polyoxyethylene sorbitan fatty acid esters, sorbitan esters, triethanolamine, protease inhibitors, sorbitol, sorbitol esters ... Pyrene glycol monolaurate, propylene glycol dilaurate, propylene glycol monocaprylate, etc. are added. Preferred emulsifiers are, for example, poloxamer, propylene glycol monolaurate, propylene glycol dilaurate, and propylene glycol monocaprylate.

[0189] In some embodiments, a buffer is used to help maintain the pH in a range that approximates physiological conditions. Suitable buffers include organic and inorganic acids and their salts, such as citrate buffers (e.g., monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture, etc.), succinate buffers (e.g., succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, fumaric acid-fumarate mixture, etc.), and the like. Examples of suitable buffers include: disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture, etc.), gluconate buffers (e.g., gluconic acid-sodium gluconate mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium gluconate mixture, etc.), oxalate buffers (e.g., oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture, etc.), lactate buffers (e.g., lactic acid-sodium lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture, etc.), and acetate buffers (e.g., acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture, etc.). Additionally, phosphate buffers, histidine buffers, and trimethylamine salts such as Tris can be used.

[0190] In some embodiments, pH adjusters are added, such as sodium hydroxide, sodium bicarbonate, magnesium oxide, potassium hydroxide, meglumine, sodium carbonate, citric acid, tartaric acid, ascorbic acid, fumaric acid, succinic acid, and malic acid.

[0191] In some embodiments, preservatives are added to prevent microbial growth.Preservatives suitable for use with the present disclosure include phenol, benzyl alcohol, metacresol, methylparaben, propylparaben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides (e.g., chloride, bromide, and iodide), hexamethonium chloride, and alkylparaben such as methylparaben or propylparaben, catechol, resorcinol, cyclohexanol, and 3-pentanol.

[0192] In some embodiments, isotonicity agents, sometimes referred to as "stabilizers," are added and include polyhydric sugar alcohols, such as trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, and mannitol. Stabilizers refer to a broad category of excipients whose function can range from bulking agents to additives that solubilize the therapeutic agent or help prevent denaturation or adhesion to container walls, or help inhibit precipitation, particle growth, or aggregation of the active ingredient. Typical stabilizers include polyhydric sugar alcohols (listed above); amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, and the like; organic sugars or sugar alcohols such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myo-inositol, galactitol, glycerol, and the like, including cyclitols such as inositol; polyethylene glycols; amino acid polymers; sulfur-containing reducing agents such as urea, glutathione, thioctic acid, sodium thioglycolate, thioglycerol, α-monothioglycerol, and sodium thiosulfate; low molecular weight polypeptides (e.g., peptides of 10 residues or less); proteins such as human serum albumin, bovine serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; poloxamer 407; cellulose derivatives such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, or hydroxypropyl methylcellulose acetate succinate; carboxymethylcellulose (Na / Ca); monosaccharides such as xylose, mannose, fructose, glucose; disaccharides such as lactose, maltose, sucrose, and trisaccharides such as raffinose; polysaccharides such as dextran; polyethylene glycol methyl ether-block-poly(DL-lactide) copolymer; poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1. Preferred stabilizers are, for example, glycerol; polyethylene glycol; polyvinylpyrrolidone; cellulose derivatives such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, or hydroxypropyl methylcellulose acetate succinate; carboxymethylcellulose (Na / Ca); polyethylene glycol methyl ether-block-poly(DL-lactide) copolymer; poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1; polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0193] In some embodiments, granulating / binder(s) are added such as, for example, starches, gums (including natural, semi-synthetic, and synthetic), microcrystalline cellulose, ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, polymers such as povidone, polyvinylpyrrolidone-polyvinyl acetate copolymer, etc. Preferred granulating agents are, for example, methyl cellulose, hydroxypropyl cellulose, povidone, and polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0194] In some embodiments, precipitation inhibitors are added, such as water-soluble derivatives of cellulose, including hydroxypropyl methylcellulose and methylcellulose, and water-soluble polymers such as polyvinylpyrrolidone, polyvinylpyrrolidone-polyvinyl acetate copolymer, polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, or poloxamer 407. Preferred precipitation inhibitors are, for example, hydroxypropyl methylcellulose and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0195] In some embodiments, lubricants are added, such as, for example, magnesium stearate, glyceryl esters, behenoyl polyoxyl-8 glyceride Nf (Compritol HD5 ATO), sodium stearyl fumarate, and the like.

[0196] In some embodiments, disintegrants are added, such as synthetics such as sodium starch glycolate, crospovidone, croscarmellose sodium, Kollidon CL, and natural origins such as locust bean gum.

[0197] In some embodiments, glidants are added such as, for example, talc, magnesium stearate, colloidal silicon dioxide, starch, and the like.

[0198] In some embodiments, diluents (or fillers) are added, such as, for example, dextrose, lactose, mannitol, microcrystalline cellulose, sorbitol, sucrose, dicalcium phosphate, calcium sulfate dehydrate, starch, and the like.

[0199] In some embodiments, adsorbents are added, such as, for example, silicon dioxide, purified aluminum silicate, and the like.

[0200] In some embodiments, the pharmaceutical compositions of the present invention are in the form of a tablet and include tabletting excipients such as granulating agents, binders, lubricants, disintegrants, glidants, diluents, adsorbents, and the like.

[0201] In some embodiments, the pharmaceutical composition of the present invention is in the form of a capsule, and the capsule shell is made of gelatin or non-animal products such as cellulose and its derivatives such as hydroxypropylmethylcellulose. Other ingredients can be included in the capsule shell, such as polyethylene glycol, which acts as a plasticizer; pigments such as titanium dioxide or iron oxide, which allow impermeability and color differentiation; lubricants such as carnauba wax; gelling agents such as carrageenan, and wetting agents such as sodium lauryl sulfate. In one embodiment, the pharmaceutical composition of the present invention is formulated as a capsule, in which the capsule shell is made of gelatin, and optionally additional ingredients, such as polyethylene glycol and sodium lauryl sulfate, are included in the capsule shell.

[0202] amount In one embodiment, the pharmaceutical composition of the present invention comprises a compound of formula (I) in an amount ranging from 1% to 20% by weight (w / w) relative to the total weight of the composition. Preferably, the pharmaceutical composition of the present invention comprises a compound of formula (I) in an amount ranging from 5% to 15% w / w, preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w.

[0203] In one embodiment, the pharmaceutical composition of the present invention comprises a lipid carrier in an amount ranging from 55% to 99% by weight (w / w) relative to the total weight of the composition. Preferably, the pharmaceutical composition of the present invention comprises an amount of lipid carrier that is in the range of 60%-95% w / w, preferably 65%-90% w / w, more preferably 70%-90% w / w, about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w.

[0204] In one embodiment, the pharmaceutical composition of the present invention comprises lauroyl polyoxyl-32 glyceride in an amount ranging from 55% to 99% by weight (w / w) relative to the total weight of the composition. Preferably, the pharmaceutical composition of the present invention contains lauroyl polyoxyl-32 glyceride in an amount ranging from 60% to 95% w / w, preferably from 65% to 90% w / w, more preferably from 70% to 90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w.

[0205] In one embodiment, the pharmaceutical composition of the present invention comprises D-α-tocopherol-polyethylene glycol-1000 succinate in an amount ranging from 55% by weight to 99% by weight (w / w) relative to the total weight of the composition. Preferably, the pharmaceutical composition of the present invention comprises an amount of D-α-tocopherol-polyethylene glycol-1000 succinate that is in the range of 60% to 95% w / w, preferably 65% ​​to 90% w / w, more preferably 70% to 90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w.

[0206] In one embodiment, the pharmaceutical composition of the present invention may contain PEG 400 in an amount ranging from 0% to 30% by weight (w / w) based on the total weight of the composition. Preferably, the pharmaceutical composition of the present invention contains PEG 400 in an amount ranging from 5% to 30% w / w, preferably 10% to 25% w / w, more preferably 15% to 20% w / w, more preferably about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w, about 20% w / w, more preferably about 18% w / w.

[0207] In one embodiment, the pharmaceutical composition of the present invention may contain PEG 3350 in an amount ranging from 0% to 30% by weight (w / w) based on the total weight of the composition. Preferably, the pharmaceutical composition of the present invention contains PEG 3350 in an amount ranging from 5% to 30% w / w, preferably 10% to 25% w / w, more preferably 15% to 20% w / w, more preferably about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w, about 20% w / w, more preferably about 18% w / w.

[0208] In one embodiment, the pharmaceutical composition of the present invention may contain caprylic acid in an amount ranging from 0% to 20% by weight (w / w) relative to the total weight of the composition. Preferably, the pharmaceutical composition of the present invention contains caprylic acid in an amount ranging from 1% to 20% w / w, preferably from 3% to 15% w / w, more preferably from 5% to 10% w / w, more preferably about 5% w / w, about 6% w / w, about 7% w / w, about 8% w / w, about 9% w / w, more preferably about 9% w / w.

[0209] In one embodiment, the pharmaceutical composition of the present invention may contain an antioxidant, preferably BHT, in an amount ranging from 0% to 5% by weight (w / w) relative to the total weight of the composition. Preferably, the pharmaceutical composition of the present invention contains BHT in an amount ranging from 0.001% to 5% w / w, preferably from 0.005% to 1% w / w, more preferably from 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w.

[0210] In one embodiment, the pharmaceutical composition of the present invention may comprise a wetting agent, preferably sodium lauryl sulfate (SLS), in an amount ranging from 0% to 10% by weight (w / w) relative to the total weight of the composition. Preferably, the pharmaceutical composition of the present invention comprises SLS in an amount ranging from 0.5% to 5% w / w, preferably from 0.5% to 2% w / w, more preferably from 0.5% to 1.5% w / w, more preferably about 1.0% w / w.

[0211] In one embodiment, the pharmaceutical composition of the present invention may contain a precipitation inhibitor, preferably hydroxypropyl methylcellulose, in an amount ranging from 0% to 10% by weight (w / w) based on the total weight of the composition. Preferably, the pharmaceutical composition of the present invention contains hydroxypropyl methylcellulose in an amount ranging from 0.5% to 5% w / w, preferably 0.5% to 2% w / w, more preferably 0.5% to 1.5% w / w, more preferably about 1% w / w.

[0212] In one embodiment, the pharmaceutical composition of the present invention may contain an alternative precipitation inhibitor, preferably polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, in an amount ranging from 0% to 10% by weight (w / w) based on the total weight of the composition. Preferably, the pharmaceutical composition of the present invention contains polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer in an amount ranging from 0.5% to 5% w / w, preferably 0.5% to 2% w / w, more preferably 0.5% to 1.5% w / w, more preferably about 1.0% w / w.

[0213] In one embodiment, the pharmaceutical composition of the present invention may contain an alternative precipitation inhibitor, preferably poloxamer 407, in an amount ranging from 0% to 10% by weight (w / w) based on the total weight of the composition. Preferably, the pharmaceutical composition of the present invention comprises poloxamer 407 in an amount ranging from 0.5% to 5% w / w, preferably from 0.5% to 2% w / w, more preferably from 0.5% to 1.5% w / w, more preferably about 1.0% w / w.

[0214] In one embodiment, the pharmaceutical composition of the present invention may comprise an alternative precipitation inhibitor, preferably polyvinylpyrrolidone-polyvinyl acetate copolymer, in an amount ranging from 0% to 10% by weight (w / w) based on the total weight of the composition. Preferably, the pharmaceutical composition of the present invention comprises polyvinylpyrrolidone-polyvinyl acetate in an amount ranging from 0.5% to 5% w / w, preferably 0.5% to 2% w / w, more preferably 0.5% to 1.5% w / w, more preferably about 1.0% w / w.

[0215] In one embodiment, the pharmaceutical composition of the invention comprises: a) from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w of a compound of formula (I) relative to the total weight of the composition; b) 55% to 99% w / w, preferably 60% to 95% w / w, preferably 65% ​​to 90% w / w, more preferably 70% to 90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w, about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, or about 90% w / w of lauroyl polyoxyl-32 glyceride.

[0216] In one embodiment, the pharmaceutical composition of the invention comprises: a) from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w of a compound of formula (I) relative to the total weight of the composition; b) 55% to 99% w / w, preferably 60% to 95% w / w, preferably 65% ​​to 90% w / w, more preferably 70% to 90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w of lauroyl polyoxyl-32 glyceride; c) PEG 400 at 0% to 30% w / w, preferably 5% to 30% w / w, preferably 10% to 25% w / w, more preferably 15% to 20% w / w, more preferably about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w, about 20% w / w, more preferably about 18% w / w; d) BHT in an amount of 0% to 5% w / w, preferably 0.001% to 5% w / w, preferably 0.005% to 1% w / w, more preferably 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w, based on the total weight of the composition.

[0217] In one embodiment, the pharmaceutical composition of the invention comprises: a) from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w of a compound of formula (I) relative to the total weight of the composition; b) 55% to 99% w / w, preferably 60% to 95% w / w, preferably 65% ​​to 90 % w / w, more preferably 70% to 90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w of lauroyl polyoxyl-32 glyceride; c) PEG3350 at 0%-30% w / w, preferably 5%-30% w / w, preferably 10%-25% w / w, more preferably 15%-20% w / w, more preferably about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w, about 20% w / w, more preferably about 18% w / w; d) BHT in an amount of 0% to 5% w / w, preferably 0.001% to 5% w / w, preferably 0.005% to 1% w / w, more preferably 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w, based on the total weight of the composition.

[0218] In one embodiment, the pharmaceutical composition of the invention comprises: a) from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w of a compound of formula (I) relative to the total weight of the composition; b) 55% to 99% w / w, preferably 60% to 95% w / w, preferably 65% ​​to 90% w / w, more preferably 70% to 90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w of lauroyl polyoxyl-32 glyceride; c) 0% to 20% w / w, preferably 1% to 20% w / w, preferably 3% to 15% w / w, more preferably 5% to 10% w / w, more preferably about 5% w / w, about 6% w / w, about 7% w / w, about 8% w / w, about 9% w / w, more preferably about 9% w / w of caprylic acid; d) BHT in an amount of 0% to 5% w / w, preferably 0.001% to 5% w / w, preferably 0.005% to 1% w / w, more preferably 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w, based on the total weight of the composition.

[0219] In one embodiment, the pharmaceutical composition of the invention comprises: a) a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt, in an amount ranging from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w, based on the total weight of the composition; b) 55% to 99% w / w, preferably 60% to 95% w / w, preferably 65% ​​to 90% w / w, more preferably 70% to 90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w, about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, or about 90% w / w Uroyl polyoxyl-32 glyceride; c) PEG 400 at 0% to 30% w / w, preferably 5% to 30% w / w, preferably 10% to 25% w / w, more preferably 15% to 20% w / w, more preferably about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w, about 20% w / w, more preferably about 18% w / w; d) BHT in an amount of 0% to 5% w / w, preferably 0.001% to 5% w / w, preferably 0.005% to 1% w / w, more preferably 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w, based on the total weight of the composition.

[0220] In one embodiment, the pharmaceutical composition of the invention comprises: a) a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt, in an amount ranging from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w, based on the total weight of the composition; b) 55% to 99% w / w, preferably 60% to 95% w / w, preferably 65% ​​to 90% w / w, more preferably 70% to 90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w of lauroyl polyoxyl-32 glyceride; c) PEG3350 at 0%-30% w / w, preferably 5%-30% w / w, preferably 10%-25% w / w, more preferably 15%-20% w / w, more preferably about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w, about 20% w / w, more preferably about 18% w / w; d) BHT in an amount of 0% to 5% w / w, preferably 0.001% to 5% w / w, preferably 0.005% to 1% w / w, more preferably 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w, based on the total weight of the composition.

[0221] In one embodiment, the pharmaceutical composition of the invention comprises: a) from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w of a compound of formula (I) relative to the total weight of the composition; b) Vitamin E TPGS of 55% to 99% w / w, preferably 60% to 95% w / w, preferably 65% ​​to 90% w / w, more preferably 70% to 90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w, about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, or about 90% w / w.

[0222] In one embodiment, the pharmaceutical composition of the invention comprises: a) 1% to 20% by weight (w / w) based on the total weight of the composition, preferably 5% to 15% w / w, more preferably 8% to 12% w / w, more preferably 9% to 11% w / w, Preferably about 10% w / w of a compound of formula (I); b) Vitamin E TPGS of 55%-99% w / w, preferably 60%-95% w / w, preferably 65%-90% w / w, more preferably 70%-90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w; c) PEG 400 at 0% to 30% w / w, preferably 5% to 30% w / w, preferably 10% to 25% w / w, more preferably 15% to 20% w / w, more preferably about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w, about 20% w / w, more preferably about 18% w / w; d) BHT in an amount of 0% to 5% w / w, preferably 0.001% to 5% w / w, preferably 0.005% to 1% w / w, more preferably 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w, based on the total weight of the composition.

[0223] In one embodiment, the pharmaceutical composition of the invention comprises: a) from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w of a compound of formula (I) relative to the total weight of the composition; b) Vitamin E TPGS of 55%-99% w / w, preferably 60%-95% w / w, preferably 65%-90% w / w, more preferably 70%-90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w; c) PEG3350 at 0%-30% w / w, preferably 5%-30% w / w, preferably 10%-25% w / w, more preferably 15%-20% w / w, more preferably about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w, about 20% w / w, more preferably about 18% w / w; d) BHT in an amount of 0% to 5% w / w, preferably 0.001% to 5% w / w, preferably 0.005% to 1% w / w, more preferably 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w, based on the total weight of the composition.

[0224] In one embodiment, the pharmaceutical composition of the invention comprises: a) from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w of a compound of formula (I) relative to the total weight of the composition; b) 55% to 99% w / w, preferably 60% to 95% w / w, preferably 65% ​​to 90% w / w, more preferably 70% to 90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w of Vitamin E TPGS; c) 0% to 20% w / w, preferably 1% to 20% w / w, preferably 3% to 15% w / w, more preferably 5% to 10% w / w, more preferably about 5% w / w, about 6% w / w, about 7% w / w, about 8% w / w, about 9% w / w, more preferably about 9% w / w of caprylic acid; d) BHT in an amount of 0% to 5% w / w, preferably 0.001% to 5% w / w, preferably 0.005% to 1% w / w, more preferably 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w, based on the total weight of the composition.

[0225] In one embodiment, the pharmaceutical composition of the invention comprises: a) a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt, in an amount ranging from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w, based on the total weight of the composition; b) Vitamin E TPGS of 55%-99% w / w, preferably 60%-95% w / w, preferably 65%-90% w / w, more preferably 70%-90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w; c) PEG 400 at 0% to 30% w / w, preferably 5% to 30% w / w, preferably 10% to 25% w / w, more preferably 15% to 20% w / w, more preferably about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w, about 20% w / w, more preferably about 18% w / w; d) BHT in an amount of 0% to 5% w / w, preferably 0.001% to 5% w / w, preferably 0.005% to 1% w / w, more preferably 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w, based on the total weight of the composition.

[0226] In one embodiment, the pharmaceutical composition of the invention comprises: a) a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt, in an amount ranging from 1% to 20% by weight (w / w), preferably from 5% to 15% w / w, more preferably from 8% to 12% w / w, more preferably from 9% to 11% w / w, more preferably about 10% w / w, based on the total weight of the composition; b) Vitamin E TPGS of 55%-99% w / w, preferably 60%-95% w / w, preferably 65%-90% w / w, more preferably 70%-90% w / w, more preferably about 70% w / w, about 71% w / w, about 72% w / w, about 73% w / w, about 74% w / w, about 75% w / w, about 76% w / w, about 77% w / w, about 78% w / w, about 79% w / w, about 80% w / w, about 81% w / w, about 82% w / w, about 83% w / w, about 84% w / w, about 85% w / w. about 86% w / w, about 87% w / w, about 88% w / w, about 89% w / w, about 90% w / w; c) 0% to 30% w / w, preferably 5% to 30% w / w, preferably 10% to 25% w / w, more preferably 15% to 20% w / w, more preferably about 15% w / w, about 16% w / w, about 17% w / w, about 18% w / w, about 19% w / w, about 20% w / w, more preferably about 18% w / w of PEG3350; d) BHT in an amount of 0% to 5% w / w, preferably 0.001% to 5% w / w, preferably 0.005% to 1% w / w, more preferably 0.01% to 0.5% w / w, more preferably about 0.01% w / w, about 0.05% w / w, about 0.10% w / w, about 0.15% w / w, about 0.20% w / w, about 0.25% w / w, about 0.30% w / w, about 0.40% w / w, about 0.50% w / w, more preferably about 0.10% w / w, based on the total weight of the composition.

[0227] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally 0.01% to 0.5% w / w BHT.

[0228] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally with 0.5%-10% w / w SLS; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0229] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0230] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of poloxamer 407.

[0231] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0232] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0233] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally 0.01% to 0.5% w / w BHT.

[0234] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally with 0.5%-10% w / w SLS; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0235] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0236] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of poloxamer 407.

[0237] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0238] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0239] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally 0.01% to 0.5% w / w BHT.

[0240] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally with 0.5%-10% w / w SLS; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0241] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0242] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of poloxamer 407.

[0243] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0244] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I); b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5-10% w / w polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0245] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally with 0.5%-10% w / w SLS; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0246] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0247] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of poloxamer 407.

[0248] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0249] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0250] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally with 0.5%-10% w / w SLS; f) optionally containing 0.5% to 10% w / w hydroxypropyl methylcellulose; nothing.

[0251] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0252] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of poloxamer 407.

[0253] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0254] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0255] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally with 0.5%-10% w / w SLS; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0256] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0257] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of poloxamer 407.

[0258] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0259] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70% to 90% w / w of lauroyl polyoxyl-32 glyceride; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0260] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally with 0.5%-10% w / w SLS; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0261] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0262] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of poloxamer 407.

[0263] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0264] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 10%-25% w / w PEG400; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0265] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally with 0.5%-10% w / w SLS; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0266] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0267] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of poloxamer 407.

[0268] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0269] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 10%-25% w / w PEG3350; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0270] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally with 0.5%-10% w / w SLS; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0271] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; f) optionally 0.5% to 10% w / w hydroxypropyl methylcellulose.

[0272] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of poloxamer 407.

[0273] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

[0274] In one embodiment, the pharmaceutical composition of the invention comprises: a) 5% to 15% w / w of a compound of formula (I) in salt form, preferably the HCl salt or the esylate salt; b) 70%-90% w / w Vitamin E TPGS; c) with 5% to 10% w / w caprylic acid; d) optionally with 0.01%~0.5% w / w BHT; e) optionally 0.5% to 10% w / w polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0275] Dosage form In one embodiment, the pharmaceutical composition of the present invention is in a form suitable for oral administration.Such suitable administration forms can be solid, semi-solid or liquid.Such suitable administration forms are clear to those skilled in the art, and can be found in the latest edition of Remington's Pharmaceutical Sciences.

[0276] Some preferred, but non-limiting examples of such forms include capsules (including soft and hard gelatin capsules), tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, and syrups.

[0277] The pharmaceutical compositions of the present invention are preferably in unit dosage form and may be suitably packaged, for example in a box, blister, vial, bottle, sachet, ampule, or any other suitable single-dose or multi-dose holder or container, which may be appropriately labeled, optionally with one or more leaflets containing product information and / or instructions for use. Such unit dosage forms may contain, for example, from about 5 mg to about 200 mg, preferably from about 10 mg to about 100 mg, of the pharma- ceutically active ingredient.

[0278] The pharmaceutical compositions of the present invention can be formulated so as to provide quick, sustained, or delayed release of the active compound(s) contained therein.

[0279] Preparation of pharmaceutical compositions The pharmaceutical compositions of the present invention can be prepared by methods well known to those skilled in the art.

[0280] In one embodiment, the pharmaceutical composition of the present invention is in solid or semi-solid form.Solid dispersions can be prepared conventionally using methods such as, for example, melting, melt granulation, solvent evaporation, spray drying, lyophilization, hot melt extrusion, electrostatic spinning, coating on sugar beads using a fluidized bed coating system, or supercritical fluid technology.

[0281] In one embodiment, the pharmaceutical composition of the present invention is in the form of a capsule, preferably a hard gelatin capsule, which can be manufactured from a common mixture using conventional blending and capsule-filling processes in accordance with good manufacturing practice.

[0282] In one embodiment, the manufacturing process for the capsules comprises the following steps: i) melting lauroyl polyoxyl-32 glyceride at a temperature of 50°C or more and less than 80°C; ii) then optionally adding further excipients such as, for example, caprylic acid, sodium lauryl sulfate, hydroxypropyl methylcellulose, PEG, polyvinylcaprolactam-polyvinylacetate-polyethyleneglycol graft copolymer, polyvinylpyrrolidone-polyvinylacetate copolymer, poloxamer 407, and / or BHT to the lauroyl polyoxyl-32 glyceride and mixing together using a suitable mixer; iii) A compound of formula (I), either the free base or a suitable salt form, preferably the HCl salt or the esylate salt, is then slowly added with continuous mixing using a suitable mixer to obtain a visually uniform distribution of the drug substance without any observable lumps or agglomerates; iv) Mixing is then continued for at least 30 minutes to ensure that the API is uniformly distributed as determined by visual inspection; v) Mixing is then continued to maintain the mixture in a molten state and filled into appropriately sized gelatin capsule shells to the target capsule fill weight.

[0283] As already mentioned above, the gelatin capsule shell may optionally contain additional ingredients such as, for example, polyethylene glycol and sodium lauryl sulfate.

[0284] Capsule filling is carried out using conventional capsule filling methods and equipment suitable for use with molten semi-solid formulations.

[0285] In another embodiment, the manufacturing process for the capsule comprises the steps of: i) melting Vitamin E TPGS at a temperature of 50°C or more and less than 80°C; ii) then optionally adding further excipients such as, for example, caprylic acid, sodium lauryl sulfate, hydroxypropyl methylcellulose, PEG, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyvinylpyrrolidone-polyvinyl acetate copolymer, poloxomer 407, and / or BHT to the lauroyl polyoxyl-32 glyceride and mixing together using a suitable mixer; iii) A compound of formula (I), either the free base or a suitable salt form, preferably the HCl salt or the esylate salt, is then slowly added with continuous mixing using a suitable mixer to obtain a visually uniform distribution of the drug substance without any observable lumps or agglomerates; iv) Mixing is then continued for at least 30 minutes to ensure that the API is uniformly distributed as determined by visual inspection; v) Mixing is then continued to maintain the mixture in a molten state and filled into appropriately sized gelatin capsule shells to the target capsule fill weight.

[0286] dose Depending on the condition to be prevented or treated and the mode of administration, the pharmaceutical composition of the present invention may be administered in a single daily dose divided into one or more administrations per day.

[0287] In one embodiment, the pharmaceutical compositions of the invention are administered in a dose equivalent to administration to a subject of about 5 mg to about 200 mg, preferably about 10 mg to about 100 mg, of pharma- ceutical active ingredient (free base equivalent) per dose.

[0288] In one embodiment, the effective dose of the pharma- ceutically active ingredient may range from about 0.08 to about 3.3 mg / kg, preferably from about 0.15 to about 1.7 mg / kg.

[0289] Purpose Another object of the invention is a medicinal product comprising the pharmaceutical composition according to the invention.

[0290] The present invention further relates to the use of the pharmaceutical composition of the present invention for inhibiting the A2A receptor.

[0291] According to a further feature of the present invention, there is provided a method for modulating A2A activity in a patient, preferably a warm-blooded animal, even more preferably a human, in need of such treatment, the treatment comprising administering to the patient an effective amount of a pharmaceutical composition of the present invention.

[0292] According to a further feature of the invention, there is provided a use of a pharmaceutical composition of the invention in the manufacture of a medicament for modulating A2A activity in a patient in need of such treatment, the treatment comprising administering to the patient an effective amount of a pharmaceutical composition of the invention.

[0293] In one embodiment, the present invention relates to the use of a pharmaceutical composition of the present invention to increase immune recognition and destruction of cancer cells.

[0294] Therefore, the pharmaceutical composition of the present invention is useful for the prevention and / or treatment of cancer, and is particularly useful for the treatment of cancer.

[0295] The present invention further relates to a method for treating cancer comprising administering a therapeutically effective amount of the pharmaceutical composition of the present invention to a mammalian species in need thereof.

[0296] The present invention further provides the use of a pharmaceutical composition of the present invention in the manufacture of a medicament for treating and / or preventing cancer.

[0297] The present invention also provides a method of delaying the onset of cancer in a patient, comprising administering to a patient in need thereof a pharma- ceutically effective amount of a pharmaceutical composition of the present invention.

[0298] Preferably, the patient is a warm-blooded animal, more preferably a human.

[0299] A variety of cancers are known in the art. The cancer can be metastatic or non-metastatic. The cancer can be familial or sporadic. In some embodiments, the cancer is selected from the group consisting of leukemia and multiple myeloma. Additional cancers that can be treated using the methods of the present invention include, for example, benign and malignant solid tumors, and benign and malignant non-solid tumors. In specific embodiments, the cancer is selected from breast cancer, carcinoid, cervical cancer, colon cancer, endometrial cancer, glioma, head and neck cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, gastric cancer, thyroid cancer, and urothelial cancer. In specific embodiments, the cancer is breast cancer. In specific embodiments, the cancer is carcinoid cancer. In specific embodiments, the cancer is cervical cancer. In specific embodiments, the cancer is colon cancer. In specific embodiments, the cancer is endometrial cancer. In specific embodiments, the cancer is glioma. In specific embodiments, the cancer is head and neck cancer. In a specific embodiment, the cancer is liver cancer. In a specific embodiment, the cancer is lung cancer. In a specific embodiment, the cancer is melanoma. In a specific embodiment, the cancer is ovarian cancer. In a specific embodiment, the cancer is pancreatic cancer. In a specific embodiment, the cancer is prostate cancer. In a specific embodiment, the cancer is renal cancer. In a specific embodiment, the cancer is gastric cancer. In a specific embodiment, the cancer is thyroid cancer. In a specific embodiment, the cancer is urothelial carcinoma.

[0300] Examples of solid tumors include biliary tract cancer, brain tumors (including glioblastoma and medulloblastoma), breast cancer, carcinoid, cervical cancer, choriocarcinoma, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, glioma, head and neck cancer, intraepithelial neoplasia (including Bowen's disease and Paget's disease), liver cancer, lung cancer, neuroblastoma, oral cancer (including squamous cell carcinoma), ovarian cancer (including those arising from epithelial cells, stromal cells, germ cells, and mesenchymal cells), pancreatic cancer, prostate cancer, rectal cancer, kidney cancer (including adenocarcinoma and Wilm's disease), and the like. These include, but are not limited to, tumors of the thyroid gland (including thyroid cancers), sarcomas (including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma), skin cancers (including melanoma, Kaposi's sarcoma, basal cell carcinoma, and squamous cell carcinoma), testicular cancer, including germ cell tumors (seminomas and non-seminomas, such as teratomas and choriocarcinomas), stromal tumors, germ cell tumors, thyroid cancer (including thyroid adenocarcinoma and medullary carcinoma), and urothelial carcinoma.

[0301] Examples of solid tumors include, but are not limited to, biliary tract cancer, brain tumors (including glioblastoma and medulloblastoma), breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, intraepithelial neoplasia (including Bowen's disease and Paget's disease), liver cancer, lung cancer, neuroblastoma, oral cancer (including squamous cell carcinoma), ovarian cancer (including those arising from epithelial cells, stromal cells, germ cells, and mesenchymal cells), pancreatic cancer, prostate cancer, rectal cancer, kidney cancer (including adenocarcinoma and Wilms' tumor), sarcomas (including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma), skin cancer (including melanoma, Kaposi's sarcoma, basal cell carcinoma, and squamous cell carcinoma), testicular cancer, including germ cell tumors (seminomas and non-seminomas, such as teratomas and choriocarcinomas), stromal tumors, germ cell tumors, and thyroid cancer (including thyroid adenocarcinoma and medullary carcinoma).

[0302] Examples of non-solid tumors include, but are not limited to, hematological neoplasms, which as used herein is a term of art that includes lymphoid disorders, myeloid disorders, and AIDS-related leukemia.

[0303] Lymphatic disorders include, but are not limited to, acute lymphocytic leukemia and chronic lymphoproliferative disorders (e.g., lymphoma, myeloma, and chronic lymphocytic leukemia). Lymphomas include, for example, Hodgkin's disease, non-Hodgkin's lymphoma, and lymphocytic lymphoma. Chronic lymphocytic leukemias include, for example, T-cell chronic lymphocytic leukemia and B-cell chronic lymphocytic leukemia.

[0304] The present invention further relates to the use of the pharmaceutical composition of the present invention in the prevention and / or treatment of radiation-induced fibrosis, connective tissue diseases (e.g., Sjogren's syndrome, i.e., scleroderma), chronic bacterial infections (e.g., Helicobacter pylori), abnormal scars (keloids), and polymicrobial sepsis.

[0305] The present invention further relates to methods for the treatment or prevention of radiation-induced fibrosis, connective tissue diseases (e.g., Sjogren's syndrome, i.e., scleroderma), chronic bacterial infections (e.g., Helicobacter pylori), abnormal scars (keloids), and polymicrobial sepsis comprising administering a therapeutically effective amount of the pharmaceutical composition of the present invention to a mammalian species in need thereof.

[0306] The present invention further provides the use of a pharmaceutical composition of the present invention in the manufacture of a medicament for the treatment and / or prevention of radiation-induced fibrosis, connective tissue diseases (e.g., Sjogren's syndrome, i.e., scleroderma), chronic bacterial infections (e.g., Helicobacter pylori), abnormal scars (keloids), and polymicrobial sepsis.

[0307] The present invention also provides a method for delaying the onset of radiation-induced fibrosis, connective tissue disease (e.g., Sjogren's syndrome, i.e., scleroderma), chronic bacterial infection (e.g., Helicobacter pylori), abnormal scars (keloids), and polymicrobial sepsis in a patient, comprising administering to a patient in need thereof a pharmacologic effective amount of a pharmaceutical composition of the present invention.

[0308] combination The present invention also provides (a) at least one A2A adenosine receptor (A2AR) inhibitor; (b) at least one anticancer agent.

[0309] In a preferred embodiment, the present invention (a) Thiocarbamate derivatives, more preferably of formula (I) [ka] (In the formula, R 1 and R 2 is as defined above), or a pharma- ceutically acceptable salt or solvate thereof; (b) at least one anti-cancer agent.

[0310] As described in more detail below, the anti-cancer agent can be selected from an immunotherapeutic agent, a chemotherapeutic agent, an anti-angiogenic agent, a multidrug resistance associated protein inhibitor, a radiotherapeutic agent, and any combination thereof.

[0311] In the context of the present invention, the term "combination" preferably means that the A2AR inhibitor and the anticancer drug are present in combination.Thus, the combination of the present invention may be present as one composition (e.g., pharmaceutical composition) that contains all components in one and the same mixture, or as a kit of parts, with different components forming different parts of the kit of parts.The administration of the A2AR inhibitor and the administration of the anticancer drug can be performed simultaneously or staggered, at approximately the same or different administration times (i.e., the number of administrations of each component is approximately the same or different), at the same administration site or at different sites, and in approximately the same or different dosage forms.

[0312] The present invention is based on the surprising finding that the combination of an A2AR inhibitor with an anticancer drug (e.g., an immunotherapeutic drug, particularly a checkpoint inhibitor, etc.) is highly advantageous in inhibiting tumor growth and / or reducing the number of cancer cells, resulting in improved survival rates that could not be expected from the prior art. Thus, the combined treatment of an A2AR inhibitor with an anticancer drug can significantly reduce the deleterious effects of the disease being treated, such as the growth rate of tumors. Such effects are illustrated in the following examples.

[0313] A2AR inhibitors The combination of the present invention comprises an A2AR inhibitor as a first component.Preferably, the A2AR inhibitor is a thiocarbamate derivative, in particular the thiocarbamate derivative as disclosed in PCT / EP2018 / 058301.More preferably, the A2AR inhibitor is the thiocarbamate derivative of formula (I) described above.

[0314] Thus, in a preferred embodiment, the combination of the present invention comprises, as an A2AR inhibitor, [ka] (In the formula, R 1 and R 2 is as defined above), or a pharma- ceutically acceptable salt or solvate thereof.

[0315] All of the embodiments relating to A2AR inhibitors detailed above apply to the combinations of the present invention.

[0316] Anticancer drugs The combination of the present invention comprises as a second component at least one anti-cancer agent.

[0317] In one embodiment, the anti-cancer agent is selected from an immunotherapeutic agent, a chemotherapeutic agent, an anti-angiogenic agent, a multidrug resistance associated protein inhibitor, a radiotherapeutic agent, and any combination thereof.

[0318] In one embodiment, the combination of the present invention comprises a single anticancer drug.In another embodiment, the combination of the present invention comprises multiple anticancer drugs, preferably two, three or four anticancer drugs as defined below.When a combination of anticancer drugs is used in the combination of the present invention, the anticancer drugs can be drugs of the same class or different classes.For example, a combination of immunotherapeutic and chemotherapeutic drugs can be used with A2AR inhibitors.

[0319] Immunotherapeutic agents In one embodiment, the combination of the present invention comprises an immunotherapeutic agent as the anti-cancer agent.

[0320] In such a case, the present invention (a) at least one A2A adenosine receptor (A2AR) inhibitor; (b) at least one immunotherapeutic agent.

[0321] In a preferred embodiment, the present invention (a) Thiocarbamate derivatives, more preferably those represented by formula (I) 1 and R 2 is as defined above), or a pharma- ceutically acceptable salt or solvate thereof; (b) at least one immunotherapeutic agent.

[0322] In the present invention, "immunotherapy" refers to a therapy that aims to induce and / or enhance an immune response against a specific target, e.g., cancer cells. In the latter case, it is called cancer immunotherapy.

[0323] For example, the immunotherapeutic agent is selected from checkpoint inhibitors, checkpoint agonists (also known as T cell agonists), IDO inhibitors, PI3K inhibitors, adenosine receptor inhibitors, adenosine-generating enzyme inhibitors, CD40 agonists, IL2 mutants, immune cells (to perform adoptive transfer), therapeutic vaccines, and combinations thereof. In a specific embodiment, the immunotherapeutic agent is a checkpoint inhibitor.

[0324] In one embodiment, the immunotherapeutic agent combined with the A2AR inhibitor of formula (I) described herein above comprises or consists of a checkpoint inhibitor, a checkpoint agonist, an IDO inhibitor, a PI3K inhibitor, an adenosine receptor inhibitor, an adenosine-generating enzyme inhibitor, a CD40 agonist, an IL2 mutant, an immune cell (to perform adoptive transfer), a therapeutic vaccine, or any mixture thereof.

[0325] In the context of the present invention, the term "combination" preferably means that the A2AR inhibitor and the immunotherapeutic agent are present in combination. Thus, the combination of the present invention may be present as one composition (e.g., pharmaceutical composition) that contains all components in one and the same mixture, or as a kit of parts, where different components form different parts of the kit of parts. The administration of the A2AR inhibitor and the administration of the immunotherapeutic agent can be performed simultaneously or staggered, at approximately the same or different administration times (i.e., the number of administrations of each component is approximately the same or different), at either the same administration site or different sites, and in approximately the same or different dosage forms. Such a combination can induce a vigorous immune response, thereby, for example, preventing tumor growth or inducing tumor regression.

[0326] Checkpoint inhibitors In one embodiment, the combination of the invention comprises at least one checkpoint inhibitor as an immunotherapeutic agent.

[0327] Checkpoint inhibitors (CPIs), sometimes referred to as immune checkpoint inhibitors (ICIs), block the interaction between inhibitory receptors expressed on T cells and their ligands. The use of checkpoint inhibitors as cancer treatment aims to prevent the inhibitory receptors expressed on T cells from being activated by ligands expressed by tumor cells. Thus, the use of checkpoint inhibitors aims to prevent the inhibition of T cells present in tumors, i.e., tumor-infiltrating T cells, and thereby enhance the subject's immune response against tumor cells.

[0328] Thus, the combination of the present invention can restore immune function in the tumor environment by using an A2AR inhibitor as a first component and can antagonize checkpoint pathway signaling by using an immunotherapeutic checkpoint inhibitor as a second component, preferably by inhibiting or suppressing signaling.

[0329] Examples of checkpoint inhibitors include, but are not limited to, the following: - Inhibitors of the cell surface receptor PD-1 (programmed cell death protein 1), also known as CD279 (cluster of differentiation 279); - inhibitors of the ligand PD-L1 (programmed death-ligand 1), also known as CD274 (cluster of differentiation 274) or B7-H1 (B7 homolog 1); - inhibitors of the cell surface receptor CTLA4 or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152); - Inhibitor of LAG-3 (lymphocyte activation gene 3), also known as CD223 (cluster of differentiation 223); - inhibitors of TIM-3 (T cell immunoglobulin and mucin domain containing 3), also known as HAVCR2 (Hepatitis A virus cellular receptor 2) or CD366 (cluster of differentiation 366);- inhibitors of TIGIT (T cell immunoreceptor with Ig and ITIM domains), also known as VSIG9 (V-set and immunoglobulin domain containing protein 9) or VSTM3 (V-set and transmembrane domain containing protein 3); - BTLA (B and T lymphocyte attenuator), also known as CD272 (cluster of differentiation 272) inhibitor; - Inhibitor of CEACAM-1 (carcinoembryonic antigen-related cell adhesion molecule 1), also known as CD66a (cluster of differentiation 66a); - Inhibitors of GITR (glucocorticoid-induced TNFR-related protein), also known as TNFRSF18 (tumor necrosis factor receptor superfamily member 18) or AITR (activation-induced TNFR family receptor).

[0330] In one embodiment, the checkpoint inhibitor is selected from the group comprising or consisting of an inhibitor of PD-1, an inhibitor of PD-L1, an inhibitor of CTLA4, an inhibitor of LAG-3, an inhibitor of TIM-3, an inhibitor of TIGIT, an inhibitor of BTLA, an inhibitor of CEACAM-1, an inhibitor of GITR, and any mixture thereof.

[0331] In one embodiment, the checkpoint inhibitor is selected from the group comprising or consisting of an inhibitor of PD-1, an inhibitor of PD-L1, an inhibitor of CTLA-4, an inhibitor of TIGIT, and any mixture thereof.

[0332] In one embodiment, the checkpoint inhibitor is selected from the group comprising or consisting of an inhibitor of PD-1, an inhibitor of PD-L1, an inhibitor of CTLA-4, and any mixture thereof.

[0333] In one embodiment, the checkpoint inhibitor is an inhibitor of PD-1, also referred to as anti-PD-1. Inhibitors of PD-1 can include antibodies, particularly monoclonal antibodies, that target PD-1, as well as non-antibody inhibitors such as small molecule inhibitors.

[0334] Examples of PD-1 inhibitors include, but are not limited to, pembrolizumab, nivolumab, cemiplimab, tislelizumab, spartalizumab, ABBV-181, JNJ-63723283, BI 754091, MAG012, TSR-042, AGEN2034. Pembrolizumab is also called MK-3475, MK03475, lambrolizumab, or SCH-900475. The trade name of pembrolizumab is Keytruda®. Nivolumab is also called ONO-4538, BMS-936558, MDX1106, or GTPL7335. The trade name of nivolumab is Opdivo®. Cemiplimab is also called REGN2810 or REGN-2810. Tislelizumab is also called BGB-A317. Spartalizumab is also called PDR001 or PDR-001.

[0335] In one embodiment, the checkpoint inhibitor is selected from the group including or consisting of pembrolizumab, nivolumab, cemiplimab, tislelizumab, spartalizumab, ABBV-181, JNJ-63723283, BI 754091, MAG012, TSR-042, AGEN2034, and any mixture thereof.

[0336] In one embodiment, the checkpoint inhibitor is an inhibitor of PD-L1, also referred to as anti-PD-L1. Inhibitors of PD-L1 can include antibodies, particularly monoclonal antibodies, that target PD-L1, as well as non-antibody inhibitors such as small molecule inhibitors.

[0337] Examples of PD-L1 inhibitors include, but are not limited to, avelumab, atezolizumab, durvalumab, and LY3300054. Avelumab is also referred to as MSB0010718C, MSB-0010718C, MSB0010682, or MSB-0010682. The trade name for avelumab is Bavencio®. Atezolizumab is also referred to as MPDL3280A (clone YW243.55.S70), MPDL-3280A, RG-7446, or RG7446. The trade name for atezolizumab is Tecentriq®. Durvalumab is also referred to as MEDI473 It is also referred to as MEDI-4736 or 6. The trade name for durvalumab is Imfinzi®.

[0338] In one embodiment, the checkpoint inhibitor is selected from the group including or consisting of avelumab, atezolizumab, durvalumab, LY3300054, and any mixture thereof.

[0339] In one embodiment, the checkpoint inhibitor is an inhibitor of CTLA-4, also referred to as anti-CTLA-4.

[0340] Inhibitors of CTLA-4 can include antibodies, particularly monoclonal antibodies, that target CTLA-4, as well as non-antibody inhibitors such as small molecule inhibitors.

[0341] Examples of CTLA-4 inhibitors include, but are not limited to, ipilimumab and tremelimumab. Ipilimumab is also called BMS-734016, MDX-010, or MDX-101. The trade name for ipilimumab is Yervoy®. Tremelimumab is also called ticilimumab, CP-675, or CP-675,206.

[0342] In one embodiment, the at least one checkpoint inhibitor is selected from the group comprising or consisting of ipilimumab, tremelimumab, and any mixtures thereof.

[0343] In one embodiment, the checkpoint inhibitor is an inhibitor of TIGIT, also referred to as anti-TIGIT.

[0344] In one embodiment of the various methods, pharmaceutical compositions, kits, or uses provided herein, the anti-human TIGIT monoclonal antibody or antigen-binding fragment thereof is BMS-986207 (Bristol-Myers Squibb, New York, NY).

[0345] In another embodiment of the various methods, pharmaceutical compositions, kits, or uses provided herein, the anti-human TIGIT monoclonal antibody or antigen-binding fragment thereof is OMP-313M32 (OncoMed Pharmaceuticals, Redwood city, CA).

[0346] In another embodiment of the various methods, pharmaceutical compositions, kits, or uses provided herein, the anti-human TIGIT monoclonal antibody or antigen-binding fragment thereof is MK-7684 (Merck & Co., Kenilworth, NJ).

[0347] In yet another embodiment of the various methods, pharmaceutical compositions, kits, or uses provided herein, the anti-human TIGIT monoclonal antibody or antigen-binding fragment thereof is MTIG7192A (also known as RG6058, U.S. Publication No. 2017 / 0088613).

[0348] In yet another embodiment of the various methods, pharmaceutical compositions, kits, or uses provided herein, the anti-human TIGIT monoclonal antibody or antigen-binding fragment thereof is PTZ-201 (Potenza Therapeutics, Cambridge, MA; also known as ASP8374, Astellas Pharma, Tokyo, Japan).

[0349] In another embodiment of the various methods, pharmaceutical compositions, kits, or uses provided herein, the anti-human TIGIT monoclonal antibody or antigen-binding fragment thereof is COM902 (Compugen LTD, Holon, IL).

[0350] In yet another embodiment of the various methods, pharmaceutical compositions, kits, or uses provided herein, the anti-human TIGIT monoclonal antibody or antigen-binding fragment thereof is described in WO2018 / 160704 (Seattle Genetics, Seattle, WA).

[0351] In yet another embodiment of the various methods, pharmaceutical compositions, kits, or uses provided herein, the anti-human TIGIT monoclonal antibody or antigen-binding fragment thereof is one described in WO2019 / 023504 (Iteos Therapeutics). In certain preferred embodiments, the anti-human TIGIT antibody or antigen-binding fragment comprises a combination of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein HCDR1 comprises or consists of SEQ ID NO:1 (YTFTSYYMH), HCDR2 comprises or consists of SEQ ID NO:2 (VIGPSGASTSYAQKFQG), HCDR3 comprises or consists of SEQ ID NO:3 (ARDHSDYWSGIMEV), LCDR1 comprises or consists of SEQ ID NO:4 (RASQSVRSSYLA), LCDR2 comprises or consists of SEQ ID NO:5 (GASSRAT), and LCDR3 comprises or consists of SEQ ID NO:6 (QQYFSPPWT).

[0352] Checkpoint agonists (T cell agonists) In one embodiment, the combination of the present invention comprises at least one checkpoint agonist (also called a T cell agonist) as an immunotherapeutic agent.

[0353] T cell agonists act by activating stimulatory receptors expressed on immune cells such as T cells. As used herein, the term "stimulatory receptor" refers to a receptor that induces a stimulatory signal upon activation, thereby resulting in an enhanced immune response. T cell agonist therapy as a cancer treatment aims to activate stimulatory receptors expressed on immune cells present in tumors. In particular, T cell agonist therapy aims to enhance the activation of T cells present in tumors, i.e., tumor-infiltrating T cells, and thereby enhance the subject's immune response against tumor cells.

[0354] Examples of T cell agonists include, but are not limited to, the following: - Agonists of CD137 (cluster of differentiation 137), also known as 4-1BB or TNFRS9 (tumor necrosis factor receptor superfamily, member 9); - Agonist of the OX40 receptor, also known as CD134 (cluster of differentiation 134), or TNFRSF4 (tumor necrosis factor receptor superfamily, member 4).

[0355] In one embodiment, the checkpoint agonist is selected from the group comprising or consisting of an agonist of CD137, an agonist of OX40, and any mixture thereof.

[0356] Examples of CD137 agonists include, but are not limited to, utomilumab and urelumab.

[0357] IDO inhibitors In one embodiment, the combination of the invention comprises at least one inhibitor of indoleamine-2,3-dioxygenase (IDO) as an immunotherapeutic agent.

[0358] The enzyme indoleamine 2,3-dioxygenase catalyzes the first and rate-limiting step in L-tryptophan (Trp) catabolism. IDO has been implicated in the ability to limit T cell function and in the immune tolerance mechanism. IDO is involved in immune regulation through its ability to mediate tumor cell proliferation and immune response. IDO activity in tumor cells acts to impair antitumor responses. Thus, inhibition of IDO can restore tumor immune surveillance.

[0359] Examples of IDO inhibitors include beta-carboline (also known as norharman), rosmarinic acid, 1-methyl-L-tryptophan (also known as L-1-MT), epacadostat, navoximod, or those disclosed in WO2015 / 173764, more preferably those of formula II, II', or II''.

[0360] In a preferred embodiment, the IDO inhibitor is selected from those disclosed in WO2015 / 173764, more preferably of formula II, II', or II''.

[0361] PI3K gamma inhibitors In one embodiment, the combination of the invention comprises at least one PI3K inhibitor as an immunotherapeutic agent.

[0362] Phosphoinositide 3-kinase inhibitors (PI3K inhibitors) are a class of medicines that work by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K / AKT / mTOR pathway, a signaling pathway important for many cellular functions, including growth control, metabolism, and translation initiation. Many types of cancer activate the PI3K pathway, which prevents cell death in tumor cells.

[0363] There are several different classes and isoforms of PI3K: Class 1 PI3K has a catalytic subunit called p110, which has four isoforms: p110 alpha, p110 beta, p110 gamma, and p110 delta.

[0364] In a preferred embodiment, the PI3K inhibitor is a PI3K-gamma inhibitor.

[0365] Examples of PI3K inhibitors include wortmannin, LY294002, demethoxyviridone, hibiscon C, idelalisib, copanlisib, duvelisib, taselisib, buparlisib, alpelisib, umbralisib, dactolisib, voxtalisib, IPI-549, RP6530, IC87114, and TG100-115.

[0366] Examples of PI3K-gamma inhibitors include copanlisib, duvelisib, IPI-549, RP6530, IC87114, and TG100-115.

[0367] Adenosine receptor inhibitors In one embodiment, the combination of the invention comprises at least one further inhibitor of an adenosine receptor as an immunotherapeutic agent.

[0368] As mentioned in the introduction, adenosine receptors are a class of purinergic G protein-coupled receptors with adenosine as the endogenous ligand. There are four known types of adenosine receptors in humans: A1, A2A, A2B, and A3.

[0369] The combination of the present invention comprises as a first component an inhibitor of A2A receptor of formula (I) as defined above.The second component of the combination can be a further inhibitor of adenosine receptor, in particular an inhibitor of A1 receptor, A2A receptor, A2B receptor or A3 receptor.Preferably, the second component of the combination of the present invention is an inhibitor of A2B receptor or an inhibitor of A3 receptor.

[0370] Examples of inhibitors of the A2B receptor include ATL-801, CVT-6883, MRS-1706, MRS-1754, OSIP-339,391, PSB-603, PSB-0788, and PSB-1115.

[0371] Examples of inhibitors of the A3 receptor include KF-26777, MRS-545, MRS-1191, MRS-1220, MRS-1334, MRS-1523, MRS-3777, MRE-3005-F20, MRE-3008-F20, PSB-11, OT-7999, VUF-5574, and SSR161421.

[0372] Adenosine synthesizing enzyme inhibitors In one embodiment, the combination of the invention comprises at least one adenosine generating enzyme inhibitor as an immunotherapeutic agent.

[0373] Ecto-nucleotidases are a family of nucleotide metabolic enzymes that metabolize nucleotides to nucleosides. Subfamilies of ectonucleotidases include CD39 / NTPDase (ecto-nucleotide triphosphate diphosphohydrolase), ecto-phosphodiesterases of the nucleotide pyrophosphatase / phosphodiesterase (NPP) type, alkaline phosphatase, and ecto-5´-nucleotidase / CD73.

[0374] Among other functions, ectonucleotidases generate extracellular adenosine. The first step involves the conversion of ATP / ADP to AMP, which is carried out by ENTPD1, ​​also known as CD39. The second step involves the conversion of AMP to adenosine, which is carried out by NT5E, also known as CD73. Thus, ectonucleotidases are adenosine-generating enzymes.

[0375] As mentioned in the introduction, high levels of extracellular adenosine play an important role in evading antitumor immune responses. Therefore, the use of inhibitors of adenosine-producing enzymes is beneficial in cancer therapy by allowing the reduction of extracellular adenosine levels.

[0376] Examples of adenosine-producing enzyme inhibitors include: - inhibitors of CD39, also known as ENTPD1 or ectonucleoside triphosphate diphosphohydrolase (EC 3.6.1.5, apyrase); - inhibitors of CD73, also known as 5´-nucleotidase (5´-NT) or ecto-5´-nucleotidase or NT5E, - inhibitors of ectonucleotide pyrophosphatases / PDEs (EC 3.6.1.9 and EC 3.1.4.1), and - inhibitors of alkaline phosphatase (AP; EC 3.1.3.1), - Inhibitors of CD38, also known as cyclic ADP-ribose hydrolase or ADP-ribosyl cyclase / cyclic ADP-ribose (cADPR) hydrolase.

[0377] Examples of adenosine-producing enzyme inhibitors include IPH5201, A001485, SRF617, ARL67156, POM-1, IPH5301, A000830, A001190, A001421, SRF373 / NZV930, and daratumumab. More precisely, examples of CD39 inhibitors include IPH5201, A001485, SRF617, ARL67156, and POM-1; examples of CD73 inhibitors include IPH5301, A000830, A001190, A001421, and SRF373 / NZV930; examples of CD38 inhibitors include daratumumab.

[0378] CD40 agonists In one embodiment, the combination of the present invention comprises at least one CD40 agonist as an immunotherapeutic agent.

[0379] CD40 is a cell surface receptor member of the tumor necrosis factor (TNF) receptor superfamily. It mediates both indirect tumor cell killing through activation of the immune system and direct tumor cell apoptosis. Similar to endogenous CD40 ligand (CD40L or CD154), CD40 agonists bind to CD40 on various immune cell types, thereby inducing cell proliferation and activation of antigen-presenting cells (APCs) and activating B cells, effector cells, and memory T cells, resulting in an enhanced immune response against tumor cells.

[0380] Examples of CD40 agonists include CD40 agonist antibodies and recombinant CD40 agonists (i.e., proteins but not antibodies). Examples of CD40 agonist antibodies include celiclerumab (formerly RO7009789 and CP-870,893), APX005M, JNJ-64457107 (formerly ADC-1013), SEA-CD40, ChiLob7 / 4, CDX-1140H, dacetuzumab (SGN-40), and ABBV-428. Examples of recombinant CD40 agonists include MEDI5083 and HERA-CD40L.

[0381] IL2 variants In one embodiment, the combination of the invention comprises at least one IL2 variant as an immunotherapeutic agent.

[0382] Interleukin-2 (IL-2) is a potent immune enhancer that plays a key role in maintaining T cell responses. Its potential to stimulate T cell proliferation without loss of functionality led to its early use in cancer immunotherapy.

[0383] Examples of IL2 variants include recombinant, pegylated, and / or mutated IL2 variants such as, for example, aldesleukin, monomethoxy PEG IL2, NKTR-214, MDNA-109, RO6874281, and ALKS-4230.

[0384] Immune cells - Adoptive cell transfer According to one embodiment, the immunotherapeutic agent is an immune cell used in adoptive transfer of cells, also referred to as adoptive cell therapy (both also referred to as ACT), in particular adoptive transfer of T cells, also referred to as adoptive T cell therapy.

[0385] As used herein, adoptive cell transfer or adoptive cell therapy is defined as the transfer, e.g., injection, of immune cells into a subject. The adoptive transfer of immune cells into a subject as cancer therapy aims to enhance the subject's immune response against cancer cells.

[0386] In one embodiment, the immune cells are T cells, in particular effector T cells. Examples of effector T cells include CD4 + T cells and CD8 + T cells are one example.

[0387] In one embodiment, the transferred T cells are cytotoxic cells. An example of a cytotoxic T cell is CD8 + These include T cells and natural killer (NK) cells, in particular natural killer (NK) T cells.

[0388] In one embodiment, the transferred immune cells as described herein above are antigen-specific cells. In one embodiment, the transferred immune cells as described herein above are antigen-specific immune cells, said antigen being specifically and / or abundantly expressed by cancer cells. In one embodiment, In one embodiment, the transferred immune cells described herein above are cancer-specific immune cells, in other words, the transferred immune cells described herein above specifically recognize cancer cells via antigens that are specifically and / or abundantly expressed by the cancer cells. In one embodiment, the transferred immune cells described herein above are cancer-specific effector T cells. In one embodiment, the transferred immune cells described herein above are cancer-specific CD8 + Effector T cells, especially cancer-specific cytotoxic CD8 + In one embodiment, the transferred immune cells described herein above are tumor-specific cytotoxic cells. In one embodiment, the transferred immune cells described herein above are cancer-specific NK cells. In one embodiment, the transferred immune cells described herein above are tumor-specific immune cells, in other words, the transferred immune cells described herein above specifically recognize tumor cells via antigens that are specifically and / or abundantly expressed by the tumor cells. In one embodiment, the transferred immune cells described herein above are tumor-specific effector T cells. In one embodiment, the transferred immune cells described herein above are tumor-specific CD8 + Effector T cells, particularly tumor-specific cytotoxic CD8 + In one embodiment, the transferred immune cells described herein above are tumor-specific cytotoxic cells. In one embodiment, the transferred immune cells described herein above are tumor-specific NK cells.

[0389] In one embodiment, the transferred immune cells described herein above are autologous immune cells, particularly autologous T cells. In another embodiment, the transferred immune cells described herein above are allogeneic (or allogeneic) immune cells, particularly allogeneic NK cells.

[0390] Methods for isolating T cells, particularly antigen-specific T cells, such as tumor-specific T cells, from a subject are well known in the art (see, for example, Rosenberg & Restifo, 2015, Science 348, 62-68; Prickett et al., 2016, Cancer Immunol Res 4, 669-678; or Hinrichs & Rosenberg, 2014, Immunol Rev 257, 56-71). Methods for expanding T cells ex vivo are well known in the art (see, for example, Rosenberg & Restifo, 2015, Science 348, 62-68; Prickett et al., 2016, Cancer Immunol Res 4, 669-678; or Hinrichs & Rosenberg, 2014, Immunol Rev 257, 56-71). Protocols for injecting T cells into a subject, including pre-infusion conditioning regimens, are well known in the art (see, e.g., Rosenberg & Restifo, 2015, Science 348, 62-68; Prickett et al., 2016, Cancer Immunol Res 4, 669-678; or Hinrichs & Rosenberg, 2014, Immunol Rev 257, 56-71).

[0391] In one embodiment, the immune cells are CAR immune cells, in particular CAR T cells, in the context of CAR immune cell therapy and CAR T cell therapy, respectively.

[0392] As used herein, CAR immune cell therapy is adoptive cell therapy, and the transferred cells are the immune cells described herein above, such as T cells or NK cells, which are genetically engineered to express chimeric antigen receptor (CAR).The adoptive transfer of CAR immune cells to a subject as cancer treatment aims to enhance the subject's immune response against cancer cells.

[0393] CARs are synthetic receptors consisting of a targeting moiety associated with one or more signaling domains in a single fusion molecule or multiple molecules. In general, the binding portion of a CAR consists of the antigen-binding domain of a single-chain antibody (scFv), which contains the light chain variable fragment of a monoclonal antibody, linked by a flexible linker. Based on receptor or ligand domains Binding moieties have also been used successfully. The signaling domains of first-generation CARs are usually derived from the cytoplasmic region of the CD3 zeta chain or the Fc receptor gamma chain. First-generation CARs have been shown to successfully redirect T cell cytotoxicity, but failed to confer long-term proliferation and antitumor activity in vivo. Therefore, signaling domains from costimulatory molecules, including CD28, OX-40 (CD134), and 4-1BB (CD137), have been added alone (second generation) or in combination (third generation) to improve survival and increase proliferation of CAR-modified T cells.

[0394] Therefore, in one embodiment, the transferred T cells described herein above are CAR T cells.The expression of CAR can redirect T cells to selected antigens, such as antigens expressed on the surface of cancer cells.In one embodiment, the transferred CAR T cells recognize tumor-specific antigens.

[0395] In another embodiment, the transferred NK cells described herein above are CAR NK cells. The expression of CAR can redirect NK cells to selected antigens, such as antigens expressed on the surface of cancer cells. In one embodiment, the transferred CAR NK cells recognize tumor-specific antigens.

[0396] In one embodiment, the CAR immune cell described herein above is an autologous CAR immune cell, particularly an autologous CAR T cell.In another embodiment, the CAR immune cell described herein above is an allogeneic (or allogeneic) CAR immune cell, particularly an allogeneic CAR NK cell.

[0397] Therapeutic Vaccines According to one embodiment, the immunotherapeutic agent is a therapeutic vaccine (also referred to as a therapeutic vaccine).

[0398] As used herein, a therapeutic vaccine is defined as the administration of at least one tumor-specific antigen (e.g., synthetic long peptides, or SLPs), or a nucleic acid encoding said tumor-specific antigen; the administration of a recombinant viral vector that selectively enters and / or replicates in tumor cells; the administration of tumor cells; and / or the administration of immune cells (e.g., dendritic cells) that have been engineered to present tumor-specific antigens and elicit an immune response against such antigens.

[0399] As a cancer treatment, therapeutic vaccines aim to enhance a subject's immune response against tumor cells.

[0400] Examples of therapeutic vaccines aimed at enhancing a subject's immune response against tumor cells include, but are not limited to, viral vector-based therapeutic vaccines such as adenoviruses (e.g., oncolytic adenoviruses), vaccinia viruses (e.g., modified vaccinia Ankara (MVA)), alphaviruses (e.g., Semliki Forest virus (SFV)), measles virus, herpes simplex virus (HSV), and coxsackievirus; synthetic long peptide (SLP) vaccines; and dendritic cell vaccines.

[0401] Chemotherapeutic agents In one embodiment, the combination of the invention comprises at least one chemotherapeutic agent as the anti-cancer agent.

[0402] The chemotherapeutic agent is selected from, for example, anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum coordination compounds, Parp inhibitors, anti-hormone-sensitive cancer agents, and any combination thereof.

[0403] In one embodiment, the chemotherapeutic agents combined with the A2AR inhibitor of formula (I) described herein above comprise or consist of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum coordination compounds, Parp inhibitors, anti-hormone sensitive cancer agents, and any combination thereof.

[0404] Anticancer alkylating agents In one embodiment, the combination of the invention comprises at least one anticancer alkylating agent as a chemotherapeutic agent.

[0405] Anticancer alkylating agents refer to alkylating agents that have anticancer activity, and as used herein, the term "alkylating agent" generally refers to an agent that donates an alkyl group in an alkylation reaction in which a hydrogen atom of an organic compound is replaced with the alkyl group.

[0406] Examples of anticancer alkylating agents include nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ramustine, nimustine, temozolomide, and carmustine.

[0407] Anticancer antimetabolites In one embodiment, the combination of the invention comprises at least one anticancer antimetabolite as a chemotherapeutic agent.

[0408] Anticancer antimetabolites refer to antimetabolites that have anticancer activity, and the term "antimetabolites" as used herein broadly includes substances that interfere with normal metabolism and inhibit electron transfer systems to prevent the production of energy-rich intermediates because of their structural or functional similarity to metabolites important to the body (vitamins, coenzymes, amino acids, and sugars).

[0409] Examples of anticancer antimetabolites include methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil (also called "5-FU"), tegafur, doxifluridine, carmofur, cytarabine, cytarabine ocphosfer, enocitabine, S-1, gemcitabine, fludarabine, and pemetrexed sodium. Preferably, the anticancer antimetabolites are selected from 5-FU, gemcitabine, and pemetrexed.

[0410] Anticancer antibiotics In one embodiment, the combination of the present invention comprises at least one anticancer antibiotic as a chemotherapeutic agent.

[0411] "Anticancer antibiotic" refers to an antibiotic having anticancer activity, and as used herein, "antibiotic" includes substances produced by microorganisms or by partial or total synthesis that inhibit cell growth and other functions of microorganisms and other organisms, and derivatives thereof.

[0412] Examples of anticancer antibiotics include actinomycin D, doxorubicin, daunorubicin, neocarzinostatin, bleomycin, peplomycin, mitomycin C, aclarubicin, pirarubicin, epirubicin, zinostatin stimalamer, idarubicin, sirolimus, and valrubicin. Preferably, the anticancer antibiotic is doxorubicin.

[0413] Plant-derived anticancer drugs In one embodiment, the combination of the present invention comprises at least one plant-derived anti-cancer agent as a chemotherapeutic agent.

[0414] As used herein, "plant-derived anti-cancer agent" includes compounds having anti-cancer activity derived from plants, or compounds prepared by chemical modifications to the aforementioned compounds.

[0415] Examples of plant-derived anticancer drugs include vincristine, vinblastine, vindesine, etoposide, sobuzoxane, docetaxel, paclitaxel, nab-paclitaxel, and vinorelbine. Preferably, the plant-derived anticancer drug is docetaxel.

[0416] Anticancer platinum coordination compounds In one embodiment, the combination of the present invention comprises at least one anticancer platinum coordination compound as a chemotherapeutic agent.

[0417] "Anti-cancer platinum coordination compound" refers to a platinum coordination compound having anti-cancer activity, and as used herein, the term "platinum coordination compound" refers to a platinum coordination compound that donates platinum in ionic form.

[0418] Preferred platinum compounds include cisplatin; cis-diamminediaquaplatinum(O)-ion; chloro(dethylenetriamine)-platinum(II) chloride; dichloro(ethylenediamine)-platinum(II); diamine(1,1-cyclobutanedicarboxylato)platinum(II) (carboplatin); spiroplatin; iproplatin; diamine(2-ethyl malonate)platinum(II); ethylenediaminemalonatoplatinum(H); aqua(1,2-diaminodicyclohexane)sulfate. Platinum(II); aqua(1,2-diaminodicyclohexane)malonatoplatinum(II); (1,2-diaminocyclohexane)malonatoplatinum(II); (4-carboxyphthalato)(1,2-diaminocyclohexane)platinum(II); (1,2-diaminocyclohexane)-(isocitrate)platinum(II); (1,2-diaminocyclohexane)oxalatoplatinum(II); ormaplatin; tetraplatin; carboplatin, nedaplatin, and oxaliplatin. Preferably, the anticancer platinum coordination compound is selected from carboplatin and oxaliplatin.

[0419] Parp inhibitors In one embodiment, the combination of the invention comprises at least one Parp inhibitor as a chemotherapeutic agent.

[0420] "Parp inhibitors" refer to inhibitors of the enzyme poly ADP-ribose polymerase (PARP). This enzyme is important for repairing single-strand breaks in DNA. If such breaks remain unrepaired until the DNA is replicated, replication can result in the formation of double-strand breaks. Thus, PARP inhibitors allow the formation of multiple double-strand breaks in tumors, resulting in tumor cell death.

[0421] Examples of Parp inhibitors include olaparib, rucaparib, niraparib, veliparib, pamiparib, iniparib, and talazoparib.

[0422] Anti-hormone-sensitive cancer drugs In one embodiment, the combination of the present invention comprises at least one anti-hormone sensitive cancer drug as a chemotherapeutic agent.

[0423] An anti-hormone-sensitive cancer agent refers to an anti-cancer agent that has activity against hormone-sensitive cancers. Examples of anti-hormone-sensitive cancer agents include antiandrogens, GnRH agonists, and GnRH antagonists.

[0424] "Antiandrogens" refers to a class of drugs that prevent androgens, such as testosterone and dihydrotestosterone (DHT), from mediating biological effects in the body. Antiandrogens can be used, for example, to treat prostate cancer. Examples of antiandrogens include bicalutamide, flutamide, nilutamide, apalutamide, enzalutamide, and abiraterone.

[0425] "Gonadotropin-releasing hormone agonists" (GnRH agonists) refer to a class of drugs that affect gonadotropins and sex hormones. They can be used in reducing sex hormone levels in the treatment of hormone-sensitive cancers such as prostate and breast cancer. Examples of GnRH agonists include goserelin, leuprorelin, and triptorelin.

[0426] "Gonadotropin-releasing hormone antagonists" (GnRH antagonists) refer to a class of drugs that antagonize the action of gonadotropin-releasing hormone (GnRH). For example, they can be used to treat prostate cancer. An example of a GnRH antagonist is degarelix.

[0427] Chemotherapy Combinations A combination of chemotherapeutic agents may be used as the second component of the combination of the present invention.

[0428] For example, the combination known as folfox can be used, which consists of the combination of fluorouracil (antimetabolite), oxaliplatin (a platinum compound), and folinic acid (a chemoprotectant).

[0429] Alternatively, a combination of carboplatin (a platinum compound) and paclitaxel (a plant-derived drug) can be used. Another example is the combination of gemcitabine (an antimetabolite) and nab-paclitaxel (a plant-derived drug).

[0430] In one embodiment, the combination of chemotherapeutic agents is selected from the following: (i) a combination of folinic acid, fluorouracil, and oxaliplatin (folfox); (ii) a combination consisting of carboplatin and paclitaxel; (iii) A combination consisting of gemcitabine and nab-paclitaxel.

[0431] Antiangiogenic Agents In one embodiment, the combination of the invention comprises at least one anti-angiogenic agent as an anti-cancer agent.

[0432] Angiogenesis, the growth of new blood vessels, plays an important role in tumor initiation and malignant tumor progression. Inhibition of angiogenesis has been shown to suppress tumor growth and metastasis. The most prominent targets of antiangiogenic agents are vascular endothelial growth factor (VEGF) and its receptors.

[0433] Several other factors are of interest as well, including integrins, matrix metalloproteinases, and endogenous anti-angiogenic factors.

[0434] Thus, anti-angiogenic agents include VEGF inhibitors, integrin inhibitors, and matrix metalloproteinase inhibitors.

[0435] Examples of antiangiogenic agents include ramucirumab, IMC-18F1, bevacizumab, Ziv-aflibercept, sorafenib, sunitinib, axitinib, nintedanib, regorafenib, pazovanib, cabozantinib, vandetanib, and thalidomide. In a specific embodiment, the antiangiogenic agent is a VEGF inhibitor, such as ramucirumab.

[0436] Multidrug resistance-associated protein inhibitors In one embodiment, the combination of the present invention comprises at least one multidrug resistance associated protein inhibitor as an anti-cancer agent.

[0437] Multidrug resistance-associated proteins (MRPs / ABCCs) are a subfamily of ATP-binding cassette transporters that can actively transport a wide variety of organic anionic compounds across the plasma membrane against their concentration gradient. Such proteins are involved in multidrug resistance by transporting a wide variety of drugs, including anticancer drugs, out of the cell. Thus, inhibition of multidrug resistance-associated proteins can improve the efficacy of anticancer drugs.

[0438] Examples of multidrug resistance associated protein inhibitors include inhibitors of MRP4 / ABCC4, inhibitors of MRP5 / ABCC5, and inhibitors of MRP8 / ABCC11.

[0439] Radiotherapy Agents - Radiation Therapy In one embodiment, the combination of the invention comprises at least one radiotherapeutic agent as an anti-cancer agent.

[0440] "Radiation therapy" refers to cancer treatment using various forms of radiation, including x-rays, gamma rays, neutrons, electrons, protons, and radioactive sources. It is used as part of cancer treatment to control or kill malignant cells. Many types of cancer can be cured with radiation therapy if they are localized to one area of ​​the body. It can also be used as part of adjuvant therapy to prevent tumors from recurring after surgery to remove the primary malignant tumor.

[0441] Radiation therapy is divided into three main categories: external beam radiation therapy (EBRT or XRT); brachytherapy or sealed source radiation therapy; and total body radioisotope therapy (RIT) or unsealed source radiation therapy. The differences relate to the location of the radiation source: external beam is outside the body, brachytherapy uses sealed sources of radiation precisely placed in the area being treated, and total body radioisotopes are given by injection or ingestion. Particle therapy is a special case of external beam radiation therapy, where the particles are protons or heavy ions. The radiation can be delivered by a linear accelerator.

[0442] Systemic radioisotope therapy (RIT) is a form of targeted therapy. Targeting can be achieved by the chemical properties of the isotope, for example, radioactive iodine is absorbed 1000 times more by the thyroid gland than by other body organs. Targeting can also be achieved by combining the radioisotope with another molecule or antibody to guide it to the target tissue and form a radiopharmaceutical agent.

[0443] Radiosensitizers can be administered during radiation therapy to enhance the radiosensitivity of the cancer. Examples of radiosensitizers include cisplatin, nimorazole, and cetuximab.

[0444] Thus, in one embodiment, the radiotherapeutic agent is selected from sealed radioactive sources, radioisotopes, radiopharmaceuticals, radiosensitizers, and the like, useful in the course of radiotherapy.

[0445] In another embodiment, the present invention also provides the use of the above-mentioned A2AR inhibitors in combination with radiation therapy, including radiation therapy administered by external beam radiation or X-ray radiation; brachytherapy; and systemic radioisotope therapy.

[0446] combination In one embodiment, the combination of the invention comprises at least one A2AR inhibitor as defined above and at least one anti-cancer agent as defined above.

[0447] In a specific embodiment, the combination of the invention comprises at least one A2AR inhibitor as defined above and at least one immunotherapeutic agent as defined above.

[0448] In a specific embodiment, the combination of the present invention comprises at least one A2AR inhibitor as defined above and at least one checkpoint inhibitor as defined above, preferably an inhibitor of PD-1, PD-L1, CTLA-4 or TIGIT, or any mixture thereof.

[0449] In a specific embodiment, the combination of the invention comprises at least one A2AR inhibitor as defined above and at least one adenosine generating enzyme inhibitor as defined above, preferably at least one inhibitor of CD39, such as, for example, ARL67156 and POM-1.

[0450] In a specific embodiment, the combination of the invention comprises at least one A2AR inhibitor as defined above and at least one chemotherapeutic agent as defined above.

[0451] In a specific embodiment, the combination of the invention comprises at least one A2AR inhibitor as defined above and at least one anticancer antibiotic as defined above, such as, for example, doxorubicin.

[0452] In a specific embodiment, the combination of the present invention comprises at least one A2AR inhibitor as defined above and at least one anticancer platinum coordination compound as defined above, such as, for example, oxaliplatin.

[0453] In a specific embodiment, the combination of the invention comprises at least one A2AR inhibitor as defined above, at least one immunotherapeutic agent as defined above, and at least one chemotherapeutic agent as defined above.

[0454] In a specific embodiment, the combination of the present invention comprises at least one A2AR inhibitor as defined above, at least one checkpoint inhibitor as defined above, and at least one chemotherapeutic agent as defined above. In a specific embodiment, the combination of the present invention comprises at least one A2AR inhibitor as defined above, at least one inhibitor of PD-L1, CTLA-4, or TIGIT, and at least one chemotherapeutic agent as defined above.

[0455] In a specific embodiment, the combination of the present invention comprises at least one A2AR inhibitor as defined above and at least one checkpoint inhibitor as defined above. In a specific embodiment, the combination of the present invention comprises at least one A2AR inhibitor as defined above and at least one checkpoint inhibitor as defined above. The present invention relates to a method for treating cancer comprising administering to a patient in need thereof at least one inhibitor of TIGIT and at least one anticancer antibiotic as defined above, such as, for example, doxorubicin.

[0456] In a specific embodiment, the combination of the present invention comprises at least one A2AR inhibitor as defined above and at least two checkpoint inhibitors as defined above. In a specific embodiment, the combination of the present invention comprises at least one A2AR inhibitor as defined above, at least one inhibitor of PD-L1 as defined above and at least one inhibitor of TIGIT as defined above.

[0457] Pharmaceutical Compositions The present invention further relates to a pharmaceutical composition comprising a combination according to the invention.

[0458] In one embodiment, the pharmaceutical composition comprises: (a) at least one A2AR inhibitor; (b) at least one anticancer drug, and (c) at least one or more pharma- ceutically acceptable carriers, diluents, excipients, and / or adjuvants.

[0459] In a preferred embodiment, the present invention provides a pharmaceutical composition comprising: (a) at least one A2AR inhibitor which is a thiocarbamate derivative as defined above, more preferably a thiocarbamate derivative of formula (I), or a pharma- ceutically acceptable salt or solvate thereof; (b) at least one anti-cancer agent as defined above, such as an immunotherapeutic agent, a chemotherapeutic agent, an anti-angiogenic agent, a multidrug resistance-associated protein inhibitor, a radiotherapeutic agent, or any combination thereof; and (c) at least one or more pharma- ceutically acceptable carriers, diluents, excipients, and / or adjuvants.

[0460] The at least one pharma- ceutically acceptable carrier, diluent, excipient, and / or adjuvant used in preparing the dosage form will be apparent to those skilled in the art, see the most recent edition of Remington's Pharmaceutical Sciences.

[0461] In particular, pharmaceutical compositions comprising the combination of the present invention may optionally contain such inactive substances commonly used in pharmaceutical formulations, such as cosolvents, lipid carriers, antioxidants, surfactants, wetting agents, emulsifiers, buffers, pH adjusters, preservatives (or preservatives), isotonicity agents, stabilizers, granulating or binding agents, precipitation inhibitors, lubricants, disintegrants, glidants, diluents or fillers, adsorbents, dispersing agents, suspending agents, bulking agents, release agents, sweeteners, flavoring agents, and the like.

[0462] In a preferred embodiment, the pharmaceutical composition comprising the combination of the present invention comprises one or more pharma- ceutically acceptable co-solvents.Preferably, the co-solvents are selected from caprylic acid, polyethylene glycol (PEG), propylene glycol, ethanol, dimethyl sulfoxide, dimethylacetamide, dimethylisosorbide, and mixtures thereof.In a specific embodiment, the pharmaceutical composition of the present invention comprises caprylic acid and / or PEG.Advantageously, when the composition comprises PEG as a co-solvent, the PEG is of low molecular weight, preferably, the PEG is PEG400.In an alternative embodiment, when the composition comprises PEG, the PEG is of medium molecular weight, preferably, the PEG is PEG3350.

[0463] In a specific embodiment, the pharmaceutical composition comprising the combination of the present invention comprises one or more pharma- ceutically acceptable lipid carriers. In a preferred embodiment, the lipid carrier is lauroyl polyoxyl-32 glyceride. This excipient is available from Gattefosse (Saint-Prince). It corresponds to Gelucire® 44 / 14 manufactured by Sigma-Aldrich (St-France). This excipient is: lauroyl polyoxyl-32 glyceride NF / USP (NF: National Formulary; USP: United States Pharmacopoeia); It is also known under the reference names Lauroyl Macrogol-32 Glycerides EP (European Pharmacopoeia); Hydrogenated Coconut PEG-32 Esters (INCI); CAS number 57107-95-6. Gelucire® 44 / 14 corresponds to a well-defined multicomponent substance composed of mono-, di- and triglycerides of lauric acid (C12) and PEG-32 mono- and diesters. Gelucire® 44 / 14 has a melting point in the range of 42.5°C to 47.5°C (44°C average) and a hydrophilic / lipophilic balance (HLB) value of 14.

[0464] In another embodiment, the lipid carrier is Vitamin E TPGS. This excipient is also known by the reference names: D-α-tocopherol polyethylene glycol-1000 succinate; Tocophersolan; Tocofersolan; VEGS; α-[4-[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-1,4-dioxobutyl]-ω-hydroxy-poly(oxy-1,2-ethanediyl); Vitamin E PEG succinate, and is formed from Vitamin E complexed with polyethylene glycol 1000 via a succinic acid linker. Vitamin E TPGS has a melting point in the range of 37-41° C. and a hydrophilic / lipophilic balance (HLB) value of 13.

[0465] In one embodiment, a pharmaceutical composition comprising the combination of the invention further comprises one or more antioxidants, preferably the antioxidant is selected from butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), citric acid, sodium metabisulfite, ascorbic acid, methionine, and vitamin E, more preferably the antioxidant is BHT.

[0466] In some embodiments, surfactants such as polyethylene glycol, polyoxyethylene sorbitan fatty acid esters, sorbitan esters, sodium docusate, sodium lauryl sulfate, polysorbates (20, 80, etc.), poloxamers (188, 407, etc.), Pluronic® polyols, polyoxyethylene sorbitan monoethers (TWEEN®-20, TWEEN®-80, etc.), vitamin E TPGS (vitamin E polyethylene glycol succinate), Cremophor RH40 (polyoxyl 40 hydrogenated castor oil), Cremophor EL (polyoxyl 35 hydrogenated castor oil), polyethylene glycol 660 12-monostearate, solutol HS15 (polyoxyethylated 12-hydroxystearic acid), labrasol (caprylocaproyl polyoxyl-8 glyceride), labrafil M1944 (oleoyl polyoxyl-6 glyceride), polylactide-polyethylene glycol copolymer, polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®), etc. are added.

[0467] In some embodiments, wetting agents are added, such as sodium lauryl sulfate, vitamin E TPGS, sodium docusate, polysorbate 80, poloxamer 407, etc. A preferred wetting agent is poloxamer 407.

[0468] In some embodiments, emulsifiers are added, such as carbomer, carrageenan, lanolin, lecithin, mineral oil, oleic acid, oleyl alcohol, pectin, poloxamer, polyoxyethylene sorbitan fatty acid esters, sorbitan esters, triethanolamine, propylene glycol monolaurate, propylene glycol dilaurate, propylene glycol monocaprylate, etc. Preferred emulsifiers are, for example, poloxamer, Propylene glycol monolaurate, propylene glycol dilaurate, and propylene glycol monocaprylate.

[0469] In some embodiments, a buffer is used to help maintain the pH in a range that approximates physiological conditions. Suitable buffers include organic and inorganic acids and their salts, such as citrate buffers (e.g., monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture, etc.), succinate buffers (e.g., succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, fumaric acid-fumarate mixture, etc.), and the like. Examples of suitable buffers include: disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture, etc.), gluconate buffers (e.g., gluconic acid-sodium gluconate mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium gluconate mixture, etc.), oxalate buffers (e.g., oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture, etc.), lactate buffers (e.g., lactic acid-sodium lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture, etc.), and acetate buffers (e.g., acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture, etc.). Additionally, phosphate buffers, histidine buffers, and trimethylamine salts such as Tris can be used.

[0470] In some embodiments, pH adjusters are added, such as sodium hydroxide, sodium bicarbonate, magnesium oxide, potassium hydroxide, meglumine, sodium carbonate, citric acid, tartaric acid, ascorbic acid, fumaric acid, succinic acid, and malic acid.

[0471] In some embodiments, preservatives are added to retard microbial growth.Preservatives suitable for use with the present disclosure include phenol, benzyl alcohol, metacresol, methylparaben, propylparaben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides (e.g., chloride, bromide, and iodide), hexamethonium chloride, and alkylparabens such as methylparaben or propylparaben, catechol, resorcinol, cyclohexanol, and 3-pentanol.

[0472] In some embodiments, isotonicity agents, sometimes referred to as "stabilizers," are added and include polyhydric sugar alcohols, such as trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, and mannitol. Stabilizers refer to a broad category of excipients whose function can range from bulking agents to additives that solubilize the therapeutic agent or help prevent denaturation or adhesion to container walls, or help inhibit precipitation, particle growth, or aggregation of the active ingredient. Typical stabilizers include polyhydric sugar alcohols (listed above); amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, etc.; organic sugars or sugar alcohols such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myo-inositol, galactitol, glycerol, etc., including cyclitols such as inositol; polyethylene glycol; amino acid polymers; urea, glutathione, glycerol, etc. sulfur-containing reducing agents such as thione, thioctic acid, sodium thioglycolate, thioglycerol, α-monothioglycerol, and sodium thiosulfate; low molecular weight polypeptides (e.g., peptides of 10 residues or less); proteins such as human serum albumin, bovine serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; poloxamer 407; hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, or hydroxypropyl methylcellulose acetate succinate. carboxymethylcellulose (Na / Ca); monosaccharides such as xylose, mannose, fructose, glucose; disaccharides such as lactose, maltose, sucrose, and trisaccharides such as raffinose; polysaccharides such as dextran; polyethylene glycol methyl ether-block-poly(DL-lactide) copolymer; poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1. Preferred stabilizers are, for example, glycerol; polyethylene glycol; polyvinylpyrrolidone; cellulose derivatives such as hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, or hydroxypropyl methylcellulose acetate succinate; carboxymethylcellulose (Na / Ca); polyethylene glycol methyl ether-block-poly(DL-lactide) copolymer; and poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1; polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0473] In some embodiments, granulating / binder(s) are added such as, for example, starches, gums (including natural, semi-synthetic, and synthetic), microcrystalline cellulose, ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, polymers such as povidone, polyvinylpyrrolidone-polyvinyl acetate copolymer, etc. Preferred granulating agents are, for example, methyl cellulose, hydroxypropyl cellulose, povidone, and polyvinylpyrrolidone-polyvinyl acetate copolymer.

[0474] In some embodiments, a precipitation inhibitor is added, such as water-soluble derivatives of cellulose including hydroxypropyl methylcellulose and methylcellulose, and water-soluble polymers such as polyvinylpyrrolidone, polyvinylpyrrolidone-polyvinyl acetate copolymer, polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, or poloxamer 407. A preferred precipitation inhibitor is hydroxypropyl methylcellulose.

[0475] In some embodiments, lubricants are added, such as, for example, magnesium stearate, glyceryl esters, behenoyl polyoxyl-8 glyceride Nf (Compritol HD5 ATO), sodium stearyl fumarate, and the like.

[0476] In some embodiments, disintegrants are added, such as synthetics such as sodium starch glycolate, crospovidone, croscarmellose sodium, Kollidon CL, and natural origins such as locust bean gum.

[0477] In some embodiments, glidants are added such as, for example, talc, magnesium stearate, colloidal silicon dioxide, starch, and the like.

[0478] In some embodiments, diluents (or fillers) are added, such as, for example, dextrose, lactose, mannitol, microcrystalline cellulose, sorbitol, sucrose, dicalcium phosphate, calcium sulfate dehydrate, starch, and the like.

[0479] In some embodiments, adsorbents are added, such as, for example, silicon dioxide, purified aluminum silicate, and the like.

[0480] In some embodiments, a pharmaceutical composition comprising the combination of the present invention is in the form of a tablet and contains tabletting excipients such as granulating agents, binders, lubricants, disintegrants, glidants, diluents, adsorbents, and the like.

[0481] In some embodiments, the pharmaceutical composition comprising the combination of the present invention is in the form of a capsule, and the capsule shell is made of gelatin or non-animal products such as cellulose and its derivatives such as hydroxypropylmethylcellulose. Other ingredients can be included in the capsule shell, such as polyethylene glycol, which acts as a plasticizer; pigments such as titanium dioxide or iron oxide, which allow impermeability and color differentiation; lubricants such as carnauba wax; gelling agents such as carrageenan, and wetting agents such as sodium lauryl sulfate. In one embodiment, the pharmaceutical composition comprising the combination of the present invention is formulated as a capsule, in which case the capsule shell is made of gelatin, and optionally additional ingredients, such as polyethylene glycol and sodium lauryl sulfate, are included in the capsule shell.

[0482] By way of non-limiting examples, pharmaceutical compositions comprising the combinations may be in a form suitable for administration orally, parenterally (such as by intravenous, intramuscular, or subcutaneous injection, or intravenous infusion), topically (including ocularly), rectally, by inhalation, skin patch, implant, suppository, etc. Such suitable dosage forms (which may be solid, semi-solid, or liquid, depending on the method of administration), as well as methods for use in their preparation, and carriers, diluents, and excipients, will be apparent to those skilled in the art, who may consult the latest edition of Remington's Pharmaceutical Sciences.

[0483] The compositions can be formulated so as to permit quick, sustained, or delayed release of the active compound(s) contained therein.

[0484] According to one embodiment, the pharmaceutical composition comprising the combination is in a form suitable for oral administration.The form suitable for oral administration can be solid, semi-solid or liquid.Some preferred but non-limiting examples of such forms include liquid compositions, paste compositions or solid compositions, more specifically tablets, tablets formulated for extended release or sustained release, capsules (including soft and hard gelatin capsules), pills, dragees, lozenges, sachets, cachets, powders, liquids, gels, syrups, slurries, elixirs, emulsions, solutions and suspensions.

[0485] According to another embodiment, the pharmaceutical composition comprising the combination is in a form suitable for injection, in particular for injection into a subject by intravenous, intramuscular, intraperitoneal, intrapleural, subcutaneous, transdermal injection or infusion.

[0486] Sterile injectable forms of the pharmaceutical compositions of the invention include sterile injectable solutions and sterile packaged powders, typically reconstituted before use, for administration as a bolus and / or continuous administration.

[0487] The sterile injectable form of the pharmaceutical composition of the present invention may be a solution or an aqueous or oily suspension. Such a suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic pharma- ceutically acceptable diluent or solvent. Acceptable vehicles and solvents that can be used include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as a solvent or suspending medium. For this purpose, any bland fixed oil may be used, including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharma-ceutically acceptable oils, such as olive oil or castor oil, particularly in their polyoxyethylated form. Such oily solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants, that are commonly used in the formulation of pharma-ceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tween®, Span®, and other emulsifiers or bioavailability enhancers, commonly used in the manufacture of pharma- ceutically acceptable solid, liquid, or other dosage forms, may also be used for formulation purposes.

[0488] According to another embodiment, the pharmaceutical composition comprising the combination of the present invention is in a form suitable for topical administration.Examples of the form suitable for topical administration include, but are not limited to, liquid composition, paste composition, or solid composition, more specifically aqueous solution, droplet, dispersion, spray, ointment, cream, lotion, microcapsule, microparticle or nanoparticle, polymer patch, or controlled release patch.

[0489] According to another embodiment, the pharmaceutical composition comprising the combination of the present invention is in a form suitable for rectal administration, including, but not limited to, suppositories, mini enemas, enemas, gels, rectal foams, creams, ointments, etc.

[0490] According to another embodiment, a pharmaceutical composition comprising the combination of the present invention is in a form suitable for administration by inhalation. Examples of forms suitable for administration by inhalation include, but are not limited to, aerosols.

[0491] The pharmaceutical preparations of the invention are preferably in unit dosage form and may be suitably packaged, for example, in boxes, blisters, vials, bottles, sachets, ampoules, or any other suitable single-dose or multi-dose holders or containers, optionally with one or more leaflets containing product information and / or instructions for use.

[0492] Parts Kits The present invention further relates to a kit-of-parts comprising the combination of the invention.

[0493] In one embodiment, the kit of parts of the invention comprises: (a) a first portion comprising at least one A2AR inhibitor; (b) a second portion comprising at least one anti-cancer drug.

[0494] In a preferred embodiment, the present invention (a) thiocarbamate derivatives, more preferably of formula (I) as defined above [ka] a first portion comprising at least one A2AR inhibitor which is a thiocarbamate derivative of, or a pharma- ceutically acceptable salt or solvate thereof; (b) a second part comprising at least one anti-cancer agent as defined above, such as an immunotherapeutic agent, a chemotherapeutic agent, an anti-angiogenic agent, a multidrug resistance associated protein inhibitor, a radiotherapeutic agent, or any combination thereof.

[0495] In one embodiment, the first part comprises a pharmaceutical composition comprising an A2AR inhibitor, preferably a thiocarbamate derivative of formula (I) as defined above, and at least one pharma- ceutically acceptable carrier, diluent, excipient, and / or adjuvant.

[0496] The pharma- ceutically acceptable carriers, diluents, excipients and / or adjuvants of the pharmaceutical composition of the first part of the kit-of-parts may be those recited above for the pharmaceutical composition of the invention.

[0497] Similarly, the dosage form and route of administration of the pharmaceutical composition of the first part of the kit of parts may be those recited above for the pharmaceutical composition of the invention.

[0498] In one embodiment, the second part comprises at least one anticancer drug as defined above. Depending on the type of anticancer drug, the second part of the kit may be in the form of a pharmaceutical composition. The excipients, dosage forms and administration routes of such pharmaceutical compositions are clear to those skilled in the art (see Remington's Pharmaceutical Sciences, latest edition), and may in particular be those listed above for the pharmaceutical composition of the present invention.

[0499] According to one embodiment, the kit of the present invention may comprise one or more additional parts comprising one or more additional anti-cancer agents.For example, the kit may comprise: (a) a first part comprising an A2AR inhibitor of formula (I); (b) a second part comprising an immunotherapeutic agent; and (c) a third part comprising a chemotherapeutic agent.In another embodiment, the kit may comprise: (a) a first part comprising an A2AR inhibitor of formula (I); (b) a second part comprising a checkpoint inhibitor; and (c) a third part comprising a chemotherapeutic agent.In another embodiment, the kit may comprise: (a) a first part comprising an A2AR inhibitor of formula (I); (b) a second part comprising a checkpoint inhibitor; and (c) a third part comprising a different checkpoint inhibitor.

[0500] As formulated below, administration of the different parts of the kit can be done simultaneously or staggered, at about the same or different administration times (i.e., the number of administrations of each component is about the same or different), either at the same administration site or at different sites, and in about the same or different dosage forms.

[0501] Regimen and Dosage In the context of the present invention, as outlined below, the A2AR inhibitor and the anti-cancer drug can be administered simultaneously or at staggered times, at approximately the same or different administration times (i.e., approximately the same or different administration times for each component), either at the same administration site or at different sites, and in approximately the same or different dosage forms.

[0502] In order to prevent the individual mechanisms induced by A2AR inhibitor and anticancer drug from being negatively affected by each other, preferably, anticancer drug and A2AR inhibitor are administered at different times (time staggered), i.e. sequentially, and / or at different administration sites.This means that A2AR inhibitor can be administered, for example, before, at the same time, or after anticancer drug, or vice versa.Alternatively or in addition, A2AR inhibitor and anticancer drug can be administered at different administration sites or at the same administration site, and in this case, it is preferred to administer them at different times.

[0503] In one embodiment, the A2AR inhibitor is administered prior to and / or simultaneously with the immunotherapeutic agent described herein above. In one embodiment, the immunotherapeutic agent is a checkpoint inhibitor, and the A2AR inhibitor is administered the day before or the same day that the checkpoint inhibitor described herein above is administered.

[0504] In one embodiment, the A2AR inhibitor is to be administered prior to and / or simultaneously with the immunotherapeutic agent described herein above, and continuously thereafter.

[0505] In one embodiment, the A2AR inhibitor is administered before or at the same time as the immunotherapeutic agent described herein above, and then at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days thereafter.In another embodiment, the A2AR inhibitor is administered before or at the same time as the immunotherapeutic agent described herein above, and then at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 weeks thereafter.In another embodiment, the A2AR inhibitor is administered before or at the same time as the immunotherapeutic agent described herein above, and then at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 months thereafter.

[0506] In one embodiment, the immunotherapeutic agent is a checkpoint inhibitor, and the A2AR inhibitor is administered before or at the same time as the checkpoint inhibitor.In one embodiment, the immunotherapeutic agent is a checkpoint inhibitor, and the A2AR inhibitor is administered before or at the same time as the checkpoint inhibitor, and is administered continuously thereafter.In one embodiment, the immunotherapeutic agent is a checkpoint inhibitor, and the A2AR inhibitor is administered before or at the same time as the checkpoint inhibitor, and is then administered for at least 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, or 10 weeks thereafter.

[0507] Depending on the condition to be prevented or treated and the mode of administration, the combination of the present invention may be administered in a single daily dose divided into one or more administrations per day.

[0508] According to one embodiment, a therapeutically effective dose of an A2AR inhibitor as described herein above is administered for use in treating cancer in a subject in need thereof, said A2AR inhibitor being combined with an anti-cancer agent, such as an immunotherapeutic agent. Thus, in one embodiment, the pharmaceutical combination or kit of parts of the present invention comprises a therapeutically effective dose of an A2AR inhibitor as described herein above and a therapeutically effective amount of an anti-cancer agent as described herein above.

[0509] It is understood that the total daily dose of the A2AR inhibitor and the anti-cancer drug will be determined by the attending physician within the scope of sound medical judgment. The specific dose for a particular subject will vary depending on a variety of factors, such as the cancer being treated, the patient's age, weight, general health, sex, and diet, as well as similar factors well known in the medical arts.

[0510] In one embodiment, the subject is a mammal, preferably a human, and the dose of the A2AR inhibitor, preferably a therapeutically effective dose, is in the range of about 0.01 mg / kg to about 5 mg / kg of body weight, preferably about 0.08 mg / kg to about 3.3 mg / kg, and more preferably about 0.15 mg / kg to about 1.7 mg / kg.

[0511] In one embodiment, the subject is a mammal, preferably a human, and the dose of the A2AR inhibitor, preferably a therapeutically effective dose, is in the range of about 0.01 mg per kilogram of body weight per day (mg / kg / day) to about 5 mg / kg / day, preferably about 0.08 mg / kg / day to about 3.3 mg / kg / day, more preferably about 0.15 mg / kg / day to about 1.7 mg / kg / day.

[0512] In one embodiment, the subject is a mammal, preferably a human, and the dose of the A2AR inhibitor, preferably a therapeutically effective dose, is in the range of about 1 mg to about 500 mg, preferably about 5 mg to about 200 mg, more preferably about 10 mg to about 100 mg.

[0513] In one embodiment, the subject is a mammal, preferably a human, and the dose of an A2AR inhibitor, preferably Preferably, the therapeutically effective dose is in the range of about 1 mg to about 500 mg per administration, preferably about 5 mg to about 200 mg per administration, more preferably about 10 mg to about 100 mg per administration.

[0514] In one embodiment, the subject is a mammal, preferably a human, and the dose of the A2AR inhibitor, preferably a therapeutically effective dose, is a daily dose in the range of about 1 mg to about 500 mg, preferably about 5 mg to about 200 mg, more preferably about 10 mg to about 100 mg.

[0515] In one embodiment, the subject is a mammal, preferably a human, and the dose of the A2AR inhibitor, preferably a therapeutically effective dose, is a daily dose administered in one, two, three or more ingestions. In one embodiment, the subject is a mammal, preferably a human, and the dose of the A2AR inhibitor, preferably a therapeutically effective dose, is a daily dose administered in one or two ingestions.

[0516] Purpose Another object of the present invention is the use of the combination of the present invention as a medicament.Accordingly, in one embodiment, the use of the combination of the present invention in the manufacture of a medicament is provided.In particular, the present invention provides the use of the pharmaceutical composition of the present invention or the kit of the present invention in the manufacture of a medicament.

[0517] In particular, the present invention provides a combination, a pharmaceutical composition or a kit-of-parts according to the invention for use in the treatment and / or prevention of cancer.

[0518] In one embodiment the present invention relates to the treatment and / or prevention of cancer comprising the administration of a therapeutically effective amount of the combination, pharmaceutical composition or kit-of-parts of the invention to a mammalian species in need thereof.

[0519] The present invention further provides the use of a combination, pharmaceutical composition or kit-of-parts according to the invention in the manufacture of a medicament for treating and / or preventing cancer.

[0520] The present invention also provides a method for delaying the onset of cancer in a patient, comprising administering to a patient in need thereof a pharma- ceutically effective amount of the combination, pharmaceutical composition or kit-of-parts of the present invention.

[0521] Various cancers are known in the art.Cancers that can be treated using the method of the present invention include solid and non-solid cancers, particularly benign and malignant solid tumors, and benign and malignant non-solid tumors.Cancers can be metastatic or non-metastatic.Cancers can be familial or sporadic.

[0522] In one embodiment, the cancer treated according to the present invention is a solid cancer. As used herein, the term "solid cancer" includes any cancer (also called a malignant tumor) that forms a discrete mass, as opposed to a cancer (or malignant tumor) that diffusely infiltrates tissue without forming a mass.

[0523] Examples of solid tumors include biliary tract cancer, brain tumors (including glioblastoma and medulloblastoma), breast cancer, carcinoid, cervical cancer, choriocarcinoma, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, glioma, head and neck cancer, intraepithelial neoplasia (including Bowen's disease and Paget's disease), liver cancer, lung cancer, neuroblastoma, oral cancer (including squamous cell carcinoma), ovarian cancer (including those arising from epithelial cells, stromal cells, germ cells, and mesenchymal cells), pancreatic cancer, prostate cancer, rectal cancer, kidney cancer (including adenocarcinoma and Wilms' tumor), sarcomas (including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma), skin cancer (including melanoma, Kaposi's sarcoma, basal cell carcinoma, and squamous cell carcinoma), germ cell tumors. Cancers that are considered to be cancerous include, but are not limited to, testicular cancers including seminomas and non-seminomas, such as teratomas and choriocarcinomas, interstitial tumors, germ cell tumors, thyroid cancers (including thyroid adenocarcinoma and medullary carcinoma), and urothelial carcinomas.

[0524] In another embodiment, the cancer treated according to the present invention is a non-solid cancer. Examples of non-solid tumors include, but are not limited to, hematological neoplasms. As used herein, hematological neoplasms is a term of art that includes lymphoid disorders, myeloid disorders, and AIDS-related leukemia.

[0525] Lymphatic disorders include, but are not limited to, acute lymphocytic leukemia and chronic lymphoproliferative disorders (e.g., lymphoma, myeloma, and chronic lymphocytic leukemia). Lymphomas include, for example, Hodgkin's disease, non-Hodgkin's lymphoma, and lymphocytic lymphoma. Chronic lymphocytic leukemias include, for example, T-cell chronic lymphocytic leukemia and B-cell chronic lymphocytic leukemia.

[0526] In specific embodiments, the cancer is selected from breast cancer, carcinoid, cervical cancer, colorectal cancer, endometrial cancer, glioma, head and neck cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, gastric cancer, thyroid cancer, and urothelial cancer.

[0527] In a specific embodiment, the cancer is breast cancer. In a specific embodiment, the cancer is carcinoid cancer. In a specific embodiment, the cancer is cervical cancer. In a specific embodiment, the cancer is colorectal cancer. In a specific embodiment, the cancer is endometrial cancer. In a specific embodiment, the cancer is glioma. In a specific embodiment, the cancer is head and neck cancer. In a specific embodiment, the cancer is liver cancer. In a specific embodiment, the cancer is lung cancer. In a specific embodiment, the cancer is melanoma. In a specific embodiment, the cancer is ovarian cancer. In a specific embodiment, the cancer is pancreatic cancer. In a specific embodiment, the cancer is prostate cancer. In a specific embodiment, the cancer is renal cancer. In a specific embodiment, the cancer is gastric cancer. In a specific embodiment, the cancer is thyroid cancer. In a specific embodiment, the cancer is urothelial carcinoma.

[0528] In another specific embodiment, the cancer is selected from the group consisting of leukemia and multiple myeloma.

[0529] In one embodiment, the present invention relates to a combination, a pharmaceutical composition or a kit-of-parts as defined herein above for use in immunotherapy, preferably as cancer immunotherapy.

[0530] In one embodiment the present invention relates to a method of immunotherapy, preferably cancer immunotherapy, comprising administering a therapeutically effective amount of a combination, a pharmaceutical composition or a kit of parts of the present invention to a mammalian species in need thereof.

[0531] The present invention further provides the use of a combination, a pharmaceutical composition or a kit of parts according to the invention in the manufacture of a medicament for performing immunotherapy, preferably cancer immunotherapy.

[0532] In one embodiment the invention relates to the use of a combination, pharmaceutical composition or kit-of-parts according to the invention for increasing the immune recognition and destruction of cancer cells.

[0533] In one embodiment, the present invention relates to a method for increasing immune recognition and destruction of cancer cells comprising administering a therapeutically effective amount of a combination, pharmaceutical composition or kit-of-parts of the present invention to a mammalian species in need thereof.

[0534] The present invention further provides the use of a combination, pharmaceutical composition or kit-of-parts according to the invention in the manufacture of a medicament for increasing the immune recognition and destruction of cancer cells.

[0535] Preferably, the patient is a warm-blooded animal, more preferably a human.

[0536] In one embodiment, the patient administered an A2AR inhibitor described herein is also administered immunotherapy, chemotherapy, radiation therapy, or a combination thereof.

[0537] In one embodiment, the subject is resistant to immunotherapy. In one embodiment, the subject is resistant to cancer immunotherapy.

[0538] In one embodiment, the subject is resistant to chemotherapy. In one embodiment, the subject is resistant to cancer chemotherapy.

[0539] In one embodiment, the subject is resistant to radiation therapy. In one embodiment, the subject is resistant to cancer radiation therapy.

[0540] The present invention also relates to a compound of formula (I) as defined above for use in combination therapy with an anti-cancer agent as defined above, in particular an immunotherapeutic agent, a chemotherapeutic agent, an anti-angiogenic agent, a multidrug resistance associated protein inhibitor, a radiotherapeutic agent, or any combination thereof.

[0541] The present invention also relates to a compound of formula (I) as defined above for use in a patient being treated with immunotherapy, chemotherapy, radiotherapy, or a combination thereof.

[0542] Therefore, the present invention also relates to a method for treating cancer in a subject resistant to an anti-cancer drug, comprising administering to the patient a compound of formula (I) as defined above and said anti-cancer drug, in one embodiment, said anti-cancer drug is immunotherapy, chemotherapy, radiation therapy, or a combination thereof.

[0543] The present invention further relates to a method for increasing the therapeutic response of a subject to an anti-cancer agent, further comprising administering to the patient a compound of formula (I) as defined above. In one embodiment, the anti-cancer agent is an immunotherapy, a chemotherapy, a radiation therapy, or a combination thereof.

[0544] The present invention also relates to an anti-cancer agent as defined above for use in combination therapy with a compound of formula (I) as defined above. [Brief description of the drawings]

[0545] [Figure 1] 1 shows the antitumor effect of the A2AR inhibitor, compound 7, administered as a single agent in a liver Hepa1-6 syngeneic tumor model. A is a graph showing the tumor volume over time after inoculation. B shows the distribution of tumor volume on day 22. [Diagram 2] Figure 2 shows A20 tumor growth upon treatment with Compound 7 used as a single agent or in combination with anti-PD-L1. A is a graph depicting tumor volume over time after inoculation. B shows the distribution of tumor volumes on day 23. [Figure 3-1] (FIG. 3A) EMT6 tumor growth upon treatment with compound 8a in combination with antagonistic anti-CTLA4 mAb. Tumor growth over time: median values ​​are shown. (FIG. 3B) EMT6 tumor growth upon treatment with compound 8a in combination with antagonistic anti-CTLA4 mAb. Number of complete responses (CR) out of 10 mice per group is shown. Tumor growth over time: vehicle treatment is shown. [Figure 3-2] (FIG. 3C) EMT6 tumor growth upon treatment with compound 8a in combination with antagonistic anti-CTLA4 mAb. The number of complete responses (CR) out of 10 mice per group is shown. Tumor growth over time: CTLA-4, 3 mg / kg, Q3D×2 (days 9, 12) treatment alone is shown. (FIG. 3D) EMT6 tumor growth upon treatment with compound 8a in combination with antagonistic anti-CTLA4 mAb. The number of complete responses (CR) out of 10 mice per group is shown. Tumor growth over time: CTLA-4, 3 mg / kg, Q3D×2 (days 9, 12) treatment combined with compound 8, 0.1 mg / kg, QDx25 is shown. [Figure 3-3] (FIG. 3E) EMT6 tumor growth upon treatment of compound 8a in combination with antagonistic anti-CTLA4 mAb. The number of complete responses (CR) out of 10 mice per group is shown. Tumor growth over time: Combination treatment of CTLA-4, 3 mg / kg, Q3Dx2 (day 9, day 12) with compound 8, 0.6 mg / kg, QDx25 is shown. [Figure 4-1](Figure 4A) A2AR inhibitor, compound 8a, in combination with anti-PD-L1 mAb, modulates T cell infiltration in the A20 tumor microenvironment. Absolute quantification of CD3+ T cell numbers was measured by calculating from 10 high power fields / section (10 HPF) averages from independent tumors (symbols represent individual mice; n=5-7 mice / group). Median and interquartile ranges are shown, and p values ​​are calculated using the Mann-Whitney nonparametric t-test. [Figure 4-2] (Figure 4B) A2AR inhibitor, compound 8a, in combination with anti-PD-L1 mAb, modulates T cell infiltration in the A20 tumor microenvironment. Absolute quantification of CD8+ T cell numbers was measured by calculating from 10 HPF averages from independent tumors (symbols represent individual mice; n=5-7 mice / group). Median and interquartile ranges are shown, and p values ​​are calculated using the Mann-Whitney nonparametric t-test. [Figure 5-1] (FIG. 5A) MCA205 tumor growth upon treatment with compound 8b used as a single agent or in combination with oxaliplatin. A graph showing median tumor volume over time following subcutaneous inoculation of tumor cells. [Figure 5-2] (FIG. 5B) MCA205 tumor growth upon treatment with compound 8b used as a single agent or in combination with oxaliplatin. Graph showing individual tumor growth volumes of vehicle-treated mice. (FIG. 5C) MCA205 tumor growth upon treatment with compound 8b used as a single agent or in combination with oxaliplatin. Graph showing treatment with compound 8b at 0.6 mg / kg, QDx25. (FIG. 5D) MCA205 tumor growth upon treatment with compound 8b used as a single agent or in combination with oxaliplatin. Graph showing treatment with oxaliplatin at 10 mg / kg, QDx1 (day 11) alone. [Figure 5-3](FIG. 5E) MCA205 tumor growth upon treatment with compound 8b used as a single agent or in combination with oxaliplatin. Graph showing treatment with a combination of oxaliplatin (day 11) at 10 mg / kg, QDx1 and compound 8b at 0.6 mg / kg, QDx25. [Figure 6-1] (FIG. 6A) CT26 tumor growth upon treatment with compound 8b at 0.6 mg / kg, QD×32, anti-TIGIT mAb at 1 mg / kg, Q3D×3 (days 9, 12, and 15), doxorubicin at 6 mg / kg, Q3D×2 (days 10 and 14), and various combinations thereof. This figure is a graph depicting the median tumor volume over time following subcutaneous inoculation of tumor cells. [Figure 6-2] (FIG. 6B) CT26 tumor growth upon treatment with compound 8b at 0.6 mg / kg, QD×32, anti-TIGIT mAb at 1 mg / kg, Q3D×3 (days 9, 12, and 15), doxorubicin at 6 mg / kg, Q3D×2 (days 10 and 14), and various combinations thereof. This figure is a graph showing the individual tumor growth volumes of mice treated with vehicle. (FIG. 6C) CT26 tumor growth upon treatment with compound 8b at 0.6 mg / kg, QD×32, anti-TIGIT mAb at 1 mg / kg, Q3D×3 (days 9, 12, and 15), doxorubicin at 6 mg / kg, Q3D×2 (days 10 and 14), and various combinations thereof. This figure is a graph showing the individual tumor growth volumes of mice treated with doxorubicin. [Figure 6-3](FIG. 6D) CT26 tumor growth upon treatment with 0.6 mg / kg, QD×32 compound 8b, 1 mg / kg, Q3D×3 (days 9, 12, and 15), anti-TIGIT mAb, doxorubicin, 6 mg / kg, Q3D×2 (days 10 and 14), and various combinations thereof. This figure is a graph showing the individual tumor growth volumes of mice treated with anti-TIGIT mAb. (FIG. 6E) CT26 tumor growth upon treatment with 0.6 mg / kg, QD×32 compound 8b, 1 mg / kg, Q3D×3 (days 9, 12, and 15), anti-TIGIT mAb, doxorubicin, 6 mg / kg, Q3D×2 (days 10 and 14), and various combinations thereof. This figure is a graph showing the individual tumor growth volumes of mice treated with a combination of doxorubicin and anti-TIGIT. [Figure 6-4] (FIG. 6F) CT26 tumor growth upon treatment with compound 8b at 0.6 mg / kg, QD×32, anti-TIGIT mAb at 1 mg / kg, Q3D×3 (days 9, 12, and 15), doxorubicin at 6 mg / kg, Q3D×2 (days 10 and 14), and various combinations thereof. This figure is a graph showing the individual tumor growth volumes of mice treated with a combination of compound 8b and doxorubicin. (FIG. 6G) CT26 tumor growth upon treatment with compound 8b at 0.6 mg / kg, QD×32, anti-TIGIT mAb at 1 mg / kg, Q3D×3 (days 9, 12, and 15), doxorubicin at 6 mg / kg, Q3D×2 (days 10 and 14), and various combinations thereof. This figure is a graph depicting individual tumor growth volumes in mice treated with the triple combination of compound 8b, doxorubicin, and anti-TIGIT. [Figure 7] A shows the proliferation rate of proliferating CD4+ cells determined by the CFSE dilution method. B shows the concentration of TNFα present in the cell culture supernatant. CD39i represents the combination of the CD39 inhibitors ARL67156 and POM-1. Dark grey bars represent wells treated with compound 8a and light grey bars represent wells treated with an equivalent concentration of DMSO. Results are shown as the mean ± standard deviation from duplicate wells. EXAMPLES

[0546] The present invention may be better understood by reference to the following examples, which are intended to represent specific embodiments of the invention and are not intended to limit the scope of the invention.

[0547] The following abbreviations are used: BHT: Butylated hydroxytoluene BID: bis in die (i.e. twice a day) ca.: approx. CR: complete response DMSO: Dimethyl sulfoxide EDTA: Ethylenediaminetetraacetic acid HPLC: High-performance liquid chromatography LC-MS: Liquid chromatography-mass spectrometry mAb: Monoclonal antibody mg: milligram MS: Mass spectrometry PBS: Phosphate-buffered saline PEG: Polyethylene glycol QD: quaque die (i.e. once a day) Q3D: quaque 3 die (i.e. every 3 days) rpm: Revolutions per minute TGI: Tumor growth inhibition TIL: tumor infiltrating lymphocytes UV: Ultraviolet light μL: microliter %v / v: Volume percent of the total volume of the composition %w / w: weight percent of the total weight of the composition

[0548] I. Compound Compounds of formula (I) are prepared as described in PCT / EP2018 / 058301.

[0549] II. Pharmaceutical Compositions II.1. Preparation of Pharmaceutical Compositions Two compositions according to the invention were prepared in capsule form containing the following ingredients (Table 2): Table 2: Composition of capsules (% w / w). [Table 2]

[0550] Capsule 2A was prepared from a common blend using conventional blending and capsule filling processes in accordance with good manufacturing practice. Lauroyl polyoxyl-32 glyceride is melted at a product temperature of 50°C or higher and less than 80°C. Caprylic acid and then butylated hydroxytoluene (BHT) are further added to the lauroyl polyoxyl-32 glyceride and mixed together using a suitable mixer. Compound 8a is then gradually added to the lauroyl polyoxyl-32 glyceride / caprylic acid / BHT blend with continuous mixing using a suitable mixer to visually uniformly distribute the drug substance without observable lumps or agglomerates. Mixing is then continued for at least 30 minutes to ensure that the drug substance is visually uniformly distributed. Mixing is then continued to maintain the blend in a molten state and filled into appropriately sized gelatin capsule shells to the target capsule fill weight. Capsule filling is performed using conventional capsule filling methods and equipment suitable for use with molten semi-solid formulations.

[0551] A similar process was carried out to manufacture all other capsule examples using Vitamin E TPGS instead of Lauroyl Polyoxyl-32 Glyceride.Polyvinylcaprolactam-Polyvinylacetate-Polyethyleneglycol Graft Copolymer and Hydroxypropylmethylcellulose are added to the molten Lauroyl Polyoxyl-32 Glyceride or Vitamin E TPGS as required.

[0552] II.2. Pharmacology Examples II.2.i. Thermodynamic Solubility by Shake Flask - HPLC The purpose of this example is to demonstrate that the compound of formula (I) is poorly soluble in water or aqueous buffers, making it necessary to provide a formulation of said compound.

[0553] Compound 8a (2.0 mg, crystalline solid) was weighed and placed in the lower chamber of a Whatman miniuniprep vial. 450 μL of test medium was added to each chamber. After this addition, the filter piston of the miniuniprep vial was placed and compressed to the liquid level to allow the medium and compound to contact the filter during incubation. The samples were vortexed for 2 minutes and then incubated at room temperature (approximately 22-25°C) for 24 hours with shaking at 880 rpm. The miniuniprep was compressed to prepare the filtrate for injection into the HPLC system. The supernatant was diluted 50-fold with medium to make dilutions. Three UV standard solutions ranging from low to high concentration were injected into the HPLC, after which the dilutions and supernatants were tested. Test samples were injected in duplicate.

[0554] The results are shown in Table 3. Table 3: Solubility of compound 8a in tested aqueous media. [Table 3]

[0555] The solubility is very low in all aqueous media tested, with studies in FaSSIF (fasting state simulated intestinal fluid) indicating low intestinal solubility.

[0556] II.2.ii. Exposure in dogs after oral dosing The purpose of this assay is to determine the exposure in dogs following oral administration of the pharmaceutical composition of the present invention. Dogs are administered pentagastrin to stimulate gastric acid secretion immediately prior to administration of the capsule formulation.

[0557] Five male beagle dogs (over 6 months old, weighing 7-9 kg) were fed in the afternoon (3:30-4:00 pm) of the day before oral administration, and the remaining food was collected at around 7:00 pm. Feeding was withheld until blood sampling 4 hours later.

[0558] Pentagastrin (Sigma, 1 mg) was dissolved in 200 μL (0.200 mL) of 10% (v / v) ammonium hydroxide (NH4OH) / 90% (v / v) phosphate buffered saline (PBS). 0.12 mL of this stock solution was then diluted by adding 4.88 mL of PBS solution, after which the vial was vortexed. The solution was filtered (under a laminar flow hood) through a 0.22 μm syringe filter into a sterile amber glass serum bottle. Animals were administered 6 μg / kg pentagastrin by intramuscular injection approximately 30 minutes (± 2 minutes) prior to capsule administration.

[0559] A dose of capsule formulation (80 mg / dog, i.e., approximately 10 mg / kg of animal) was administered by placing the capsule at the back of the dog's throat and pushing it down the pharynx using the thumb or index finger. To facilitate administration, the capsules were moistened with water. After administration, swallowing was induced by gently stroking the dog's throat or tapping the dog under the chin, if necessary. Immediately after capsule administration, the animals were given water (4 mL / kg) or an aqueous HCl solution at pH 2.5 (4 mL / kg) orally to encourage swallowing of the capsule. After administration, the animals' oral cavity was examined to ensure that the drug had been swallowed.

[0560] At the time points shown in Table 4, blood was collected into tubes (Jiangsu Kangjian medical supplies co., LTD) on wet ice containing potassium (K2)EDTA*2H2O (0.85-1.15 mg) and centrifuged (3,000xg, 2-8°C for 10 min) within 1 h of collection to obtain plasma. Plasma samples (0.2 mL) were transferred to labeled polypropylene microcentrifuge tubes and stored frozen at -60°C or below until bioanalysis.

[0561] Plasma concentrations of compound 8a were quantified by LC-MS / MS. The measured concentrations (average of 5 dogs) are shown in Table 4, and the main pharmacokinetic parameters are shown in Table 5. Table 4. Plasma concentrations of compound 8a. [Table 4] Table 5. Pharmacokinetic parameters. [Table 5] C max : Maximum plasma concentration of the active ingredient obtained after administration; T max :C max AUC: area under the curve, equivalent to the integral of the concentration-time curve (AUC last : AUC until the last sample collection; AUC inf : AUC up to infinite time).

[0562] The above results indicate that the use of the pharmaceutical composition of the present invention can be used to favorably administer thiocarbamate A2A inhibitors. This is clear evidence that oral bioavailability is possible.

[0563] III. Combination with anticancer drugs - in vivo testing Summary of results: Compound 7 at 3 mg / kg BID significantly delayed the growth of HEPA-1-6 tumors compared to vehicle controls in syngeneic hosts.

[0564] Compound 7, in combination with anti-PD-L1, demonstrated anti-tumor activity at 0.3 mg / kg BID in a syngeneic mouse lymphoma model and significantly delayed tumor growth at 3 mg / kg BID compared to the A20 anti-PD-L1 control.

[0565] In combination with anti-CTLA-4, compound 8a showed antitumor activity at 0.1 mg / kg in the EMT6 syngeneic mouse breast cancer model, significantly delayed tumor growth starting at 0.6 mg / kg in a dose-dependent manner, and in cured mice, growth was prevented after reinoculation, suggesting the induction of a specific memory response.

[0566] Further illustrating the mechanism of action, compound 8a at 3 mg / kg BID in combination with anti-PD-L1 significantly increased CD3+ and CD8+ cell infiltration without affecting FOXP3-expressing cells.

[0567] Compound 8b, in combination with oxaliplatin, showed significant antitumor activity at 0.6 mg / kg in the MCA205 syngeneic murine fibrosarcoma cancer model by slowing tumor growth.

[0568] Compound 8b, when combined with doxorubicin, showed significant antitumor activity at 0.6mg / kg by slowing tumor growth in CT26 syngeneic mouse colon cancer model. In the same example, the triple combination of doxorubicin, 1mg / kg anti-TIGIT mAb, and 0.6mg / kg compound 8b showed significantly enhanced antitumor activity in CT26 syngeneic mouse colon cancer model compared with the binary combination of doxorubicin and compound 8b or doxorubicin and anti-TIGIT mAb.

[0569] III.1. Syngeneic HEPA1-6 Mouse Liver Tumor Model In this study, the antitumor activity of compound 7 in a mouse hepatocellular carcinoma model (NCR-A2A-032) was evaluated.

[0570] Hepa 1-6 tumor cells were inoculated subcutaneously into the right flank region of C57BL / 6 female mice (8 weeks old) (day 0). The tumor size was approximately 50 mm 3 Upon reaching this age (day 4), mice were randomly assigned to experimental groups and treated from day 4 to day 25. Mice were administered vehicle (10% DMSO, 10% Solutol HS15 in dH2O, pH 3) po or Compound 7 at 0.3 and 3 mg / kg, po, BIDx21.

[0571] Compound 7 at 3 mg / kg demonstrated significant antitumor efficacy, with a tumor growth inhibition (TGI) of 44% measured at day 22 (p=0.024) (Figure 1, A and B).

[0572] III.2. Syngeneic A20 Experimental Lymphoma Model in Combination with Anti-PD-L1 In this study, the antitumor efficacy of compound 7 as a single agent (monotherapy) or in combination with an antagonist, anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody (10F.9G2, BioXcell), was evaluated in a model of B-cell lymphoma (NCR-A2A-031).

[0573] A20 murine B-cell tumor cells were inoculated subcutaneously into the right lower flank region of BALB / c female mice (8 weeks old) (day 0). Tumors were approximately 50 mm in size. 3 At the time of reaching 100 mg / kg (day 7), mice were randomly assigned to groups and treatment was initiated. Mice were administered vehicle (10% DMSO, 10% Solutol HS15 in dH2O, pH 3) as a control po, or Compound 7 at 0.3 and 3 mg / kg, po, BIDx21 (days 7-28), or anti-PD-L1 mAb at 5 mg / kg, ip (intraperitoneal), Q3Dx3 (days 9, 12, 15), either as single agents or in combination.

[0574] Compound 7, administered po at 0.3 mg / kg BID in combination with anti-PD-L1 mAb, demonstrated antitumor activity (TGI=76%, measured on day 23) compared to anti-PD-L1 monotherapy (TGI=49%), although this did not reach statistical significance (p=0.106).

[0575] Compound 7, administered at 3 mg / kg BID in combination with anti-PD-L1 mAb, demonstrated significantly enhanced anti-tumor activity (p=0.039 for TGI, p=0.0008 for overall inhibition of tumor growth) compared with single-agent anti-PD-L1 mAb (TGI=82% and 49%, respectively, observed on day 23) ( Figure 2, A and B ).

[0576] Statistical analysis also revealed that compound 7 synergized with anti-PD-L1 mAb to significantly inhibit the growth of established A20 syngeneic tumors (p=0.017).

[0577] III.3. Syngeneic EMT6 breast cancer model in combination with anti-CTLA-4 The antitumor efficacy of compound 8a in combination with an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antagonist mAb (9H10, BioXcell) was evaluated in a triple-negative breast cancer model.

[0578] EMT6 mammary tumor cells were orthotopically inoculated into the right lower mammary fat pad of 8-week-old female BALB / c mice (day 0). Tumors were approximately 60 mm in size. 3 At the time of reaching 100 mg / kg (day 9), mice were randomly assigned to groups. Mice were administered control vehicle (10% DMSO, 10% Solutol HS15 in dH2O, pH 3) po or anti-CTLA-4 mAb at 3 mg / kg, ip, Q3Dx2 (days 9, 12) alone or in combination with compound 8a at 0.1 mg / kg, po, QDx25 or 0.6 mg / kg, po, QDx25.

[0579] Compound 8a in combination with anti-CTLA-4 significantly reduced tumor growth when administered at 0.6 mg / kg (p=0.0153, mean TGI=99%, measured at day 31--complete response (CR)=7 / 10) versus anti-CTLA4 alone (CR=3, mean TGI=72%, measured at day 31) (Figure 3A, B, C, and E). Compound 8a at 0.1 mg / kg in combination with anti-CTLA-4 mAb (as above) did not reach statistical significance (p=0.8665) versus anti-CTLA4 mAb as a single agent, but did result in CR=5 (group of n=10 mice) and mean TGI=85% (Figure 3A and D). In addition, there was no statistically significant difference between doses. This suggests that compound 8a already shows in vivo activity at 0.1 mg / kg in combination with anti-CTLA4 mAb (Figure 1).

[0580] When complete responders (cured mice) were re-inoculated with EMT6 tumor cells (specific antigen) or xenogeneic colon CT26 cells (non-specific antigen), mice previously treated with 0.1 and 0.6 mg / kg of compound 8a in combination with anti-CTLA-4 mAb were not protected from challenge with xenogeneic CT26 cells (100% tumor incidence), but completely rejected the EMT6 cells in 66% (0.1 mg / kg) and 100% (0.6 mg / kg) of mice, respectively. (No tumor formation).

[0581] Thus, compound 8a, in combination with an anti-CTLA-4 antagonist mAb, significantly inhibits the growth of established EMT6 syngeneic tumors and induces a long-term memory response that results in a durable specific anti-tumor response.

[0582] III.4.Mechanism of action of compound 8A in reducing tumor growth in the A20 lymphoma model Compound 8a (or its racemic mixture, compound 7) has been determined to exhibit antitumor activity at well-tolerated doses in several experimental tumor models. In this study, the mechanism of action responsible for this effect was evaluated.

[0583] Compound 8a was evaluated as a single agent and in combination with an antagonist anti-PD-L1 mAb in a B cell lymphoma tumor model. A20 tumor-bearing mice (tumor size approx. 70 mm3, day 12 post-inoculation) were treated with control vehicle (10% DMSO, 10% Solutol HS15 in dH2O, pH 3) po, or anti-PD-L1 mAb at 1 mg / kg, ip, Q3Dx3 (days 14, 17, and 20), and compound 8a at 3 mg / kg, po, BIDx10 as a single agent or in combination with anti-PD-L1 mAb. Total CD3 + T cells, CD8 + T cells and FOXP3 + Tumor infiltrating lymphocytes (TILs), including Treg cells, were characterized by IHC staining and compared using semiquantitative methods.

[0584] Compound 8a at 3 mg / kg as a single agent regimen inhibited CD3 + TIL and CD8 + Although it had a modest effect on TILs, the increase in infiltration did not reach significance. The combination of 3 mg / kg compound 8a with anti-PDL-1 mAb significantly increased CD3+ in tumors compared to anti-PDL-1 mAb used as a single agent. + T cells (p=0.0068) and CD8 + There was a significant increase in T cell (p=0.0035) infiltration (FIGS. 4A and 4B). Treatment with either the single agents or the combination did not show a statistically significant change in Treg infiltration.

[0585] These results strongly suggest that the combination of compound 8a with aPDL-1 mAb significantly modulates the immunosuppressive nature of the tumor microenvironment by increasing the infiltration of TILs.

[0586] III.5. Syngeneic MCA205 Experimental Fibrosarcoma Model in Combination with Oxaliplatin The antitumor efficacy of compound 8b in combination with oxaliplatin was evaluated in an established mouse syngeneic MCA205 fibrosarcoma tumor model.

[0587] MCA205 tumor cells were inoculated subcutaneously into the right flank of C57BL / 6 mice. The average tumor size was approximately 80 mm 3 At the time of reaching 100 mg / kg, mice were randomly assigned to groups. Mice were administered vehicle (10% DMSO, 10% Solutol HS15 in dH2O, pH 3) as a control po, or compound 8b at 0.6 mg / kg, QDx25 (days 11-36), or oxaliplatin at 10 mg / kg, ip, QDx1 (day 11), either as single agents or in combination.

[0588] Oxaliplatin administered as a single dose ip on day 11 demonstrated significant tumor growth delay (p=0.0202) compared to vehicle (Figure 5).

[0589] Compound 8b administered po at 0.6 mg / kg once daily (QD) for 25 consecutive days in combination with oxaliplatin showed significant tumor growth retardation compared to vehicle (p <0.0001), and also showed significant tumor growth delay when compared with oxaliplatin monotherapy (p=0.0284) (Figure 5).

[0590] III.6. Syngeneic CT26 Experimental Colon Cancer Model in Combination with Doxorubicin and / or Anti-TIGIT MAb In this study, the antitumor efficacy of compound 8b in combination with the chemotherapeutic agent doxorubicin and anti-TIGIT mAb was evaluated in a colon tumor model (CT26).

[0591] CT26 mouse tumor cells were inoculated subcutaneously into the right lower flank region of BALB / c female mice (8 weeks old) (day 0). Tumors were approximately 90 mm in size. 3 At the time of reaching 100 mg / kg (day 9), mice were randomly assigned to groups and treatment was initiated. Mice were administered vehicle (10% DMSO, 10% Solutol HS15 in dH2O, pH 3) po as a control, or doxorubicin at 6 mg / kg, iv, Q4Dx2 (days 10 and 14), or anti-TIGIT mAb, 29527 (see US10329349), at 1 mg / kg, ip, Q3Dx3 (days 9, 12, and 15), either as a single agent or in combination with compound 8b at 0.6 mg / kg, po, QDx32 (days 9-41).

[0592] Intraperitoneal injection of 1 mg / kg of the anti-TIGIT mAb, 29527 (see US10329349), on days 9, 12, and 15 after tumor cell inoculation significantly inhibited tumor growth compared to vehicle-treated mice (p=0.0009, FIG. 6).

[0593] Doxorubicin at 6 mg / kg given twice on days 10 and 14 did not significantly affect tumor growth (p=0.14, Figure 6), but when combined with anti-TIGIT mAb, the anti-tumor effect was improved (p=0.008 and p=0.0002, compared with anti-TIGIT mAb or doxorubicin monotherapy, respectively) (Figure 6).

[0594] Compound 8b at 0.6 mg / kg administered QD from day 9 in combination with doxorubicin at 6 mg / kg administered on days 10 and 14 achieved significant antitumor efficacy when compared to doxorubicin administered alone (p=0.0003, FIG. 6). Antitumor growth efficacy in mice treated with the triple combination of compound 8b, doxorubicin, and anti-TIGIT was significantly improved when compared to doxorubicin + compound 8b (p<0.0001) or anti-TIGIT + doxorubicin (p=0.003). In this triple combination treatment group, 5 of 8 mice achieved complete response (CR) versus 0 and 1 of 10 mice for the doxorubicin + compound 8b and anti-TIGIT + doxorubicin combinations, respectively (FIG. 6).

[0595] III.7. Restoration of human T cell function in combination with CD39 inhibitors Objective: When T cells are activated, they proliferate and produce proinflammatory cytokines. Addition of adenosine triphosphate (ATP) to the culture provides a source of adenosine, as ATP is first converted to adenosine monophosphate by CD39 and then converted to adenosine by CD73. Adenosine is a cytotoxic agent that inhibits the proliferation and proliferation of T cells. 2A ATP binds to the Aβ receptor, partially suppressing T cell proliferation and cytokine production. Therefore, the purpose of this assay is to determine whether inhibition of proliferation and inflammatory cytokine production by T cells in the presence of ATP is consistent with that of Aβ. 2A The objective of this study was to demonstrate that this could be reversed by combination of the receptor antagonist compound 8a with the CD39 inhibitors ARL67156 and POM-1.

[0596] PBMC and CD3+ Isolation of T cells. Venous blood from healthy volunteers was obtained from ImmuneHealth (Centre Hospitalier Universitaire Tivoli, La Louviere, Belgium). SepMate- Peripheral blood mononuclear cells (PBMCs) were collected by density gradient centrifugation using 50 tubes (StemCell Technologies, Grenoble, France) and Lymphoprep (Axis-shield, Oslo, Norway) according to the manufacturer's instructions. PBMCs were stored in heat-inactivated fetal bovine serum (hiFBS; Gibco, ThermoFisher Scientific, Merelbeke, Belgium) containing 10% DMSO in liquid nitrogen until needed. PBMCs were thawed, washed with PBS (containing 10% hiFBS) and labeled with 1 μM CFSE (Life Technologies) for 5 min at room temperature. Cells were washed with StemCell isolation buffer and CD3 T cells were isolated by negative selection for immunomagnetic separation using the EasySep Human T Cell Isolation Kit (StemCell Technologies) according to the manufacturer's instructions. + T cells were isolated.

[0597] Human T cell activation assay. Human CD3 + T cells were washed with X-VIVO15 medium (LONZA) and plated in 96 round-bottom well plates at 8 × 10 cells per well. 4 Distributed in cells. 2A Wells received either the receptor antagonist compound 8a at a final concentration of 100 nM or a matching concentration of DMSO (Sigma-Aldrich). In addition, some wells received the CD39 inhibitors ARL67156 (Tocris Bioscience, 100 μM) and POM-1 (Tocris Bioscience, 10 μM), or a combination of both the CD39 inhibitor and compound 8a. Cells were cultured in the presence or absence of ATP (Sigma-Aldrich) at a final concentration of 100 μM and incubated with anti-CD3 and anti-CD28 coated microbeads (Dynabeads human T-activating factor CD3 / CD28; Life Sciences, Inc.). The antibody was activated by adding 100% glycerol (Technologies).

[0598] The cells were placed in a humidified tissue culture incubator at 37°C with 5% CO2 for 72 hours. After 72 hours, the supernatant was sampled and stored at -20°C. CD4 + T cell proliferation was assessed by determining CFSE dilution by flow cytometry using a BD LSRFortessa (BD Biosciences). Supernatants were then thawed and TNFα was quantified using the AlphaLISA human TNFα biotin-free detection kit (AL325; Perkin-Elmer, Zaventem, Belgium) according to the manufacturer's instructions.

[0599] Results: The presence of ATP is related to CD4 + ATP significantly inhibited T cell proliferation, which was almost completely rescued by the CD39 inhibitors ARL67156 and POM-1 (Figure 7A). The presence of compound 8a contributed slightly to this increased cell proliferation. ATP also significantly inhibited TNFα production. Compound 8a and CD39 inhibitors both individually restored approximately 50% of TNFα production, but in combination completely rescued it (Figure 7B). Collectively, these data indicate that the combination of compound 8a and CD39 inhibitors is beneficial for cancer immunotherapy aimed at fully restoring T cell function in an ATP-rich tumor microenvironment.

Claims

1. (a) Formula (I): [C15] [In the formula, R 1 represents a 5- or 6-membered heteroaryl or a 5- or 6-membered aryl, the heteroaryl or aryl group being optionally substituted with one or more substituents selected from C1-C6 alkyl (preferably methyl) and halo (preferably fluoro or chloro), preferably R 1 represents a 5-membered heteroaryl, more preferably R 1 represents a frill; R 2 represents a 6-membered aryl or a 6-membered heteroaryl; The heteroaryl or aryl group is optionally substituted with one or more substituents selected from halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino, and alkylsulfonealkyl; The substituents are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydrocarbyl, hydroxyalkyl, hydroxyalkylamino ... or substituted with one or more substituents selected from oxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; Alternatively, said heteroaryl or aryl group is optionally substituted with two substituents which, together with the atoms to which they are attached, form a 5- or 6-membered aryl ring, a 5- or 6-membered heteroaryl ring, a 5- or 6-membered cycloalkyl ring, or a 5- or 6-membered heterocyclyl ring, and is optionally substituted with oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, or a pharmaceutically acceptable salt or solvate thereof; (b) a lipid carrier selected from lauroyl polyoxyl-32 glyceride, D-α-tocopherol-polyethylene glycol-1000 succinate, and mixtures thereof; and (c) optionally, one or more other pharma- ceutically acceptable carriers, diluents, excipients, and / or adjuvants.

2. The compound has the formula (Ia) [C16] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is as defined in claim 1; X 1 and X 2 each independently represents C or N; X 1 If N, then R 1’ does not exist or X 1 If C, then R 1’ represents H, halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino, or alkylsulfonealkyl; The substituents are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydride, substituted with one or more substituents selected from alkyloxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; R 2’ represents H, halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino, or alkylsulfonealkyl; The substituents are optionally selected from oxo, halo, hydroxy, cyano, alkyl, alkenyl, or substituted with one or more substituents selected from aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; Or, R 1’ and R 2’together with the atoms to which they are attached form a 5- or 6-membered aryl ring, a 5- or 6-membered heteroaryl ring, a 5- or 6-membered cycloalkyl ring, or a 5- or 6-membered heterocyclyl ring, and are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkyla substituted with one or more substituents selected from amino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; X 2 If N, then R 3’ does not exist or X 2 If C, then R 3’ represents H or halo, preferably H or F; R 4’ represents H or halo, preferably H or F; R 5’ The pharmaceutical composition according to claim 1 , wherein represents H or halo, preferably H or F.

3. The compound represented by formula (Ia-1) [C17] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 , R 1’ , R 2’ , R 3’ , R 4’ , and R 5’ The pharmaceutical composition according to claim 1 or claim 2, wherein is as defined in claim 2.

4. The compound represented by formula (Ia-1a) [C18] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 and R 3’ is as defined in claim 2; R 1’’ is an oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl 4. The pharmaceutical composition according to claim 1, wherein the aryl or heterocyclyl group is substituted by one or more groups selected from: nyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

5. The compound represented by formula (Ia-1b) [C19] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 and R 3’ is as defined in claim 2; R 1’ represents H or halo, preferably H or F; R 2’’ is oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)amino 4. The pharmaceutical composition according to any one of claims 1 to 3, which represents an alkyl or heterocyclyl group substituted with one or more groups selected from carbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

6. The compound has the formula (Ia-1c) or (Ia-1d) [C20] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 and R 3’ is as defined in claim 2; R 1’ represents H or halo, preferably H or F; R 2’ represents H or halo, preferably H or F; R 1i and R 1ii each independently represents hydrogen, hydroxy, alkyl, alkenyl, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkynealkyl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxidealkyl, or alkylsulfonealkyl; R 2i and R 2iiare each independently hydrogen, hydroxy, alkyl, alkenyl, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkynealkyl, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl 4. The pharmaceutical composition according to any one of claims 1 to 3, wherein R represents an alkyl group selected from the group consisting of aryl, ...

7. The compound of formula (I) 3-(2-(4-(4-((1H-1,2,3-triazol-4yl)methoxy-2-fluorophenyl)piperazin-1-yl)ethyl)-5-amino-(8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-((4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)methyl)-1,3,4-oxadiazol-2(3H)-one; 5-amino-3-(2-(4-(3-fluoropyridin-4-yl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)acetamide; (S)-5-amino-3-(2-(4-(2-fluoro-4-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(2-fluoro-4-(2-(methylsulfinyl)ethoxy)phenyl)-piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R,S)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-8-(furan-2-yl)-3-(2-(4-(4-(2-hydroxyethoxy)phenyl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)phenoxy)acetic acid; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)phenoxy)acetamide; 5-amino-3-(2-(4-(4-(2,3-dihydroxypropoxy)phenyl)pyridine (perazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(4-(2-aminoethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-methylbenzamide; 5-amino-8-(furan-2-yl)-3-(2-(4-(4-(2-morpholinoethoxy)phenyl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(4-(2-(dimethylamino)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)benzenesulfonamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-methylbenzenesulfonamide; 5-amino-8-(furan-2-yl)-3-(2-(4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-8-(furan-2-yl)-3-(2-(4-(4-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 3-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)benzamide; 5-amino-8-(furan-2-yl)-3-(2-(4-(3-(2-hydroxyethoxy)phenyl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(2-oxo-2-(piperazin-1-yl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(piperidin-4-ylmethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(piperazine-1-carbonyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(2-(piperazin-1-yl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-Amino-3-(2-(4-(2-fluoro-4-(piperazin-1-ylsulfonyl )phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(methylsulfonyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2-aminoethyl)-3-fluorobenzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-(methylamino)ethyl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2-(dimethylamino)ethyl)-3-fluorobenzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-hydroxyethyl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2,3-dihydroxypropyl)-3-fluorobenzamide; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)acetic acid; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3,5-difluorophenoxy)acetic acid; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)propanoic acid; (S)-2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)propanoic acid; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-2-methylpropanoic acid; 3-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenyl)propanoic acid; 4-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)butanoic acid; 2-(3-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,6-difluorophenoxy)acetic acid; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo [5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)acetic acid; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorobenzoic acid; 2-((2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)ethyl)amino)acetamide; 2-((2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)ethyl)(methyl)amino)acetamide; 5-amino-3-(2-(4-(2-fluoro-4-(piperidin-4-yloxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(pyrrolidin-3-yloxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 3-(2-(4-(4-((1H-1,2,4-triazol-3-yl)methoxy)-2-fluorophenyl)piperazin-1-yl)ethyl)-5-amino-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-N-(2-(methylamino)ethyl)acetamide; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-N-(2-(dimethylamino)ethyl)acetamide; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-N-(2-aminoethyl)acetamide; (R)-2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)propanoic acid; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)acetamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-methyl-N-(2-(methylamino)ethyl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2-(dimethylamino)ethyl)-3-fluoro-N-methylbenzamide; (R)-4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolidine b[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(1-(dimethylamino)propan-2-yl)-3-fluorobenzamide; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-N-methyl-N-(2-(methylamino)ethyl)acetamide; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)-2-methylpropanoic acid; (S)-2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)propanoic acid; (R)-2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)propanoic acid; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)-N-(2-(methylamino)ethyl)acetamide; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)-N-(2-(dimethylamino)ethyl)acetamide; 5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2-(dimethylamino)ethyl)-2,4-difluoro-N-methylbenzamide; 4-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)butanoic acid; 3-(2-(4-(5-((1H-tetrazol-5-yl)methoxy)-2,4-difluorophenyl)piperazin-1-yl)ethyl)-5-amino-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-(methyl(oxetan-3-yl)amino)ethyl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-((2-hydroxyethyl)amino)ethyl)benzamide; 2-amino-N-(2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)ethyl)acetamide; (S)-2-amino-N-(2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)ethyl)-3-methylbutanamide; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)ethyl acetate; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)acetonitrile; 5-amino-8-(furan-2-yl)-3-(2-(4-(pyridin-4-yl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-8-(furan-2-yl)-3-(2-(4-(pyrimidin-4-yl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfonyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(2-(methylsulfonyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(6-fluoro-2-oxoindolin-5-yl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(S-methylsulfonimidoyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2-(dimethylamino)ethyl)-2,4-difluorobenzamide; 5-amino-3-(2-(4-(5-fluoro-2-methylpyridin-4-yl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3R,4R)-4-hydroxytetrahydrofuran-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)oxy)phenyl)piperazin-1-yl)ethyl) -8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(2-hydroxypropan-2-yl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(3,3,3-trifluoro-2-hydroxypropoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-5-(2-hydroxyethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(morpholin-2-ylmethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(morpholin-3-ylmethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(((3S,4S)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(((3S,4S)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(((3R,4S)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(((3S,4R)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(2,4-difluoro-5-((2-oxopyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(2,4-difluoro-5-((2-oxopyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl )ethyl)piperazin-1-yl)-2,4-difluorophenoxy)-N-(2-morpholinoethyl)acetamide; 5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluoro-N-(morpholin-3-ylmethyl)benzamide; 5-amino-3-(2-(4-(2-fluoro-4-(morpholin-3-ylmethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(morpholin-2-ylmethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3R,4R)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3S,4S)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3R,4S)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3S,4R)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-N-(2-morpholinoethyl)acetamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-morpholinoethyl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(morpholin-3-ylmethyl)benzamide; 5-amino-3-(2-(4-(4-(azetidin-3-yloxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(2,4-difluoro-5-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(2,4-difluoro-5-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(((1s,4s)-1-o oxidetetrahydro-2H-thiopyran-4-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(((1r,4r)-1-oxidotetrahydro-2H-thiopyran-4-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluoro-N-(2-(methylsulfinyl)ethyl)benzamide; (R)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluoro-N-(2-(methylsulfinyl)ethyl)benzamide; (S)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluoro-N-methyl-N-(2-(methylsulfinyl)ethyl)benzamide; (R)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluoro-N-methyl-N-(2-(methylsulfinyl)ethyl)benzamide; 5-amino-3-(2-(4-(2,4-difluoro-5-(1-oxidothiomorpholine-4-carbonyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(1-oxidothiomorpholino)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(2-fluoro-4-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(2-fluoro-4-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((1s,4s)-1-oxidotetrahydro-2H-thiopyran-4-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((1r,4r)-1-oxidotetrahydro-2H-thiopyran-4-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-(methylsulfinyl)ethyl)benzamide; (R)-4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-3(2H)-yl n-(2-(methylsulfinyl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-(methylsulfinyl)ethyl)benzamide; 5-amino-3-(2-(4-(2-fluoro-4-(1-oxidothiomorpholine-4-carbonyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(1-oxidothiomorpholino)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(5-(2,3-dihydroxypropoxy)-2,4-difluorophenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(5-(2,3-dihydroxypropoxy)-2,4-difluorophenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2,3-dihydroxypropyl)-2,4-difluorobenzamide; (R)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2,3-dihydroxypropyl)-2,4-difluorobenzamide; 5-amino-3-(2-(4-(4-(azetidin-3-yloxy)-2-fluorophenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(5-(azetidin-3-yloxy)-2,4-difluorophenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(2,4-difluoro-5-(3-(methylsulfinyl)propoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; The pharmaceutical composition according to any one of claims 1 to 6, wherein the compound is selected from the group consisting of: and a pharma- ceutically acceptable salt or solvate thereof.

8. The compound of formula (I) (R,S)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (+)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; The pharmaceutical composition according to any one of claims 1 to 7, which is selected from the group consisting of: and a pharma- ceutically acceptable salt or solvate thereof.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the salt of the compound is a hydrochloride or an esylate.

10. The pharmaceutical composition of any one of claims 1 to 9, further comprising PEG 400, PEG 3350, and / or caprylic acid.

11. 11. The pharmaceutical composition according to any one of claims 1 to 10, further comprising an antioxidant, preferably said antioxidant is selected from butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), citric acid, sodium metabisulfite, ascorbic acid, methionine and vitamin E, more preferably said antioxidant is BHT.

12. It further comprises a humectant, preferably the humectant is sodium lauryl sulfate, vitamin E. The pharmaceutical composition according to any one of claims 1 to 11, wherein said wetting agent is selected from TPGS, docusate sodium, polysorbate 80, and poloxamer 407, more preferably said wetting agent is sodium lauryl sulfate.

13. The pharmaceutical composition according to any one of claims 1 to 12, further comprising a precipitation inhibitor, preferably the precipitation inhibitor is selected from hydroxypropyl methylcellulose, methylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone-polyvinyl acetate copolymer, polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and poloxamer 407, more preferably the precipitation inhibitor is hydroxypropyl methylcellulose.

14. 14. The pharmaceutical composition according to any one of claims 1 to 13, wherein said compound of formula (I) is present in an amount ranging from 1% to 20% w / w, preferably from 5% to 15% w / w, more preferably about 10% w / w.

15. 15. The pharmaceutical composition according to any one of claims 1 to 14, wherein the lipid carrier is present in an amount ranging from 55% to 99% w / w, preferably from 60% to 95% w / w, more preferably from 70% to 90% w / w.

16. The pharmaceutical composition according to any one of claims 1 to 15, wherein the composition can be formulated into different dosage forms, such as capsules, tablets, or granules.

17. 17. The pharmaceutical composition of any one of claims 1 to 16, formulated as a capsule, wherein the capsule shell is composed of gelatin and optionally further ingredients such as polyethylene glycol and sodium lauryl sulfate are included in the capsule shell.

18. A pharmaceutical composition according to any one of claims 1 to 17 for use in the treatment and / or prevention of cancer.

19. 19. The pharmaceutical composition for use according to claim 18, wherein the cancer is selected from breast cancer, carcinoid, cervical cancer, colon cancer, endometrial cancer, glioma, head and neck cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, gastric cancer, thyroid cancer, and urothelial cancer.

20. (a) Formula (I): [C21] [In the formula, R 1 represents a 5- or 6-membered heteroaryl or a 5- or 6-membered aryl, the heteroaryl or aryl group being optionally substituted with one or more substituents selected from C1-C6 alkyl (preferably methyl) and halo (preferably fluoro or chloro), preferably R 1 represents a 5-membered heteroaryl, more preferably R 1 represents a frill; R 2 represents a 6-membered aryl or a 6-membered heteroaryl; The heteroaryl or aryl group is optionally substituted with one or more substituents selected from halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino, and alkylsulfonealkyl; The substituents are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydrocarbyl, hydroxyalkyl, hydroxyalkylamino ... or substituted with one or more substituents selected from oxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; Alternatively, said heteroaryl or aryl group is optionally substituted with two substituents which, together with the atom to which they are attached, form a 5- or 6-membered aryl ring, a 5- or 6-membered heteroaryl ring, a 5- or 6-membered cycloalkyl ring, or a 5- or 6-membered heterocyclyl ring, and is optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroalkyl, aryl ... alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkyl substituted with one or more substituents selected from alkylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl, or a pharma- ceutically acceptable salt or solvate thereof; (b) at least one anticancer agent.

21. The compound has the formula (Ia) [C22] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 is as defined in claim 1; X 1 and X 2each independently represents C or N; X 1 If N, then R 1’ does not exist or X 1 If C, then R 1’ represents H, halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino, or alkylsulfonealkyl; The substituents are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydride, substituted with one or more substituents selected from alkyloxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; R 2’represents H, halo, alkyl, heterocyclyl, alkoxy, cycloalkyloxy, heterocyclyloxy, carbonyl, alkylcarbonyl, aminocarbonyl, hydroxycarbonyl, heterocyclylcarbonyl, alkylsulfoxide, alkylsulfonyl, aminosulfonyl, heterocyclylsulfonyl, alkylsulfonimidoyl, carbonylamino, sulfonylamino, or alkylsulfonealkyl; The substituents are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, or substituted with one or more substituents selected from alkyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; Or, R 1’ and R 2’together with the atoms to which they are attached form a 5- or 6-membered aryl ring, a 5- or 6-membered heteroaryl ring, a 5- or 6-membered cycloalkyl ring, or a 5- or 6-membered heterocyclyl ring, and are optionally selected from the group consisting of oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkyla substituted with one or more substituents selected from amino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl; X 2 If N, then R 3’ does not exist or X 2 If C, then R 3’ represents H or halo, preferably H or F; R 4’ represents H or halo, preferably H or F; R 5’ 21. The combination according to claim 20, wherein represents H or halo, preferably H or F.

22. The compound represented by formula (Ia-1) [C23] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 , R 1’ , R 2’ , R 3’ , R 4’ , and R 5’ The combination according to claim 20 or claim 21, wherein:

23. The compound represented by formula (Ia-1b) [C24] or a pharma- ceutically acceptable salt or solvate thereof, wherein R 1 and R 3’ is as defined in claim 2; R 1’ represents H or halo, preferably H or F; R 2’’is an oxo, halo, hydroxy, cyano, alkyl, alkenyl, aldehyde, heterocyclylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (heterocyclyl)(alkyl)aminoalkyl, heterocyclyl, heteroaryl, alkylheteroaryl, alkyne, alkoxy, amino, dialkylamino, aminoalkylcarbonylamino, aminocarbonylalkylamino, (aminocarbonylalkyl)(alkyl)amino, alkenylcarbonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl 23. The combination of any one of claims 20 to 22, wherein the alkyl or heterocyclyl group is substituted with one or more groups selected from: aryl, aminoalkylaminocarbonyl, alkylaminoalkylaminocarbonyl, dialkylaminoalkylaminocarbonyl, heterocyclylalkylaminocarbonyl, (alkylaminoalkyl)(alkyl)aminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocyclylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfoxide, alkylsulfoxidealkyl, alkylsulfonyl, and alkylsulfonealkyl.

24. The compound of formula (I) 3-(2-(4-(4-((1H-1,2,3-triazol-4yl)methoxy-2-fluorophenyl)piperazin-1-yl)ethyl)-5-amino-(8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-((4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)methyl)-1,3,4-oxadiazol-2(3H)-one; 5-amino-3-(2-(4-(3-fluoropyridin-4-yl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)acetamide; (S)-5-amino-3-(2-(4-(2-fluoro-4-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(2-fluoro-4-(2-(methylsulfinyl)ethoxy)phenyl)-piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R,S)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (+)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (-)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-8-(furan-2-yl)-3-(2-(4-(4-(2-hydroxyethoxy)phenyl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)phenoxy)acetic acid; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)phenoxy)acetamide; 5-amino-3-(2-(4-(4-(2,3-dihydroxypropoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(4-(2-aminoethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-methylbenzamide; 5-amino-8-(furan-2-yl)-3-(2-(4-(4-(2-morpholinoethoxy)phenyl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(4-(2-(dimethylamino)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)benzenesulfonamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-methylbenzenesulfonamide; 5-amino-8-(furan-2-yl)-3-(2-(4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-Amino-8-(furan-2-yl)-3-(2-(4-(4-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]t Riazolo[1,5-c]pyrimidin-2(3H)-one; 3-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)benzamide; 5-amino-8-(furan-2-yl)-3-(2-(4-(3-(2-hydroxyethoxy)phenyl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(2-oxo-2-(piperazin-1-yl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(piperidin-4-ylmethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(piperazine-1-carbonyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(2-(piperazin-1-yl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(piperazin-1-ylsulfonyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(methylsulfonyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2-aminoethyl)-3-fluorobenzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-methylamino)ethyl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2-(dimethylamino)ethyl)-3-fluorobenzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-hydroxyethyl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2,3-dihydroxypropyl)-3-fluorobenzamide; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)acetic acid; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo [5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3,5-difluorophenoxy)acetic acid; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)propanoic acid; (S)-2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)propanoic acid; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-2-methylpropanoic acid; 3-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenyl)propanoic acid; 4-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1yl)-3-fluorophenoxy)butanoic acid; 2-(3-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,6-difluorophenoxy)acetic acid; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)acetic acid; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorobenzoic acid; 2-((2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)ethyl)amino)acetamide; 2-((2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)ethyl)(methyl)amino)acetamide; 5-amino-3-(2-(4-(2-fluoro-4-(piperidin-4-yloxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(pyrrolidin-3-yloxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 3-(2-(4-(4-((1H-1,2,4-triazol-3-yl)methoxy)-2-fluorophenyl)piperazin-1-yl)ethyl)-5-amino-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-N-(2-(methylamino)ethyl)acetamide; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo [5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-N-(2-(dimethylamino)ethyl)acetamide; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-N-(2-aminoethyl)acetamide; (R)-2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)propanoic acid; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)acetamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-methyl-N-(2-(methylamino)ethyl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2-(dimethylamino)ethyl)-3-fluoro-N-methylbenzamide; (R)-4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(1-(dimethylamino)propan-2-yl)-3-fluorobenzamide; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-N-methyl-N-(2-(methylamino)ethyl)acetamide; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)-2-methylpropanoic acid; (S)-2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)propanoic acid; (R)-2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)propanoic acid; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)-N-(2-(methylamino)ethyl)acetamide; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)-N-(2-(dimethylamino)ethyl)acetamide; 5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5, 4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2-(dimethylamino)ethyl)-2,4-difluoro-N-methylbenzamide; 4-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)butanoic acid; 3-(2-(4-(5-((1H-tetrazol-5-yl)methoxy)-2,4-difluorophenyl)piperazin-1-yl)ethyl)-5-amino-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-(methyl(oxetan-3-yl)amino)ethyl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-((2-hydroxyethyl)amino)ethyl)benzamide; 2-amino-N-(2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)ethyl)acetamide; (S)-2-amino-N-(2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)ethyl)-3-methylbutanamide; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)ethyl acetate; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)acetonitrile; 5-amino-8-(furan-2-yl)-3-(2-(4-(pyridin-4-yl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-8-(furan-2-yl)-3-(2-(4-(pyrimidin-4-yl)piperazin-1-yl)ethyl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfonyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(2-(methylsulfonyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(6-fluoro-2-oxoindolin-5-yl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(S-methylsulfonimidoyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2-(dimethylamino)ethyl)-2,4-difluorobenzamide; 5-amino-3-(2-(4-(5-fluoro-2-methylpyridin-4-yl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3R,4R)-4-hydroxytetrahydrofuran-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(2-hydroxypropan-2-yl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(3,3,3-trifluoro-2-hydroxypropoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-5-(2-hydroxyethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(morpholin-2-ylmethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(morpholin-3-ylmethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(((3S,4S)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(((3S,4S)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(((3R,4S)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2,4-difluoro-5-(((3S,4R)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(2,4-difluoro-5-((2-oxopyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(2,4-difluoro-5-((2-oxopyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 2-(5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluorophenoxy)-N-(2-morpholinoethyl)acetamide; 5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluoro-N-(morpholin-3-ylmethyl)benzamide; 5-amino-3-(2-(4-(2-fluoro-4-(morpholin-3-ylmethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(morpholin-2-ylmethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3R,4R)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3S,4S)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3R,4S)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((3S,4R)-4-fluoropyrrolidin-3-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 2-(4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluorophenoxy)-N-(2-morpholinoethyl)acetamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-morpholinoethyl)benzamide; 4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(morpholin-3-ylmethyl)benzamide; 5-amino-3-(2-(4-(4-(azetidin-3-yloxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(2,4-difluoro-5-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(2,4-difluoro-5-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one 5-amino-3-(2-(4-(2,4-difluoro-5-(((1s,4s)-1-oxidotetrahydro-2H-thiopyran-4-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; ... 5-amino-3-(2-(4-(2,4-difluoro-5-(((1r,4r)-1-oxidotetrahydro-2H-thiopyran-4-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluoro-N-(2-(methylsulfinyl)ethyl)benzamide; (R)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluoro-N-(2-(methylsulfinyl)ethyl)benzamide; (S)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluoro-N-methyl-N-(2-(methylsulfinyl)ethyl)benzamide; (R)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-2,4-difluoro-N-methyl-N-(2-(methylsulfinyl)ethyl)benzamide; 5-amino-3-(2-(4-(2,4-difluoro-5-(1-oxidothiomorpholine-4-carbonyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-Amino-3-(2-(4-(2,4-difluoro-5-(1-oxidothiomorpholino (R)-5-amino-3-(2-(4-(2-fluoro-4-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(2-fluoro-4-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(2-fluoro-4-(methylsulfinyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((1s,4s)-1-oxidotetrahydro-2H-thiopyran-4-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(((1r,4r)-1-oxidotetrahydro-2H-thiopyran-4-yl)oxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-(methylsulfinyl)ethyl)benzamide; (R)-4-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-3-fluoro-N-(2-(methylsulfinyl)ethyl)benzamide; 5-amino-3-(2-(4-(2-fluoro-4-(1-oxidothiomorpholine-4-carbonyl)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(2-fluoro-4-(1-oxidothiomorpholino)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(5-(2,3-dihydroxypropoxy)-2,4-difluorophenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (R)-5-amino-3-(2-(4-(5-(2,3-dihydroxypropoxy)-2,4-difluorophenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2,3-dihydroxypropyl)-2,4-difluorobenzamide; (R)-5-(4-(2-(5-amino-8-(furan-2-yl)-2-oxothiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-3(2H)-yl)ethyl)piperazin-1-yl)-N-(2,3-dihydroxypropyl)-2,4-difluorobenzamide; 5-amino-3-(2-(4-(4-(azetidin-3-yloxy)-2-fluorophenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; 5-amino-3-(2-(4-(5-(azetidin-3-yloxy)-2,4-difluorophenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (S)-5-amino-3-(2-(4-(2,4-difluoro-5-(3-(methylsulfinyl)propoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; and a pharma- ceutically acceptable salt or solvate thereof.

25. The compound of formula (I) (R,S)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; (+)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one; and a pharma- ceutically acceptable salt or solvate thereof.

26. 26. The combination of any one of claims 20 to 25, wherein the anti-cancer agent is selected from an immunotherapeutic agent, a chemotherapeutic agent, an anti-angiogenic agent, a multidrug resistance associated protein inhibitor, a radiotherapeutic agent, and any combination thereof.

27. 27. The combination of claim 26, wherein the immunotherapeutic agent is selected from a checkpoint inhibitor, a checkpoint agonist, an IDO inhibitor, a PI3K inhibitor, an adenosine receptor inhibitor, an adenosine generating enzyme inhibitor, a CD40 agonist, an IL2 mutant, an immune cell, a therapeutic vaccine, or any combination thereof.

28. 28. The combination of claim 27, wherein the checkpoint inhibitor is an inhibitor of a checkpoint protein selected from PD-1, PD-L1, CTLA-4, and TIGIT.

29. 29. The combination of claim 28, wherein the inhibitor of PD-1 is an anti-PD-1 antibody, the inhibitor of PD-L1 is an anti-PD-L1 antibody, the inhibitor of CTLA-4 is an anti-CTLA-4 antibody, and the inhibitor of TIGIT is an anti-TIGIT antibody.

30. 27. The combination of claim 26, wherein the chemotherapeutic agent is selected from anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum coordination compounds, Parp inhibitors, anti-hormone sensitive cancer agents, and any combination thereof.

31. 31. The combination of claim 30, wherein the anticancer antibiotic is doxorubicin, the anticancer platinum coordination compound is oxaliplatin, and the combination of chemotherapeutic agents is selected from: (i) a combination consisting of folinic acid, fluorouracil, and oxaliplatin; (ii) a combination consisting of carboplatin and paclitaxel; and (iii) a combination consisting of gemcitabine and nab-paclitaxel.

32. At least one compound of formula (I) as defined in any one of the preceding claims and 32. The combination according to any one of claims 20 to 31, comprising at least two anti-cancer agents as defined in any one of claims 20 to 31.

33. 1. A pharmaceutical composition comprising: (a) at least one compound of formula (I) as defined in any one of the preceding claims; and (b) at least one anti-cancer agent as defined in any one of the preceding claims.

34. (a) a first part comprising at least one compound of formula (I) as defined in any one of the preceding claims; (b) a second part comprising at least one anti-cancer drug as defined in any one of the preceding claims.

35. A combination according to any one of claims 20 to 32, a pharmaceutical composition according to claim 33 or a kit of parts according to claim 34, for medical use.

36. A combination according to any one of claims 20 to 32, a pharmaceutical composition according to claim 33 or a kit of parts according to claim 34 for use in the treatment and / or prevention of cancer.

37. 37. The combination for use, pharmaceutical composition for use, or kit of parts for use according to claim 36, wherein the cancer is selected from breast cancer, carcinoid, cervical cancer, colon cancer, endometrial cancer, glioma, head and neck cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, gastric cancer, thyroid cancer, and urothelial cancer.

38. The combination for use or kit of parts for use according to any one of claims 35 to 37, wherein said anti-cancer agent and said compound of formula (I) are administered sequentially and / or simultaneously to a patient in need thereof.

39. The combination for use or kit of parts for use according to any one of claims 35 to 37, wherein said anti-cancer agent and said compound of formula (I) are administered via different routes of administration to a patient in need thereof.

Citation Information

Patent Citations

  • Natural combination hormone replacement therapy agents and therapies

    JP2018024688A

  • Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

    JP2019023189A

  • 2-OXO-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers

    WO2018178338A1